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I. Introduction     1 
I. INTRODUCTION 
Diabetes mellitus is a major public health problem that shows an alarming steady 
increase in prevalence numbers (Scully 2012; Shaw et al. 2010). Over 90% of all 
diabetic patients suffer from type 2 diabetes, a progressive metabolic disorder 
with dangerous and fatal impact on the organism (ADA 2013a). Therefore, new 
treatment strategies are urgently needed that address the core problem responsible 
for its clinical manifestation and progressive course: The failure and decline of 
pancreatic beta-cells (Prentki et al. 2006). Glucagon-like peptide-1 receptor (GLP-
1R) agonists as representatives for incretin-based therapies are a promising 
approach for diabetes treatment. It has been shown for this class of drugs that they 
seem to have beneficial effects on pancreatic beta-cells: In vitro they showed the 
potential to stimulate beta-cell proliferation and decrease apoptosis rate and in 
vivo they were able to increase the beta-cell volume in rodent animal models 
(Bregenholt et al. 2005; Friedrichsen et al. 2006; Miao et al. 2013; Rolin et al. 
2002; Sturis et al. 2003; Tews et al. 2009; Tourrel et al. 2002; Tourrel et al. 2001; 
Xu et al. 1999). However, the beta-cells of rodents show a much higher capacity 
for regeneration and proliferation compared to the human beta-cells and it is 
therefore questionable if the liraglutide mediated increases of the beta-cell volume 
in rodents are representative for the human organism (Butler et al. 2007; Menge et 
al. 2008). Data are still completely lacking about the in vivo effect of GLP-1R 
agonists on beta-cells in humans because there are no appropriate non-invasive 
imaging techniques for the quantification and evaluation of human total beta-cell 
volume (Malaisse 2005). Furthermore, the effect of GLP-1R agonists on 
adolescent organisms has not been appropriately investigated yet and these drugs 
are only approved for the use in adult type 2 diabetic patients (Amylin 2012, 
2011; EMEA 2009b; Novo Nordisk 2010). However, appropriate 
pharmacotherapy for younger type 2 diabetic patients gets more and more 
important given the facts that prevalence numbers of adolescent people suffering 
from this disease are also steadily increasing (Bloomgarden 2004; Flint et al. 
2011; George et al. 2013). A large animal model like the pig can help to close the 
gap between rodent models and human patients because of its strong 
physiological and pathophysiological similarities to human beings (Aigner et al. 
2010; Swindle et al. 2012). Thus, the effect of the GLP-1R agonist liraglutide on 
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glycemic control, body weight, food intake and especially the total beta-cell 
volume was evaluated in adolescent transgenic pigs that express a dominant-
negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn) in the 
pancreatic beta-cells. This transgenic pig model seemed to be particularly suitable 
for this study because it shows key findings of a prediabetic state including 
impaired function of the incretin hormone glucose-dependent insulinotropic 
polypeptide (GIP) as well as a progressive decline of beta-cells (Renner et al. 
2010). 
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II. REVIEW OF THE LITERATURE 
1. Type 2 diabetes mellitus 
1.1. Prevalence of diabetes mellitus 
According to the American Diabetes Association (ADA) diabetes mellitus is 
defined as a “group of metabolic disorders characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both” (ADA 2013a). 
Due to its frequent and progressive occurrence this disease has become a major 
public health problem, also indicated by alarming steady increases in prevalence 
(Scully 2012): While in 2010 it was estimated that about 6.4% of adult people 
worldwide were suffering from diabetes, already 7.7% will suffer from this 
disease in 2030. In numbers, this means an increase from 285 to 439 million 
diabetic patients, excluding undiagnosed cases (Shaw et al. 2010). The highest 
prevalence can be found in upper-middle as well as middle-income countries like 
China or India with over 10% of diabetic people, while prevalence numbers are 
lower in high-income countries like Japan or most of the European countries 
(Scully 2012; Shaw et al. 2010). Diabetes mellitus is not only a priority health 
problem, it is also a huge burden regarding consequential costs: In 2010, about 
12% of the total global health expenditure (approximately 376 billion US dollars) 
were invested in diabetes mellitus, an amount of money that will not be sufficient 
in coming years regarding the rapid increase of diabetes prevalence (Scully 2012; 
Zhang et al. 2010). With a proportion of 90-95% type 2 diabetes is the most 
common form of diabetes mellitus worldwide. As it was formerly known as 
“adult-onset diabetes” it has to be mentioned that also the prevalence numbers of 
children and adolescent people suffering from type 2 diabetes are steadily 
increasing within the last years (ADA 2013a; Bloomgarden 2004). Taken together 
this underlines the urgent need of a better comprehension of diabetes pathogenesis 
and following consequences to slow down the explosive expansion of this disease 
by development of prevention methods and appropriate treatment strategies 
(Zimmet et al. 2001). 
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1.2. Pathophysiology and consequences of type 2 diabetes 
The development of type 2 diabetes mellitus is a complex and often longsome 
process as it can take years before a clinically overt diabetes characterized by 
chronic hyperglycemia takes shape (Campbell 2009b). Although the 
pathophysiologic aspects during this progressive development process are not 
completely understood yet, two major pathogenetic principles are included: 
Insulin resistance and beta-cell failure (Prentki et al. 2006). Insulin resistance 
mainly describes the inability of insulin to appropriately stimulate glucose uptake 
in peripheral tissues, especially in muscle tissue, and additionally to suppress 
glucose output and production from the liver, all in all going along with the 
development of a prediabetic state (DeFronzo 2004). However, in an early state of 
insulin resistance normoglycemia and normal glucose tolerance are conserved 
because the pancreatic beta-cells show enhanced function and compensate for the 
metabolic disorder by increasing insulin secretion and also total beta-cell volume 
(Prentki et al. 2006). Provided that beta-cells are completely functional, this 
compensation can be effective for the whole human lifetime (Campbell 2009a). 
The principle reason for the manifestation of a clinically overt type 2 diabetes 
mellitus is the dysfunction of susceptible beta-cells characterized by decreased 
insulin secretory capacity, impaired glucose tolerance and increased beta-cell 
apoptosis rate followed by progressive loss of functional beta-cell volume (Butler 
et al. 2003; Campbell 2009a; Prentki et al. 2006). Beta-cell failure and decrease of 
beta-cell volume are even worsening during the course of the disease due to 
several reasons: As beta-cells are quite sensitive to elevated glucose levels, the 
chronic hyperglycemia shows destructive effects because it causes decreased 
insulin secretion as well as multiple cellular stress response processes and 
supports increased beta-cell apoptosis. Additionally, elevated levels of free fatty 
acids as well as the accumulation of cytotoxic islet amyloid polypeptide (IAPP) in 
the beta-cells can further trigger beta-cell destruction (Campbell 2009a; 
Wajchenberg 2007). Plenty of risk factors like obesity, hypertension, lack of 
physical activity, smoking or excessive consummation of alcohol increase the 
danger of developing type 2 diabetes and are unfortunately more and more 
becoming part of modern lifestyle (Olokoba et al. 2012). Development of 
overweight or obesity, particularly intra-abdominal obesity, is a major cause for 
the development of insulin resistance and thereby one of the most important risk 
factors that is tightly connected to type 2 diabetes (Wajchenberg 2007). Based on 
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a long-term observation Ford et al. even suggested that every kilogram body 
weight gain accounts for a 4.5% higher risk of developing diabetes (Ford et al. 
1997). This is especially alarming knowing that the prevalence of obesity is also 
steadily increasing (Campbell 2009b). Additionally, genetic predispositions play 
an important role as risk factors for type 2 diabetes (ADA 2013a; Olokoba et al. 
2012). The disease occurs more often in aging people, females that showed 
gestational diabetes before or people suffering from depression. Race and 
ethnicity seem to influence the susceptibility to develop type 2 diabetes, as for 
example African Americans show a higher risk for this disease than white people 
(Deshpande et al. 2008). The long-term impact of a chronic hyperglycemia on the 
organism is dangerous: It promotes pathologic changes in small blood vessels 
leading to nephropathy right up to end-stage renal failure, retinopathy leading to 
blindness, impotence or peripheral neuropathy going along with foot ulcers right 
up to extremity amputation. Macroangiopathies also reflect a big problem because 
they can promote cardiovascular diseases like stroke, heart attack, congestive 
heart failure or coronary heart disease that account for about 65% of all cases of 
death in diabetic patients (ADA 2013a; Campbell 2009b; Deshpande et al. 2008).  
1.3. Diagnosis criteria for type 2 diabetes in humans 
A committee of the ADA developed a categorization system for the clinical 
diagnosis of diabetes that is steadily updated. It is based on fasting plasma glucose 
(FPG) as well as postprandial glucose (PG) levels two hours after a standardized 
oral glucose tolerance test in humans that should indicate the state of glucose 
tolerance. Glycated hemoglobin (HbA1c), a monitoring parameter of long-term 
blood glucose, can also be used as diagnostic criteria (ADA 2013a; Little et al. 
2013). The disease diabetes mellitus can be diagnosed in 4 cases: HbA1c shows 
values over 6.5% or FPG is greater than 126 mg/dl or PG reaches levels higher 
than 200 mg/dl or a patient shows values over 200 mg/dl in a random blood 
sample and additionally classical clinical symptoms of elevated blood glucose. 
Furthermore, FPG between 100-125 mg/dl, PG between 140-199 mg/dl or HbA1c 
between 5.7–6.4% can be interpreted as a prediabetic state in which a human 
shows higher risk of developing diabetes mellitus (ADA 2013a). 
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1.4. Therapeutic approaches for type 2 diabetes 
Regarding the complex pathogenesis of type 2 diabetes mellitus and the manifold 
consequences on the organism, the successful therapy of this disease can be 
challenging. Main goals of therapy are to fight hyperglycemia and get glucose 
homeostasis under control to prevent further complication, particularly damages 
of blood vessels (Campbell 2009b; Patel et al. 2008). But even more important 
should be the effort to protect and restore beta-cells, as their progressive 
dysfunction and loss is responsible for the development and worsening of the 
course of diabetes mellitus (Campbell 2009a). Additionally, it is necessary to 
work on strategies that lead to a complete prevention of a clinical manifestation of 
the disease during a prediabetic state (Chaturvedi 2007). Although therapy goals 
have to be defined individually for every patient, the general state of glycemic 
control as recommended by the ADA should include HbA1c levels <7%, 
preprandial glucose values between 70 and 130 mg/dl and postprandial glucose 
values lower than 180 mg/dl (ADA 2013b). Classical diabetes treatment starts 
with the attempt to improve the metabolic situation by changes of lifestyle 
including controlled diet and promotion of physical activity with the main goal to 
achieve a reduction of body mass index (ADA 2013b; Klein et al. 2004). If this 
approach does not show the desired success pharmacological agents are used, 
mainly starting within the group of oral antidiabetic drugs. Metformin, a 
biguanide that acts blood glucose lowering because it primarily decreases hepatic 
glucose production and increases glucose uptake in peripheral tissues, is 
recommended as initial pharmacotherapy for type 2 diabetic patients and is 
thereby commonly used. It does not affect body weight or even slightly decreases 
it and gastrointestinal disorders are the mostly seen side effects (ADA 2013b; 
Campbell 2009b; Nathan et al. 2009; Olokoba et al. 2012). If glycemic control 
does not improve appropriately after 3-6 months, combination therapy with other 
pharmacological agents can be introduced. Besides biguanides the following 
groups of oral antidiabetic drugs are available: Sulfonylureas like glimepiride, 
glyburide or glypizide and glinides like repaglinide directly influence the beta-
cells to produce more insulin and thereby lower blood glucose, but mainly 
sulfonylureas are therefore also connected with the risk of hypoglycemia and 
additionally cause weight gain (Nathan et al. 2009; Olokoba et al. 2012). 
Thiazolidinediones like pioglitazone or rosiglitazone enhance the sensitivity of the 
organism (mainly skeletal muscles and the liver) to insulin. Unfortunately this 
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group of drugs also shows adverse effects like an increased risk for congestive 
heart failure, peripheral edema and can cause weight gain (Nathan et al. 2009; 
Olokoba et al. 2012; Singh et al. 2007). Reduction of glucose uptake within the 
intestine by inhibition of α-glucosidase and thereby improvement of postprandial 
blood glucose is caused by drugs like acarbose and voglibose. However, the 
application of α-glucosidase inhibitors is not widespread in diabetes treatment 
because of their frequent gastrointestinal side effects (Campbell 2009b; Olokoba 
et al. 2012). Another group of orally active substances that cause a reduced 
reabsorption of glucose in the kidney by inhibiting the responsible sodium glucose 
cotransporter-2 (SGLT-2) with following glucosuria but also lower blood glucose 
levels is currently under development (Ferrannini et al. 2012). Subcutaneous 
injection of exogenic insulin is one of the most effective methods to lower blood 
glucose levels and is applied for a long time in diabetes treatment. However, 
insulin therapy needs an appropriate individual management to prevent the risk of 
hypoglycemic episodes and additionally weight gain has to be considered as side 
effect (Campbell 2009b; Nathan et al. 2009). A new therapeutic approach on the 
market is represented by drugs that are based on the incretin hormone system, 
namely dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1R agonists. Beside of 
a glucose-dependent stimulation of insulin secretion without the risk of severe 
hypoglycemia these agents show weight reducing or weight neutral effects 
(Russell 2012). They are the first group of drugs that seem to address the 
fundamental cause of type 2 diabetes mellitus as it was shown in rodent models 
that they have the potential to preserve beta-cell function and volume (Mu et al. 
2006; Rolin et al. 2002; Shimizu et al. 2012; Sturis et al. 2003; Tourrel et al. 2002; 
Tourrel et al. 2001; Xu et al. 1999). 
2. The incretin hormone system 
2.1. Discovery of the incretin hormones and the incretin effect 
During studies with dogs Bayliss and Starling discovered in 1902 a substance that 
is produced by intestinal epithelial cells independent from innervation and that 
this substance they called “secretin” is able to activate pancreatic juice secretion 
(Bayliss et al. 1902). From this time on the prospect that the intestine can give 
some sort of signal to the endocrine pancreas in response to nutrient ingestion and 
affect the disposal of carbohydrates was born. La Barre introduced in 1932 for the 
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first time the term “incretin”, describing an extract from the upper gut mucosa that 
is able to provoke reduced blood glucose levels in dogs, but does not induce 
exocrine pancreatic secretion (La Barre 1932). Rapid progress concerning incretin 
hormone research was made after the development of the radioimmunoassay 
(RIA) for insulin in 1960 by Yalow and Berson (Yalow et al. 1960) when insulin 
plasma concentrations could be determined reliably: It was shown in humans that 
a glucose load given orally provokes a greater and more sustained increase in 
plasma insulin than the same amount of glucose given intravenously, indicating an 
additional stimulus for insulin release (Elrick et al. 1964; McIntyre et al. 1964). 
This phenomenon was later called the incretin effect and the search for 
responsible hormones to clarify the underlying mechanisms was intensified. The 
sought-after incretin hormones should fulfill the following classical properties: 
Secreted from enteroendocrine cells in response to nutrient ingestion, especially 
carbohydrates, they should be able to stimulate insulin release at states of elevated 
glucose levels (Creutzfeldt 2005). The first hormone that fulfilled these 
requirements was discovered by Brown and colleagues in extracts of porcine 
small intestine and originally named “gastric inhibitory peptide” for its capability 
to inhibit gastric acid secretion in dogs (Brown et al. 1975). However, further 
research showed that this hormone at physiological levels also triggers insulin 
release glucose dependently in animals as well as in humans and thereby reveals 
classical insulinotropic properties (Dupre et al. 1973; Pederson et al. 1975). To 
grant this function priority over the inhibition of gastric acid secretion that was 
only seen after the administration of pharmacological doses, GIP was renamed 
into “glucose-dependent insulinotropic polypeptide” while keeping the same 
abbreviation. As the incretin effect after immunoneutralization of endogenous GIP 
with the help of antisera was blunted, but not completely inhibited, it was 
suspected that another substance might contribute to the incretin effect (Ebert et 
al. 1982). While sequencing mammalian proglucagon genes two fragments with 
similar sequence to glucagon were found: glucagon-like peptide-1 (GLP-1) and 
glucagon-like peptide-2 (GLP-2). As they were synthesized and tested for their 
biological function GLP-1 revealed, contrary to GLP-2, potent glucose-dependent 
insulinotropic activity and was therefore characterized as the second incretin 
hormone (Bell et al. 1983; Schmidt et al. 1985). Both incretin hormones work in 
an additive manner, while the contribution of GIP to the incretin effect 
quantitatively seems to be stronger than that of GLP-1 (Nauck et al. 1993a). 
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Together, they seem to be responsible for up to 60% of total postprandial insulin 
secretion in normal healthy subjects after administration of an oral glucose load 
(Nauck et al. 1986). 
2.2. Glucagon-like peptide-1 (GLP-1) 
2.2.1. Biosynthesis, secretion and degradation of GLP-1 
The sequence of GLP-1 is encoded in the proglucagon gene that is mainly 
expressed in alpha-cells within the pancreas, L-cells of the intestinal mucosa and 
additionally in neurons of specialized regions of the brainstem and hypothalamus 
(Baggio et al. 2007). The posttranslational processing of the proglucagon 
precursor is cell-type specific: In pancreatic alpha-cells glucagon, glicentin-related 
polypeptide (GRPP) and major proglucagon peptide (MPGF) are the mainly 
delivered products, whereas intestinal L-cells and neurons in the brain mostly 
liberate GLP-1, GLP-2, glicentin and oxyntomodulin (Larsen et al. 1997; Mojsov 
et al. 1986). Although pigs show higher density of GLP-1 immunoreactive L-cells 
along the intestine compared to humans, cell distribution seems to be similar 
between the two species throughout small and large intestine with highest 
amounts of L-cells in the distal jejunum, ileum and colon (Eissele et al. 1992). 
The main stimulators of GLP-1 secretion are nutrients like fat and carbohydrates 
(Brubaker 2006) and the following biphasic secretion pattern results in a rapidly 
starting increase in GLP-1 plasma concentration within 5 to 15 minutes followed 
by a second secretion interval after 30 to 60 minutes (Herrmann et al. 1995). As 
the early GLP-1 secretion pattern can hardly be explained by direct contact of 
nutrients with L-cells at rather distal parts of the intestine it is likely that 
mechanisms of GLP-1 secretion are complex and also involve other stimulators 
like neural and endocrine factors (Brubaker 1991; Roberge et al. 1993; Rocca et 
al. 1999). GLP-1 appears in the organism in two biologically active and 
functionally equal forms: The mainly circulating GLP-1 (7-36)-amide and the 
minor GLP-1 (7-37), that is extended by a glycine residue (Orskov et al. 1994; 
Orskov et al. 1993). These bioactive forms show a very short half-life of less than 
2 minutes due to partial proteolytic cleavage by the enzyme DPP-4 and thereby 
conversion to the inactive forms GLP-1 (9-36)-amide or GLP-1 (9-37) (Deacon et 
al. 1995a; Deacon et al. 1995b; Mentlein et al. 1993). As DPP-4 is inter alia 
membrane-bound to endothelial cells of capillaries regulating blood outflow of the 
II. Review of the literature     10 
intestinal mucosa, it is in close vicinity to GLP-1 secreting L-cells. Thereby the 
degree of degradation is extensive, as 50% of secreted bioactive GLP-1 is already 
converted to inactive forms by DPP-4 before even entering the systemic blood 
circulation (Hansen et al. 1999). 
2.2.2. GLP-1 receptor (GLP-1R) and signal transduction 
Like the receptor for glucagon and GIP, the GLP-1R belongs to the class 2 of 
heterotrimeric guanine nucleotide-binding protein (G-protein) coupled receptors 
containing a N-terminal extracellular domain for ligand binding, seven 
membrane-spanning domains linked by intra and extracellular loops and a C-
terminal cytoplasmic domain for further intracellular signaling (Mayo et al. 2003). 
However, binding of the ligand GLP-1 to its receptor is highly specific as GIP 
cannot bind to the GLP-1R and glucagon only with 100- to 1000-fold less affinity 
(Doyle et al. 2007; Fehmann et al. 1994; Thorens 1992). Expression of the GLP-1 
receptor is confirmed for a lot of tissues including alpha-, beta- and delta-cells in 
the pancreas as well as brain, heart, lung, kidney, stomach, intestine, pituitary, 
skin, thyroid C-cells and specialized regions of the peripheral and central nervous 
system like the vagus nerve, the hypothalamus or the hippocampus (Baggio et al. 
2007; Kim et al. 2008). Binding of GLP-1 to the N-terminal extracellular domain 
leads to a conformational change of the receptor with further activation and 
dissociation of the alpha subunit of the G-protein that is located at the third 
intracellular loop. This causes multiple and complex effects on further messenger 
systems (Hallbrink et al. 2001). The enzyme adenylate cyclase (AC) gets 
activated going along with enhanced production of cyclic adenosine 
monophosphate (cAMP) (Drucker et al. 1987). Increased cAMP concentrations 
lead to the activation of two main important downstream effectors: Protein kinase 
A (PKA) and guanine nucleotide exchange factor 2 (Epac2) that subsequently 
activate further messenger systems (Holz 2004; Kang et al. 2001; Wheeler et al. 
1993). Additionally, GLP-1 binding to its receptor can lead to the activation of 
phosphatidylinositol-3-kinase (PI3K) as well as mitogen-activated protein kinase 
(MAPK) and their downstream messenger systems (Buteau et al. 1999; Montrose-
Rafizadeh et al. 1999). 
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2.2.3. Effects of GLP-1 on the endocrine pancreas 
The binding of GLP-1 to the GLP-1R located on the cell membrane of pancreatic 
beta-cells leads to multiple cellular actions that mediate its strong glucose-
dependent insulinotropic effect, mainly caused by increased cAMP levels in the 
cell with further activation of PKA and Epac2 (Holst et al. 2004). The most 
important cellular events are the closure of ATP-dependent potassium channels, 
leading to depolarization of the cell membrane and opening of voltage-dependent 
calcium channels with further influx of calcium. Cytosolic calcium concentration 
gets additionally increased by mobilization of calcium from intracellular stores, 
which altogether triggers fusion of insulin containing secretory granules and 
exocytosis of insulin (Holst 2007; Holst et al. 2004). An important factor in this 
cascade which may cause about 70% of the stimulatory action of GLP-1 on 
insulin secretion is the ability of cAMP to increase the number of insulin 
containing granules that are rapidly ready for release independently of PKA and 
Epac2 (Gromada et al. 1998). The effect of GLP-1 induced promotion of insulin 
secretion absolutely requires a certain threshold of glucose levels in the beta-cell 
(Holst et al. 2004; Nauck et al. 1993c; Qualmann et al. 1995). Activation of the 
GLP-1R also results in an up-regulation of insulin biosynthesis and gene 
transcription by cAMP/PKA-dependent but also -independent messenger 
pathways and thereby secures intracellular insulin reserves (Drucker et al. 1987; 
Fehmann et al. 1992). Furthermore it was shown that GLP-1 has beneficial trophic 
effects on the beta-cells as it is able to inhibit apoptosis rate in isolated human 
islets as well as in the beta-cells of rodent models (Farilla et al. 2003; Farilla et al. 
2002; Li et al. 2003) and stimulates beta-cell proliferation in rodents (Farilla et al. 
2002; Perfetti et al. 2000; Stoffers et al. 2000). GLP-1 signaling is able to provide 
the differentiation of progenitor cells in pancreatic duct epithelium to insulin-
producing beta-cells (Zhou et al. 1999). These findings were particularly 
interesting regarding the prospect that GLP-1 could be a new treatment option for 
type 2 diabetic patients that show decreased beta-cell volume going along with 
increased apoptosis rate, but they still have to be confirmed in humans in vivo 
(Butler et al. 2003). The underlying molecular mechanisms of the protective 
function of GLP-1 on the beta-cells are complex and not completely understood. 
Messenger pathways including cAMP/PKA, PI3K and MAPK systems inter alia 
result in an up-regulation of insulin receptor 2 substrate (Irs2) gene expression 
and increased transcription of the pancreatic and duodenal homeobox gene 1 
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(Pdx1) (Baggio et al. 2007). Beside its impact on the beta-cells, GLP-1 is able to 
inhibit glucagon secretion in humans, perhaps supported by its ability to stimulate 
somatostatin secretion which was shown in pig and rat pancreata as well as in 
isolated islets (Creutzfeldt et al. 1996; Fehmann et al. 1995; Orskov et al. 1988; 
Schmid et al. 1990). The stimulatory action on somatostatin release seems to be 
independent of glucose levels and may be caused by direct contact of GLP-1 to a 
GLP-1R on pancreatic delta-cells (Fehmann et al. 1995; Fehmann et al. 1991). 
2.2.4. Extrapancreatic effects of GLP-1 
GLP-1 shows additional functions in other tissues beside its effect on the pancreas 
as also indicated by the versatile distribution of GLP-1Rs within the organism 
(Baggio et al. 2007; Kim et al. 2008). First of all, GLP-1 seems to be involved in 
the regulation of appetite, as short-term as well as long-term administration of 
GLP-1 forces up the feeling of satiety resulting in a distinct and sustained reduced 
food intake with the consequence of lower body weight gain (Flint et al. 1998; 
Gutzwiller et al. 1999; Zander et al. 2002). Moreover, GLP-1 reduces gastric 
secretion and most notably delays dose-dependently gastric emptying, which 
consequently leads to decelerated appearance of glucose from the meal in the 
bloodstream (Nauck et al. 1997; Wettergren et al. 1993; Wishart et al. 1998). 
Thereby GLP-1 shows a relevant second blood glucose-lowering effect that is 
independent from an increase in insulin secretion and is even going along with 
decreased postprandial insulin levels (Meier et al. 2003; Nauck et al. 1997). An 
important factor gaining more and more interest in recent research is the effect of 
GLP-1 on the cardiovascular system. Although in rodent models GLP-1 seems to 
increase blood pressure as well as heart rate (Barragan et al. 1994; Yamamoto et 
al. 2002), these findings are not in agreement with the neutral effects on these 
parameters seen in humans (Toft-Nielsen et al. 1999). In dogs with dilated 
cardiomyopathy continuous infusion with recombinant GLP-1 over 48 hours 
improved left ventricular and systemic hemodynamics and furthermore it was able 
to decrease myocardial infarction size in rat models of ischemia/reperfusion, 
indicating a cardioprotective function of GLP-1 (Bose et al. 2005; Nikolaidis et al. 
2004). In humans it was shown that GLP-1 has beneficial effects on endothelial 
function in type 2 diabetic patients suffering from coronary artery disease and 
enhances myocardial function during chronic heart failure, making GLP-1 and 
GLP-1R agonists a promising approach for the application in the treatment of 
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cardiovascular diseases (Nystrom et al. 2004; Thrainsdottir et al. 2004). The 
central nervous system seems to play a major role mediating functions of GLP-1 
as GLP-1 and GLP-1Rs are expressed in the brainstem, the hypothalamus, the 
area postrema or the nodose ganglion of abdominal vagal afferent nerve fibers 
which all are specialized regions implicated in the regulation of appetite and 
feeding behavior, gastric motility and cardiovascular function (Baggio et al. 
2007). Thereby it is likely that these effects caused by GLP-1 are partially due to 
direct interactions with GLP-1Rs, for example on stomach and heart, but mainly 
influenced by central neuronal regulation (Kim et al. 2008). But GLP-1 also 
shows further effects on the organism: Because of its neuroprotective effects 
studies are ongoing in rodent models to prove the use of GLP-1 and GLP-1R 
agonists in the therapy of neurodegenerative diseases like Alzheimer´s disease 
(Holscher 2010). The glucose-lowering effect of GLP-1 is additionally supported 
by an enhanced glucose uptake and storage in fat and muscle tissue as well as 
decreased glucose production but enhanced glycogen storage in the liver (Baggio 
et al. 2007). GLP-1 seems to influence the hypothalamic-pituitary axis because it 
is able to stimulate secretion of thyroid-stimulating hormone, luteininizing 
hormone, corticosterone, adrenocorticotropin and vasopressin in rodent models or 
rodent cell lines (Kim et al. 2008). However, GLP-1R deficient mice (GLP1r-/-) 
show no considerable disorders regarding function of the hypothalamic-pituitary 
axis (MacLusky et al. 2000). In thyroid C-cells, GLP-1 increases release of 
calcitonin which could be correlated with an indirect function on bone, because 
calcitonin is an inhibitor of the activity of osteoclasts and it was shown that 
GLP1r-/- mice show great bone fragility and decrease of bone density (Kim et al. 
2008; Lamari et al. 1996). 
2.3. Glucose-dependent insulinotropic polypeptide (GIP) 
2.3.1. Biosynthesis, secretion and degradation of GIP 
The second incretin hormone GIP is a 42-amino acid peptide that is synthesized in 
K-cells within the intestinal mucosa that can mainly be found along the duodenum 
and proximal jejunum (Buchan et al. 1978; Moody et al. 1984). Release of GIP 
from these cells is mostly stimulated by nutrient absorption in a species-specific 
manner: While fat uptake is the greatest inducer of GIP secretion in humans, 
carbohydrates are the main stimulus in rodents and pigs (Baggio et al. 2007). The 
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way of degradation for GIP is similar as for GLP-1 because also in this case the 
enzyme DPP-4 splits the molecule at the N-terminus, resulting in a conversion to 
the biological inactive form GIP (3-42) and thereby a short half-life of 5-7 
minutes in humans (Deacon et al. 2000). 
2.3.2. GIP receptor (GIPR) and signal transduction 
As the GLP-1R, the GIPR belongs to the heterotrimeric G-protein coupled 
receptors (Mayo et al. 2003). While the N-terminal extracellular domain is 
responsible for ligand binding and the first transmembrane domain for receptor 
activation, the third intracellular loop of the receptor is particularly important for 
the interaction with the G-protein and thereby for the further signal transduction 
(Brubaker 1991; Cypess et al. 1999; Gelling et al. 1997; Harmar 2001; Salapatek 
et al. 1999). With following activation of the enzyme AC to produce cAMP and 
further messenger systems including PKA, MAPK and PI3K the molecular signal 
mechanisms of GLP-1R and GIPR clearly coincide, which is also reflected in a lot 
of similar biological functions (Baggio et al. 2007). The GIPR shows a 
widespread distribution within the organism including expression in pancreatic 
alpha- and beta-cells, intestine, heart, lung, kidney, adrenal cortex, pituitary, bone, 
adipose tissue and specialized areas within the brain (Kim et al. 2008). 
2.3.3. Biological functions of GIP 
Regarding the beta-cells, GIP generally shows the same effects as described for 
GLP-1 mainly via similar molecular mechanisms: A glucose-dependent boost of 
insulin secretion, up-regulation of insulin biosynthesis and gene transcription as 
well as pro-proliferative and anti-apoptotic effects on the beta-cells mainly shown 
in vitro (Dupre et al. 1973; Fehmann et al. 1995; Kim et al. 2005; Trumper et al. 
2002; Trumper et al. 2001). With this knowledge it is understandable that GIP and 
GLP-1 work in an additive manner mediating the incretin effect (Nauck et al. 
1993a). In contrast to GLP-1, GIP is only a poor stimulator of somatostatin 
release and does not influence glucagon secretion except simultaneous glucose 
levels of 5 mmol/l or lower are present, then it even stimulates glucagon secretion 
(Fehmann et al. 1995). The ability to inhibit gastric acid secretion was the first 
described function of GIP and the decisive factor for its former name “gastric 
inhibitory peptide” (Brown et al. 1975). Stimulation of progenitor cell 
proliferation in the brain and of fatty acid synthesis in adipocytes as well as an 
II. Review of the literature     15 
anabolic effect on bone can additionally be counted to the functions of GIP 
(Baggio et al. 2007).  
3. Liraglutide as an incretin-based therapeutic agent 
3.1. Fundamental concept of incretin-based therapeutics 
Type 2 diabetic patients show a different metabolic reaction pattern in response to 
nutrient uptake compared to healthy human subjects: During food or nutrient 
ingestion their enteroendocrine L-cells and K-cells also secrete the two incretin 
hormones, but while the function of GLP-1 is preserved GIP shows a clearly 
diminished insulinotropic action, leading to a distinct reduced incretin effect 
(Nauck et al. 1986; Nauck et al. 1993b). As postprandial secretion levels of GIP 
are similar in comparison to healthy subjects (Toft-Nielsen et al. 2001; Vilsboll et 
al. 2001) the underlying mechanism for the body´s inability to respond to GIP is 
not completely clarified yet. Reasons could be sequence variants in the coding 
region of the GIPR gene leading to altered structure and/or expression of the 
receptor (Almind et al. 1998; Kubota et al. 1996; Lynn et al. 2001; Saxena et al. 
2010). The lack of responsiveness of GIP in type 2 diabetic patients leads to 
disturbed insulin response and higher blood glucose levels. These findings led to 
the idea to compensate the insufficient GIP function by potentiating the preserved 
insulinotropic function of GLP-1 and thereby improve glucose homeostasis. GLP-
1 shows desirable properties for the clinical treatment of type 2 diabetes: An 
existing hyperglycemia can be lowered to physiological levels by enhancing of 
insulin secretion and, as insulin secretion only gets stimulated during 
hyperglycemic stages, the danger of hypoglycemia is, in comparison to classical 
insulin treatment, very low (Drucker 2003; Holst 1999). Another useful function 
of GLP-1 for patients suffering from type 2 diabetes and often showing excessive 
overweight is that it acts as a mediator of satiety and delays gastric emptying 
(Alvarez et al. 2005; Nauck et al. 1997). Two big groups of incretin-based drugs 
are available. As native GLP-1 administration is not practical because of the very 
short half-life (< 2 min) (Deacon et al. 1995a) the GLP-1 sequence was either 
changed to ensure a longer half-life while directly stimulating the GLP-1R (GLP-
1R agonists) or molecules were developed that slow down GLP-1 degradation by 
inhibiting the enzyme DPP-4 and thereby increase endogenous GLP-1 
concentration (DPP-4 inhibitors). 
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3.1.1. DPP-4 inhibitors 
Endogenous as well as exogenous administered GLP-1 gets rapidly and 
extensively degraded to biological inactive GLP-1 (9-36)-amide or GLP-1 (9-37) 
by partial proteolytic cleavage of the enzyme DPP-4 (Deacon et al. 1995a; Deacon 
et al. 1995b; Mentlein et al. 1993). From the 1990s up to the present, major 
advances have been made in developing small molecules that block the active 
center of this enzyme and thereby save GLP-1 from degradation. Studies with 
different rodent models showed that molecules like Ile-thiazolidide or valine-
pyrrolidide are capable to augment insulin response and improve glucose 
tolerance (Ahren et al. 2000; Pauly et al. 1999; Pederson et al. 1998). It was also 
shown in anesthetized pigs that one single administration of DPP-4 inhibitor 
valine-pyrrolidide is able to completely block the conversion from biological 
active GLP-1 into its degradation product (Deacon et al. 1998a). Nowadays, 
advanced DPP-4 inhibitors have already shown their potential to improve 
glycemic control while having neutral effects on body weight in type 2 diabetic 
patients treated by monotherapy or add-on therapy (Ahren 2009; Idris et al. 2007; 
Karagiannis et al. 2012; Richter et al. 2008). Generally these drugs seem to be 
well tolerated (Duez et al. 2012) and show potential for preserving beta-cell 
function and volume in rodent models (Jelsing et al. 2012b; Mu et al. 2006; 
Shimizu et al. 2012). Already approved DPP-4 inhibitors are sitagliptin 
(Januvia®), vildgliptin (Galvus®), saxagliptin (Onglyza®) and linagliptin 
(Trajenta®). It has to be considered that unit cost is increased in comparison to 
older drugs like sulfonylureas while having similar effects on glucose levels and 
additionally long-term safety is not completely assured yet (Karagiannis et al. 
2012). Beside its enzymatic action DPP-4 is a membrane-associated molecule on 
the surface of T-cells (named CD26) and plays a role in transduction of activation 
signaling dependent on the interaction with other membrane-associated antigens 
(Fleischer 1994; Torimoto et al. 1991). It seems that the enzymatic activity of 
DPP-4 is not obligatory for the activation of T-cells so that blockage of the active 
catalytic center should not compromise its immune functions (von Bonin et al. 
1998). As GLP-1 is not the only substrate for DPP-4 but also a number of other 
regulatory peptides including members of the pancreatic polypeptide and 
glucagon family as well as some interleukins and analgesic brain peptides, it is 
important to further determine in what way blockage of DPP-4 activity influences 
metabolism of these peptides (Mentlein 1999). Interestingly, DPP-4 deficient 
II. Review of the literature     17 
Fischer rats are viable and show normal phenotype, also regarding glucose 
tolerance (Pederson et al. 1996).  
3.1.2. GLP-1R agonists 
The aim during development of GLP-1R agonists was to create and discover 
molecules with elongated duration of action while full biological GLP-1 actions 
are conserved. A lot of studies characterized structural determinants of GLP-1 
action: It was shown that analogues carrying a substitution at position 8 of GLP-1 
(7-37) are resistant to DPP-4 degradation, show longer half-life in vivo but still are 
biologically active (Deacon et al. 1998b). This is comprehensible with the 
knowledge that DPP-4 is a specialized exopeptidase that removes dipeptides from 
bioactive peptides when amino acids proline or alanine are the penultimate N-
terminal residues (Mentlein 1999). Native GLP-1 (7-37) contains an alanine as 
penultimate N-terminal residue and is thereby an excellent substrate for the DPP-4 
(Kieffer et al. 1999). In contrast to the native GLP-1 structure N- and C-terminally 
truncated peptides show less or no biological action (Gefel et al. 1990; Mojsov 
1992; Suzuki et al. 1989), while C-terminally extended peptides show nearly 
identical efficacy compared to GLP-1 (Goke et al. 1993; Nathan et al. 1992). 
Particularly the side chain of position 7 (histidine), but also of position 10, 12, 13, 
15, 28, 29 seem to be important for receptor interaction, as substitution leads to 
significant loss in receptor affinity (Adelhorst et al. 1994; Hareter et al. 1997). 
The attachment of fatty acids enforces the ability to bind serum albumin and 
thereby slows down renal elimination of GLP-1 (Knudsen et al. 2000). Nowadays 
several GLP-1 agonists are available for subcutaneous injection and play an 
important role in modern diabetes treatment. Exenatide was the first GLP-1R 
agonist on the market, gaining U.S. Food and Drug Administration (FDA) 
approval in 2005 under the trade name Byetta® (Amylin 2011). It is a synthetic 
form of exendin-4, a naturally existing GLP-1 mimetic that was originally isolated 
from the salivary gland of the lizard Heloderma suspectum and shares 53% 
sequence homology to native GLP-1 (Eng et al. 1992). With a half-life of 2.4 
hours it shows higher DPP-4 resistance but still strong affinity to the GLP-1R 
(Bray 2006; Goke et al. 1993). Byetta® is indicated as an adjunct to diet or 
exercise in adult patients with type 2 diabetes mellitus or in combination with 
other oral antidiabetic drugs and has to be administered subcutaneously twice 
daily (Amylin 2011). During research and clinical trials Byetta® showed 
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biological effects of native GLP-1 desired for diabetes treatment: It has beneficial 
effects on glucose homeostasis by enhancing insulin secretion in a glucose 
dependent manner, reducing postprandial hyperglycemia and suppressing 
glucagon secretion in humans (Bunck et al. 2009; Buse et al. 2004; Cervera et al. 
2008; DeFronzo et al. 2005; Fehse et al. 2005; Kolterman et al. 2003; Moretto et 
al. 2008) as well as in rodent and primate models of diabetes (Greig et al. 1999; 
Parkes et al. 2001; Young et al. 1999). Gastric emptying is slowed down dose-
dependently and satiety is increased by the use of Byetta®, leading to weight loss 
(Buse et al. 2004; Linnebjerg et al. 2008; Meier et al. 2003; Moretto et al. 2008; 
Toft-Nielsen et al. 1999; Vilsboll et al. 2012; Young et al. 1999). Beneficial 
effects on blood pressure and lipid profiles have also been reported (Klonoff et al. 
2008). A great point of interest is the fact that exenatide seems to be able to 
increase beta-cell volume and function, thereby leading to a cessation or even a 
reversing of disease progression. These effects on pancreatic beta-cells were not 
shown in humans so far, but there are several reports using cell lines or rodent 
models: exendin-4 showed 10-fold higher potency to stimulate the conversion of 
AR42J cells that were derived from a chemically induced pancreatic tumor from 
negative for islet hormones to insulin, pancreatic polypeptide and glucagon 
producing cells (Zhou et al. 1999). Treatment with exendin-4 led to an increase of 
the beta-cell volume going along with amplified beta-cell proliferation and/or 
decreased beta-cell apoptosis rate in several diabetic rodent models, e.g. partially 
pancreatectomized rats, streptozotocin-treated Wistar rats and C57BL/6 mice, 
intrauterine growth-retarded neonatal Sprague-Dawley rats, Goto-Kakizaki rats, 
diabetic db/db mice or fa/fa Zucker rats (Gedulin et al. 2005; Li et al. 2003; Park 
et al. 2008; Stoffers et al. 2003; Tourrel et al. 2002; Tourrel et al. 2001; Wang et 
al. 2002; Xu et al. 1999). Although it is a priority goal of diabetes research there is 
still a lack of approaches for reliably non-invasive visualization of beta-cells that 
could prove this theory in humans (Malaisse 2005). To further increase patient 
compliance a new formulation of exenatide called Bydureon® was approved in 
2012 (Amylin 2012). By encapsulation of exenatide into small spherical particles 
the drug is released over an extended period and only has to be injected once 
weekly subcutaneously while having similar effects as Byetta® (Aroda et al. 2011; 
DeYoung et al. 2011). Liraglutide under the trade name Victoza® is the third 
GLP-1R agonist formulation on the market with approval of the European 
Medicine Agency (EMEA) in 2009 (EMEA 2009a). As it is the drug used in the 
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present study pharmacokinetics and pharmacodynamic effects should be clarified 
in more detail (see II 3.2, II 3.3, II 3.4). With agents like albiglutide and 
lixisenatide that are currently undergoing phase 3 trials there is an ongoing 
development of new GLP-1R agonists (Khan et al. 2012). In conclusion GLP-1R 
agonists show a bigger extent of reduction in glycated hemoglobin and weight as 
well as greater treatment satisfaction and efficiency compared to DPP-4 inhibitors 
and will sure gain an even more important role in the treatment of type 2 diabetes 
mellitus (Russell 2012). 
3.2. Pharmacokinetics of liraglutide 
The success and effectiveness of exenatide amplified the efforts to develop GLP-
1R agonists with prolonged half-life suitable for a less frequent subcutaneous 
administration. During these studies liraglutide with the former name NN2211 
was discovered, an incretin mimetic that shows 97% homology to native GLP-1. 
The peptide portion of liraglutide was produced recombinantly in Saccharomyces 
cerevisiae and shows only one difference to the structure of human GLP-1(7-37): 
Lysine at position 34 is replaced by arginine. Additionally, a C16 palmitoyl fatty 
acid chain is chemically attached to lysine at position 26 via glutamic acid spacer, 
allowing intensified binding to serum albumin as well as self-association into 
heptamers at the injection site and thereby resulting in delayed absorption from 
the subcutis (Drucker et al. 2010; Knudsen et al. 2000; Novo Nordisk 2010; 
Steensgard DB 2008). Because of these modifications liraglutide can be cleaved 
by DPP-4 in the same position as GLP-1, but at a much slower rate (Malm-
Erjefalt et al. 2010). It still retains high affinity to the GLP-1 receptor while 
showing a plasma half-life of about 11-15 hours after subcutaneous administration 
in humans and is thereby suitable for a once daily administration (EMEA 2009a; 
Knudsen et al. 2000; Novo Nordisk 2010). While pigs show similar terminal half-
life of about 14 hours it seems to be shorter in mice, rats, rabbits and monkeys (4-
8 hours) (EMEA 2009a). After subcutaneous injection liraglutide is slowly 
absorbed in the human organism with maximum plasma concentrations obtained 
9-14 hours after dosing (Agerso et al. 2002; Elbrond et al. 2002). Maximum peak 
liraglutide concentration after subcutaneous injection of 0.6 mg in human is 
approximately 9.4 nmol/l and increases proportionally with dose in the therapeutic 
range from 0.6 mg up to 1.8 mg (Agerso et al. 2002; EMEA 2009b). Although a 
slight tendency towards accumulation was noticed in mice, rats and monkeys, 
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accumulation ratio was low (< 2%) and comparable to the results seen in humans. 
Overall bioavailability accounts approximately 53% for monkeys and 55% for 
humans while pigs show higher bioavailability of 76% (EMEA 2009a). Despite 
slight variances concerning relative bioavailability it was shown in humans that 
the pharmacokinetic properties of a 0.6 mg liraglutide dose did not differ when 
administered to different injection sites like thigh, upper arm or abdomen (Kapitza 
et al. 2011b). Additionally, liraglutide seems to be able to cross the blood-brain 
barrier as well as the placental barrier (EMEA 2009a; Hunter et al. 2012). The 
volume of distribution after subcutaneous dosing (0.6 mg) is approximately 13 
liter with a mean apparent clearance of 1.2 liter/hour. During the initial 24 hours 
after administration this GLP-1 agonist seems to be mainly distributed in the 
plasma compartment in its intact form and extensively (> 98%) bound to proteins 
(Malm-Erjefalt et al. 2010; Novo Nordisk 2010). As no intact liraglutide can be 
detected in urine or feces it seems likely that it is completely catabolized within 
the body into amino acids and fatty acid fragments that either get recycled or 
eliminated. Two minor metabolites were determined, but they don´t seem to have 
relevant activities (Malm-Erjefalt et al. 2010). Plasma exposure of liraglutide was 
not increased in patients suffering from renal dysfunction or hepatic impairment, 
leading to the conclusion that the kidney or the liver do not play a single major 
role during elimination (Flint et al. 2010; Jacobsen et al. 2009). Pharmacokinetics 
seems not to be influenced by age, gender, race or ethnicity and is similar between 
healthy men and patients with type 2 diabetes (Damholt et al. 2006; Novo Nordisk 
2010). As liraglutide delays gastric emptying it is important to evaluate the 
influence of this GLP-1 agonist on absorption rate and drug-drug interaction of 
simultaneously given oral drugs. Liraglutide seems not to interfere with function 
of cytochrome P450 enzymes and shows no clinically significant interactions with 
the co-administered drugs acetaminophen, atorvastatin, griseofulvin, digoxin, 
lisinopril or an oral contraceptive formulation (EMEA 2009a; Jacobsen et al. 
2011; Kapitza et al. 2011a; Malm-Erjefalt M 2008; Novo Nordisk 2010). 
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3.3. Pharmacodynamic effects of liraglutide in animal models 
3.3.1. Pharmacodynamic effects of liraglutide in animal models of 
diabetes 
3.3.1.1. Liraglutide administration in rodent models of diabetes 
A consistent key finding during investigations of liraglutide administration in 
hyperglycemic rodent models of diabetes was the potent, dose-dependent and 
long-lasting blood glucose lowering effect during basal glucose profiling as well 
as after glucose challenge (Brand et al. 2009; Larsen et al. 2008; Rolin et al. 2002; 
Shimoda et al. 2011; Sturis et al. 2003; Vrang et al. 2012). No effect on basal 
blood glucose was seen in normoglycemic rodent models, indicating that this 
effect is glucose-dependent (Bock et al. 2003b; Shimoda et al. 2011). A part of the 
glucose-lowering effect seems to be due to a reduction of food intake that mostly 
could be observed acutely after liraglutide administration (Rolin et al. 2002) and 
was even persistent during the whole liraglutide treatment period in some studies 
(Larsen et al. 2008; Sturis et al. 2003). As a consequence body weight reductions 
were monitored in liraglutide-treated animals and analysis of body composition in 
obese rats revealed that the weight loss was mainly due to a decrease of fat mass 
(Raun et al. 2007a). On the one hand, the decrease of food intake and body weight 
is provoked by a delayed gastric emptying caused by liraglutide, but on the other 
hand regulation of the central nervous system seems to be involved, particularly 
regarding long-term body weight reduction (Jelsing et al. 2012a). A reducing 
effect on food intake and body weight could also be shown in non-diabetic normal 
and obese rats (Bock et al. 2003b; Larsen et al. 2001b). Native GLP-1 is known to 
increase insulin secretion in a glucose-dependent manner and thereby it inter alia 
mediates its anti-hyperglycemic effect (Holst et al. 2004). An increase of insulin 
secretion during basal insulin profiling or after glucose challenging caused by 
liraglutide administration could also be shown in diabetic ZDF rats (Brand et al. 
2009; Sturis et al. 2003) and diabetic ob/ob mice (Rolin et al. 2002). In diabetic 
db/db mice fasting insulin was increased after 2 days of liraglutide treatment, but 
decreased after 2 weeks of liraglutide administration. In normoglycemic m/m mice 
no difference was seen regarding fasting insulin levels (Shimoda et al. 2011). In 
UCD-T2DM (University of California, Davis, type 2 diabetes mellitus) rats, a 
model of polygenic obesity that shows a late onset of diabetes, liraglutide 
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treatment caused a delayed development of diabetes and this was going along with 
significantly reduced fasting plasma insulin and glucose, indicating an 
improvement in insulin sensitivity (Cummings et al. 2010). In obese but non-
diabetic Sprague Dawley rats no significant differences in insulin levels were seen 
during an oral glucose tolerance test after 12 weeks of liraglutide treatment in 
comparison to placebo treatment (Raun et al. 2007a). As native GLP-1 is known 
to have trophic effects on beta-cells (Farilla et al. 2003; Farilla et al. 2002) most 
studies using rodent models also determined the effect of the GLP-1R agonist 
liraglutide on the beta-cell volume, beta-cell proliferation and apoptosis showing 
variable results: Liraglutide treatment (200 µg/kg twice daily) for 15 days could 
cause a beta-cell volume increase of about 35% as well as a distinct increase in 
beta-cell proliferation in diabetic db/db mice in comparison to placebo-treated 
animals, but same treatment interval (100 µg/kg twice daily) provoked only a 
tendency of increased beta-cell proliferation and beta-cell volume without 
significant differences in diabetic ob/ob mice (Rolin et al. 2002). Also in a study 
of Shimoda et al. two weeks of liraglutide administration (200 µg/kg twice daily) 
provoked a rise of beta-cell volume of approximately 36% in the diabetic db/db 
mouse model, accompanied by greater beta-cell proliferation rate, suppressed 
beta-cell apoptosis rate and decreased oxidative stress rate. In this study 
liraglutide additionally caused a 30% increase of beta-cell volume and increased 
beta-cell proliferation in a normoglycemic m/m mouse model (Shimoda et al. 
2011). Sturis et al. investigated the effects of liraglutide in the male ZDF rat 
model. A treatment period of 6 weeks (30 µg or 150 µg/kg twice daily) in ZDF 
rats that in this time interval developed hyperglycemia provoked an increase of 
beta-cell volume in comparison to placebo treatment. Liraglutide administration 
over a shorter term of 2 weeks caused significantly lower beta-cell volume and 
proliferation in ZDF rats that did not develop hyperglycemia during this treatment 
interval compared to placebo treatment. The authors concluded that a certain level 
of glucose could be necessary for an effect of liraglutide on beta-cell dynamics 
(Sturis et al. 2003). However, no differences in beta-cell volume were seen in 
older severely diabetic male ZDF rats after 6 weeks of liraglutide treatment (200 
µg/kg twice daily) or 30 days of liraglutide treatment (15 µg or 50 µg/kg twice 
daily) in comparison to placebo treatment (Brand et al. 2009; Larsen et al. 2008). 
On the other hand, Vrang et al. could show that 13 weeks of liraglutide 
administration (1 mg/kg/day) leads to increased beta-cell volume in female, but 
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not in male diabetic ZDF rats (Vrang et al. 2012). Non-diabetic Sprague Dawley 
rats showed greater beta-cell volume after one week of liraglutide administration 
(200 µg/kg twice daily) compared to placebo, but this effect was vanished after 6 
weeks as no more differences in beta-cell volume were visible (Bock et al. 
2003b). 12 weeks of liraglutide treatment (200 µg/kg twice daily) in candy-fed 
non-diabetic obese Sprague Dawley rats caused weight loss and reduced beta-cell 
volume compared to the obesity-associated increase of beta-cells in placebo-
treated rats (Raun et al. 2007a). 
3.3.1.2. Liraglutide administration in porcine models of diabetes 
Although the bigger part of animal studies was carried out with rodent models 
there are still a few reports of anti-hyperglycemic and body weight reducing 
effects of liraglutide in the Göttingen Minipig model (Raun et al. 2007b; Ribel et 
al. 2002): During a study of Ribel et al. streptozotocin was used to induce either 
diabetes or impaired glucose tolerance in male Göttingen Minipigs (Ribel et al. 
2002). During hyperglycemic clamp experiments these pigs acutely pre-treated 
with liraglutide required a higher glucose infusion rate to hold blood glucose on a 
constant level and still they even showed a weak tendency of lower plasma 
glucose levels, while insulin plasma levels were distinctly and glucose-
dependently increased in comparison to placebo pre-treatment. During a chronic 
treatment study with daily subcutaneous liraglutide administration of 3.3 µg/kg 
for 4 weeks liraglutide-treated pigs showed significantly improved oral glucose 
tolerance during oral glucose tolerance tests while insulin responses did not 
change in comparison to placebo-treated animals. Additionally, it was shown that 
liraglutide administration significantly reduced gastric emptying in this pig model 
and improved insulin sensitivity as indicated by the parameter glucose to insulin 
ratio (Ribel et al. 2002). In a study of Raun et al. ad libitum fed adult female 
Göttingen Minipigs were used that did not show diabetes or impaired glucose 
tolerance, but developed insulin resistance while showing intense obesity (Raun et 
al. 2007b). After a 3-week acclimatization period where subcutaneous liraglutide 
dosage was titrated for each pig, animals were treated with 7 µg/kg for another 4 
weeks. Liraglutide caused a strong and sustained suppression of food intake that 
accounted over 60% in comparison to untreated obese minipigs, going along with 
reductions in body weight of about 4-5% (Raun et al. 2007b). An in vitro study 
showed that liraglutide administration improves survival of isolated porcine islets 
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going along with reduction of beta-cell apoptosis, improved glucose 
responsiveness and cellular viability seen at 24 h of culture (Emamaullee et al. 
2009). In pancreaticoduodenectomized Yucutan miniature pigs that received an 
infusion of a marginal mass of pancreatic islets into the portal circulation, a 6-
week administration of liraglutide (20 µg/kg maintenance dose) could enhance 
metabolic function by increasing serum insulin during glucose tolerance testing. 
However, the quantitative proportion of beta-cells in the transplanted islet did not 
differ between liraglutide- and placebo-treated animals (Emamaullee et al. 2009). 
3.4. Pharmacodynamic effects of liraglutide in human clinical trials 
Liraglutide under the trade name Victoza® is an isotonic colorless solution that 
has to be injected subcutaneously once daily. In Europe, it is not approved as 
monotherapy but in combination with metformin and/or a sulphonylurea as well 
as metformin and a thiazolidinedione with the main goal to improve glycemic 
control (EMEA 2009a). It is recommended in humans to start with the dosage 0.6 
mg once daily and rise to 1.2 mg not before one week later. For some patients it 
can be beneficial to further increase the dosage to a maximum of 1.8 mg once 
daily to achieve better therapy results (Novo Nordisk 2009). Before the EMEA 
and FDA granted marketing authorization for Victoza® in 2009, comprehensive 
clinical study programs were performed to evaluate the potential, clinical efficacy 
and safety of this drug as monotherapy or in combination with other commonly 
used therapeutics for diabetes treatment as reviewed in Ryan et al. (2011). The 
first clinical trial study was published by Matsbach et al. in 2004 and already 
showed that 12 weeks of liraglutide treatment in type 2 diabetic patients at 
dosages up from 0.6 mg can significantly decrease HbA1c in comparison to 
placebo (Madsbad et al. 2004). During further phase 1 and 2 development trials, 
when liraglutide was mainly administered short-term or within a maximum 
duration of 14 weeks, the glucose-lowering effect was also seen, going along with 
a glucose-dependent increased insulin secretory response, weight loss and 
decrease of systolic blood pressure in diabetic patients (Schmidt 2010). Altogether 
these studies and findings showed the promising abilities of liraglutide in the 
treatment of type 2 diabetes and reinforced the efforts of more detailed and 
longer-term research. Therefore, the largest clinical trials were performed during 
the phase 3 clinical trial program and included six extensive studies that together 
form the Liraglutide Effect and Action in Diabetes (LEAD) program. All LEAD 
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studies were carried out for 26 weeks, except LEAD-3 that lasted even longer for 
52 weeks, and liraglutide initial dosages of 0.6 mg mostly increasing to 1.2 mg or 
1.8 mg were used (Buse et al. 2009; Garber et al. 2009; Marre et al. 2009; Nauck 
et al. 2009; Russell-Jones et al. 2009; Zinman et al. 2009). A large number of 
overall about 4500 type 2 diabetic patients was included into the LEAD program 
at different therapeutic stages of the disease: Some of them showed early phase 
diabetes and thereby had not yet been treated or only for a short time with one oral 
antidiabetic drug, others were used to be treated with a combination of two oral 
antidiabetic drugs that still failed to reach the therapeutic goal of maintained 
glucose control. In the six LEAD trials, liraglutide efficacy and safety as 
monotherapy, dual-drug therapy or triple-drug therapy was evaluated mostly 
compared to other standard diabetic treatments like glimepiride, rosiglitazone or 
exenatide as active comparators (Nauck 2012). 
3.4.1. Efficacy of liraglutide on glycemic control during LEAD trials 
The improvement of glycemic control by liraglutide treatment was proven in 
detail during LEAD trials and demonstrated with the influence on parameters 
including HbA1c, FPG and PG: HbA1c after liraglutide treatment was generally 
reduced in comparison to mean baseline HbA1c prior to liraglutide administration, 
both when liraglutide was administered alone and in combination with one or two 
oral antidiabetic drugs (Blonde et al. 2009; Buse et al. 2009). When used as 
monotherapy (LEAD-3), 1.2 mg liraglutide could cause HbA1c reduction of 0.84% 
from the baseline prior to the treatment while 1.8 mg even mediated a decrease of 
1.14%, and thereby greater reduction than seen for the sulfonylurea glimepiride 
(Garber et al. 2009). Liraglutide in combination with other oral antidiabetic drugs 
additionally provoked greater HbA1c reductions compared to exenatide twice daily 
(Buse et al. 2009), thiazolidinedione rosiglitazone (Marre et al. 2009) and insulin 
glargine (Russell-Jones et al. 2009) that also were administered in combination 
with the same oral antidiabetic drugs. Throughout all LEAD studies liraglutide 
monotherapy as well as combination therapy with oral antidiabetic drugs 
provoked a reduction of FPG and PG in comparison to baseline values at the 
beginning of the trials and placebo treatment (Blonde et al. 2009; Buse et al. 
2009). The extent of these reductions caused by 1.2 mg or 1.8 mg liraglutide 
combination treatment was similar to active comparators like insulin glargine or 
glimepiride (Nauck et al. 2009; Russell-Jones et al. 2009) or even greater 
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compared to rosiglitazone (Marre et al. 2009). Liraglutide therapy decreased FPG 
significantly more than exenatide twice daily when both agents were combined 
with other pharmacological agents. However, PG reductions were similar after 
lunch but showed greater extent in response to exenatide combined treatment after 
breakfast and dinner (Buse et al. 2009). When given as monotherapy, liraglutide 
mediated greater reductions in FPG and PG than glimepiride monotherapy 
(Garber et al. 2009).  
3.4.2. Efficacy of liraglutide on beta-cell function during LEAD trials 
Beta-cell function during LEAD studies was evaluated by calculating parameters 
using fasting insulin and glucose levels, like the homeostasis model assessment of 
insulin resistance (HOMA-IR) and of beta-cell function (HOMA-β) or by 
determination of the proinsulin : insulin ratio (Blonde et al. 2009). HOMA-β was 
improved between 20% and 44% by liraglutide treatment in all six LEAD studies 
compared to baseline at the beginning of the trial. Therefore the increase in 
HOMA-β was greater compared to the one caused by rosiglitazone (LEAD-1) or 
exenatide (LEAD-6) treatment with concomitant background therapies 
respectively (Garber 2011). HOMA-IR was not continuously determined in all 
LEAD studies, but Garber et al. assessed that liraglutide monotherapy mediated 
significantly decreased HOMA-IR values in comparison to glimepiride 
monotherapy (Garber et al. 2009). Furthermore, the proinsulin : insulin ration was 
found to be lower compared to baseline at the beginning of the trial during all 
LEAD studies (Matthews 2008). Taken together, these calculations propose 
beneficial effects on beta-cell function and improvement of insulin sensitivity by 
liraglutide treatment (Garber 2011).  
3.4.3. Efficacy of liraglutide on body weight and blood pressure during 
LEAD trials 
Regarding body weight, liraglutide administration with or without concomitant 
drugs caused weight loss in comparison to baseline values or placebo during 
LEAD studies 2-6. During 52 weeks of liraglutide monotherapy (LEAD-3), 
diabetic patients showed a mean body weight loss of 2.5 kg when being treated 
with 1.8 mg liraglutide and 2.1 kg when being treated with 1.2 mg liraglutide. 
This body weight reduction mainly occurred within the first 16 weeks of treatment 
and was sustained thenceforward (Blonde et al. 2009; Garber et al. 2009). 
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Liraglutide administration caused similar weight loss as exenatide twice daily 
when both drugs were combined with oral antidiabetic agents (Buse et al. 2009). 
When liraglutide was combined with metformin (LEAD-2) or with metformin and 
rosiglitazone (LEAD-4), the weight lowering effect was found to be dose-
dependent (Nauck et al. 2009; Zinman et al. 2009). LEAD-1 was the only study 
that reported weight-neutral effects for liraglutide therapy combined with the 
sulfonylurea glimepiride (Marre et al. 2009). Generally, the extent of weight loss 
seems to be greater in diabetic patients that additionally show a high initial body 
weight and mainly includes the loss of visceral adipose tissue (Blonde et al. 
2009). During all LEAD studies liraglutide treatment alone as well as dual or 
triple treatment was associated with decreased systolic blood pressure (SBP) 
(Blonde et al. 2009; Buse et al. 2009). When given as monotherapy for a period of 
52 weeks, 1.2 mg liraglutide caused SBP reductions of 2.1 mm Hg and 1.8 mg 
liraglutide even 3.6 mm Hg in comparison to baseline prior to the treatment. 
Regarding diastolic blood pressure there was also a tendency observed for 
reductions after liraglutide treatment but this effect was not significant (Garber et 
al. 2009). 
3.4.4. Safety and tolerability of liraglutide during LEAD trials 
Liraglutide was generally well tolerated during all trials with low rates of 
hypoglycemia (Blonde et al. 2009). During monotherapy, 12% of patients treated 
with 1.2 mg liraglutide and 8% of patients treated with 1.8 mg liraglutide showed 
minor hypoglycemic events defined as plasma glucose <3.1 mmol/l (Garber et al. 
2009). However, rate of hypoglycemia seemed to increase when liraglutide 
treatment was coupled with a sulfonylurea like glimepiride. Mild to moderate 
gastrointestinal symptoms like a different range of nausea, vomiting and diarrhea 
were the main detected adverse effects (Ryan et al. 2011). Generation of 
antibodies in response to liraglutide treatment was observed in about 8.6% of 
patients included in the LEAD studies. However, appearance of antibodies 
seemed not to change pharmacodynamic actions of liraglutide (Perry 2011). With 
the knowledge that GLP-1 agonists are able to stimulate calcitonin release in 
rodent thyroid C-cells and increase the occurrence of C-cell hyperplasia and C-
cell tumor formation in rats it was additionally important to accurately evaluate 
the impact of liraglutide on C-cells (Bjerre Knudsen et al. 2010). Analysis of 
clinical data from the six LEAD studies and three additional clinical studies up to 
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a treatment period of about two years revealed no evidence for a connection of 
liraglutide to pathological changes of thyroid C-cells (Chiu et al. 2012). Although 
some studies reported the occurrence of pancreatitis combined with liraglutide 
treatment, the incidence rate during LEAD studies was low compared to the 
general susceptibility of type 2 diabetic patients to develop pancreatitis described 
in previous studies (Noel et al. 2009; Ryan et al. 2011). 
4. The GIPRdn transgenic pig model 
4.1.  The pig as a large animal model for diabetes research 
In regard to the increasing prevalence of type 2 diabetes mellitus appropriate 
animal models play an irreplaceable role to clarify its pathogenesis as well as to 
test the efficacy and safety of new drugs for the development of novel therapeutic 
concepts. According to the Federal Ministry for Food, Agriculture and Consumer 
Protection, rodents (mainly mice and rats) have been the most commonly used 
mammalian laboratory animals in Germany with a percentage of about 95% in 
2011, followed by rabbits (3%) and pigs (0.6%) (BMELV 2013). Reasons for the 
predominant use of rodent animal models are the availability of strains with well-
defined genetic background adapted to a lot of important fields of medical 
research, early sexual maturity and short reproductive cycle, high cost 
effectiveness and the possibility of good experimental standardization (Bogue 
2003; Clee et al. 2007). However, the translation of scientific results gained from 
rodents in basic research to human clinical application is often difficult. In this 
context the use of the pig as a large animal model can help to close the gap 
between rodent and man by sharing a lot of anatomical, physiological and 
pathophysiological similarities with humans, especially with regard to diabetes 
research (Aigner et al. 2010; Douglas 1972; Larsen et al. 2004; Lunney 2007; 
Matsunari et al. 2009; Swindle et al. 2012). Porcine and human sequences of 
GLP-1 are highly conserved (Kieffer et al. 1999) and GIP amino acid sequence 
only distinguishes at residue 18 (human: histidine, porcine: arginine) and residue 
34 (human: asparagine, porcine: serine) (Moody et al. 1984). Structurally, porcine 
insulin differs from human insulin by one single amino acid at the C-terminal 
alanine, position 30 of the B-chain, and seems to have similar therapeutic efficacy 
in clinical use (Brogden et al. 1987; Heinemann et al. 1993; Richter et al. 2005). 
Despite some differences regarding pancreatic duct system both pig and human 
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pancreas show comparable size, anatomical orientation and localization as well as 
similar pancreatic blood supply (Ferrer et al. 2008; Murakami et al. 1997; Swindle 
1998; Swindle et al. 2012; Truty et al. 2008). In both species pancreatic endocrine 
cells are mainly located in the islets of Langerhans with some single cells or small 
cell clusters arranged in the exocrine pancreatic tissue (Jay et al. 1999; Wieczorek 
et al. 1998). Islet structure of pig and human shows differences regarding 
proportion of each type of endocrine cells. Although insulin-producing beta-cells 
are the main fraction of endocrine cells in both species, the amount of beta-cells in 
porcine islets (< 80%, depending on age) is higher than in human islets in situ (< 
50%). Accordingly human islets show a bigger percentage of non-beta-cells 
(mostly alpha-cells) (Cabrera et al. 2006; Dufrane et al. 2012). While pigs at the 
age of 5 weeks show diffuse islet structure containing beta-cells with small 
diameter, the development of larger cell clusters is visible as the age of the pigs 
increases. That is the reason why islet structure of older pigs is comparable to islet 
structure of adult humans (Jay et al. 1999). The number of islets in the whole 
pancreas seems to differ greatly between different pig breeds (Ulrichs 1995). As 
in humans, IAPP is expressed mainly in the beta-cells but has a changed sequence 
in the amyloidogenic domain (Betsholtz et al. 1989; Lukinius et al. 1996). 
Thereby dangerous accumulation of cytotoxic amyloid plaque accompanied by a 
progressive increase of beta-cell apoptosis rate does not occur in pigs (Clark et al. 
1988; Potter et al. 2010). Physiological blood glucose levels are comparable 
(human: 70-100 mg/dl, porcine: 70-115 mg/dl), with the exception of the minipig 
that shows lower values (Classen 2004; Kixmöller 2004; Kraft 2005; Larsen et al. 
2004; Larsen et al. 2001a; Plonait 1988; Waldmann 2001). For interpretation of 
glucose tolerance it is important to consider that pigs show less increase in plasma 
glucose during an oral glucose tolerance test and dispose an intravenous glucose 
load more efficiently than humans (Anderson 1973; Ferrannini et al. 1985; 
Hanawalt et al. 1947; Larsen et al. 2002a; Larsen et al. 2002b). The capacity for 
insulin secretion after stimulation with glucose in vivo is extensive and peripheral 
insulin concentrations show very rapid dynamics (Kjems et al. 2001; Larsen et al. 
2003). Both species show a slight deterioration in glucose tolerance with age, 
going along with higher glucose and insulin plasma levels (Broughton et al. 1991; 
Larsen et al. 2001a; Rosenthal et al. 1982). The morphology and the physiology of 
the porcine gastrointestinal system resemble those of humans with both species 
being omnivorous and thereby showing similar ingesta transit times, ion transport, 
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motility and digestive effectiveness (Miller et al. 1987; Swindle 1998). Pigs are a 
desirable model for testing new treatment strategies given subcutaneously. 
Composition, permeability, metabolic properties and sparse hair coat of porcine 
skin are comparable to man and enable similar percutaneous absorption rate, 
kinetics and dynamics of chemical compounds after injection (Benech-Kieffer et 
al. 2000; Bode et al. 2010; Sullivan et al. 2001; Swindle et al. 2012). 
4.2. Generation and characterization of GIPRdn transgenic pigs 
To clarify the role of a reduced function of GIP on metabolism and its role in the 
pathogenesis of type 2 diabetes genetically modified pigs were developed that 
express a GIPRdn in the pancreatic beta-cells (Renner et al. 2010). The GIPRdn 
differs from the endogenous GIPR by an eight amino acid deletion (amino acid 
position 319-326, nucleotide position 955-978) and two point mutations (amino 
acid position 340, nucleotide position 1018-1020) that further lead to an amino 
acid exchange from alanine to glutamate in the sequence of the third intracellular 
loop of the receptor. As it is known that this loop is especially important for signal 
transduction (Cypess et al. 1999; Harmar 2001; Salapatek et al. 1999) GIP can 
bind to the GIPRdn with almost equal affinity as it has to the endogenous GIPR, 
but the binding does not provoke any further biological functions (Herbach et al. 
2005). As a result of the competition between GIPRdn and endogenous GIPR for 
their ligand GIP a reduction of the insulinotropic action of GIP can be seen, but 
not a complete loss. Thereby the metabolic situation observed in type 2 diabetic 
patients is well imitated. GIPRdn transgenic pigs were created by a highly efficient 
gene transfer technology based on lentiviral vectors that in this case consisted of 
the complementary DNA of the human GIPRdn under the control of the rat insulin 
2 (Ins 2) gene promoter (RIP2) (Hofmann et al. 2003; Renner et al. 2010). Vectors 
were injected into the perivitelline space of pig zygotes and subsequently embryos 
were laparoscopically transferred to cycle synchronized recipient gilts. After birth 
pigs were genotyped using polymerase chain reaction (PCR) and Southern blot. 
Expression of GIPRdn mRNA was successfully proven in isolated pancreatic islets 
using real-time PCR. Transgenic offspring was established by mating male 
founder boars to wild-type sows. During the characterization of this pig model it 
was shown that GIPRdn transgenic pigs develop normally and do not show a 
clinically overt diabetes mellitus, at least throughout an evaluation period of 24 
months, indicated by normal blood glucose and fructosamine levels (Renner et al. 
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2010). In contrast, the also well characterized GIPRdn  transgenic mouse model 
shows a severe diabetic phenotype just before weaning going along with 
glucosuria, elevated serum glucose levels, reduced insulin levels and increased 
glucagon concentration (Herbach et al. 2005). However, different physiological 
tests and quantitative-stereological analyses in the GIPRdn transgenic pig model 
showed distinct modifications in comparison to non-transgenic control groups: 
Stimulation tests with GIP and exendin-4, a potent GLP-1R agonist, showed that 
the insulinotropic effect of intravenously administered GIP was blunted, whereas 
GLP-1R agonist exendin-4 elicited significantly higher serum insulin levels in 
GIPRdn transgenic pigs than in wild-type controls. This proves that GLP-1R 
function is, in comparison to GIPR function, undisturbed and even compensatory 
hyperactive in this animal model (Renner et al. 2010). Immunohistochemical 
staining of GIPR and GLP-1R showed that there is no distinct difference in 
expression levels and spatial distribution of the receptors between transgenic and 
wild-type control pigs. Glucose tolerance tests provided more information 
regarding glucose homeostasis and insulin secretion. During an oral glucose 
tolerance test GIPRdn transgenic pigs at the age of 11 weeks showed clearly higher 
blood glucose level as well as delayed insulin secretion while total insulin release 
was unchanged. At 5 months of age oral glucose tolerance was already disturbed 
due to a significant decreased insulin secretion (Figure 2). Intravenous glucose 
tolerance tests showed no abnormalities in 11-week-old transgenic pigs, but an 
ongoing deterioration regarding intravenous glucose tolerance and insulin 













Figure 1: Intravenous glucose tolerance observed during the 
characterization of the GIPRdn transgenic pig model 
Unchanged intravenous glucose tolerance (A) and insulin secretion (B) in GIPRdn 
transgenic pigs (tg) at the age of 11 weeks; tendency of higher blood glucose (C) 
and reduced insulin secretion (D) at the age of 5 months; significantly disturbed 
intravenous glucose tolerance (E) and reduced insulin secretion (F) at the age of 
11 months compared to wild-type controls (wt); 0 minutes = point of glucose 
administration; n: number of animals investigated. Data are means ± SEM; *: 
p<0.05 vs. control, **: p<0.01 vs. control, ***: p<0.001 vs. control. (Published in 
Renner et al., 2010, Copyright 2010 American Diabetes Association, From 
Diabetes®, Vol. 59, 2010, 1228-1238, reprinted with permission from The 
American Diabetes Association) 




Figure 2: Oral glucose tolerance observed during the characterization of 
the GIPRdn transgenic pig model 
Disturbed oral glucose tolerance in GIPRdn transgenic pigs (tg) at the age of 11 
weeks (A) and 5 months (C) going along with delayed insulin secretion (B) and 
reduced insulin secretion (D) compared to wild-type controls (wt); 0 minutes = 
point of glucose administration; n = number of animals investigated. Data are 
means ± SEM; *: p<0.05 vs. control, **: p<0.01 vs. controls, ***: p<0.001 vs. 
controls. (Published in Renner et al., 2010, Copyright 2010 American Diabetes 
Association, From Diabetes®, Vol. 59, 2010, 1228-1238, reprinted with 
permission from The American Diabetes Association) 
 
These findings suggested the idea that an expression of the GIPRdn could cause a 
general disturbance of insulin secretion and/or changes in structure and integrity 
of pancreatic islets of Langerhans with increasing age. This suspicion was 
confirmed by the result of quantitative-stereological analyses of the pancreata. 
The total beta-cell volume was significantly decreased in 5-month-old GIPRdn 
transgenic pigs (35% reduction) and even more in 1 to 1.4-year-old animals (60% 
reduction) (Figure 3). Expression of the GIPRdn also led to a significant reduction 
II. Review of the literature     34 
of beta-cell proliferation rate in 11-week-old pigs that was no longer visible in 
older transgenic pigs, and a tendency of higher beta-cell apoptosis rate in 1 to 1.4-
year-old transgenic animals. These results show for the first time in a large animal 
model that GIP plays an important role in the physiological development and 




Figure 3: Beta-cell volume of GIPRdn transgenic pigs at different age 
(A) Unchanged beta-cell volume in 11-week-old GIPRdn transgenic pigs (tg), but 
(B, C) reduced beta-cell volume in 5-month-old and 1-1.4-year-old GIPRdn 
transgenic pigs compared to non-transgenic control wild-type pigs (wt). Data are 
means ± SEM; n = number of animals investigated; *: p<0.05 vs. control, **: 
p<0.01vs. control. (Published in Renner et al., 2010, Copyright 2010 American 
Diabetes Association, From Diabetes®, Vol. 59, 2010, 1228-1238, reprinted with 
permission from The American Diabetes Association) 
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Taken together, GIPRdn transgenic pigs show reduced insulinotropic action of 
GIP, decreased glucose tolerance and insulin secretion as well as a progressive 
age-related reduction of beta-cell volume. Thereby this interesting pig model 
reflects important aspects of prediabetes seen in type 2 diabetic patients and offers 
manifold options for translational diabetes research like for example the 
evaluation of new treatment strategies for type 2 diabetes (Renner et al. 2010). 
Thus, the GIPRdn transgenic pig model was used in the present study for the 
evaluation of the effects of the GLP-1R agonist liraglutide on glycemic control, 
growth, food intake and especially on the total beta-cell volume. 
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III. RESEARCH DESIGN 
The present study was designed to evaluate the effects of the GLP-1R agonist 
liraglutide on glucose control, food intake, growth and especially on the total beta-
cell volume of GIPRdn transgenic pigs. Overall twenty-nine GIPRdn transgenic 
pigs were randomly chosen by lot to be either treated with liraglutide or 0.9% 
sodium chloride as placebo, injected subcutaneously for 90 days once daily. 
During this treatment period the animals had access to an ad libitum chow. 
Liraglutide dosages in the range of 0.6 mg to 1.8 mg were used based on the 
recommended human dosages and pig body weight. Food intake, weight gain as 
well as the health status were monitored on a regular basis and levels of 
somatostatin and components of the insulin-like growth factor (IGF) system were 
determined prior to and after the treatment period. Additionally, metabolic tests 
including intravenous and oral glucose tolerance tests were carried out prior to the 
therapy and at the end to evaluate changes in glucose control. After the final post-
treatment metabolic tests GIPRdn transgenic pigs were euthanized, pancreata were 
harvested, systematically sampled and quantitative-stereological analyses were 
carried out for the determination of the total beta-cell volume. Two different age 
groups of GIPRdn transgenic pigs were investigated in this study: 
Prophylactic group: This group (n=18) consisted of GIPRdn transgenic pigs that 
were either treated with liraglutide (n=9; 5 female, 4 male) or placebo (n=9; 5 
female, 4 male) from 2 months until 5 months of age. It is known from previous 
studies that GIPRdn transgenic pigs around the age of 2 months show undisturbed 
intravenous, but disturbed oral glucose tolerance. Although beta-cell volume is 
unaltered at an age of 2 months, it will be reduced about 35% at the time these 
pigs are 5 months of age, going along with deterioration in oral glucose tolerance 
and delayed insulin secretion during intravenous glucose tolerance test (Renner et 
al. 2010). The aim of this study part was to evaluate in what way a therapy of 
GIPRdn transgenic pigs with liraglutide influences metabolic status, glucose 
homeostasis and especially if it is able to cause a retardation of the forthcoming 
reduction of the total beta-cell volume or if it can even prophylactically prevent it 
in comparison to placebo-treated GIPRdn transgenic pigs. 
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Therapeutic group: GIPRdn transgenic pigs in this group (n=11) were treated 
with liraglutide (n=5, 3 female, 2 male) or placebo (n=6, 3 female, 3 male) from 5 
months until 8 months of age. At 5 months of age GIPRdn transgenic pigs 
normally show a clear reduction of their total beta-cell volume of about 35% that 
even deteriorates with age to a reduction of 60% at the age of about one year, 
associated with disturbed oral and intravenous glucose tolerance (Renner et al. 
2010). Beside effects on metabolic status and glucose homeostasis, this study part 
should show if a therapy of GIPRdn transgenic pigs with liraglutide can prevent or 
slow down the progressive reduction of beta-cell volume or even restores beta-






Figure 4: Study outline of liraglutide treatment trial 
Overview of general research design with two determined age groups (trial 1: 
prophylactic group, trial 2: therapeutic group) and liraglutide dosage regimen; n = 
number of animals investigated; mo = months of age; GTT = glucose tolerance 
test; mg = milligram. 
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IV. ANIMALS, MATERIALS AND METHODS 
1. Animals 
Animals included in this study were hemizygous male and female transgenic pigs 
expressing a dominant-negative GIP receptor. During the whole treatment period 
pigs were housed in planar single pens covered with straw and had ad libitum 
access to water and a commercial diet (Table 1). Careful training before treatment 
and experimental tests ensured the work with conscious animals. All animal 
experiments were approved by the responsible animal welfare authority 
(Regierung von Oberbayern, Munich; AZ-55.2-1-54-2532-43-11). 
Table 1: Diet composition 
Diets were produced by Zimmerer-Werk, Landshut, Germany 
	   Ferkelstarter	  UNI	  
(piglets	  up	  to	  25	  kg)	  
Zuchtschwein	  
Getreidemischung	  UNI	  
(growing	  and	  adult	  pigs)	  
MJ	  ME/kg	   13.1	   10.9	  
Crude	  protein	  %	   17.5	   13.6	  
Crude	  fat	  %	   2.9	   3.2	  
Crude	  ash	  %	   5.3	   5.9	  
Crude	  fiber	  %	   3.5	   7.9	  
Calcium	  %	   0.7	   0.9	  
Phosphorus	  %	   0.6	   0.6	  
Sodium	  %	   0.2	   0.2	  
Magnesium	  %	   0.2	   0.3	  




Accu-jet® pro pipette controller   Brand, Wertheim 
Agarose gel electrophoresis chamber  OWL Inc., USA 
Analytic balance     Sartorius, Göttingen 
Analytic balance MS 100    Schippers GmbH, Kerken 
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Animal balance Fstar 125 Meier-Brakenberg GmbH, 
 Exertal 
AU 400 autoanalyzer     Olympus, Hamburg 
Benchtop 96 tube working rack   Stratagene, USA 
BX41 light microscope    Olympus, Hamburg 
Celltek® blood cell counter    Bayer Diagnostics, Fernwalde 
DP72 video camera     Olympus, Hamburg 
Gel documentation system    Bio Rad, Munich 
HM 315 microtome     Microm, Walldorf 
Incubator 37°C     Wagner + Munz, Munich 
Incubator 60°C     Memmert, Schwabach 
Inhalation anaesthesia device K1   Koch KG, Bad Ems 
Hitachi 911® autoanalyzer    Boehringer, Ingelheim 
LB 2111 γ-counter     Berthold, Bad Wildbad 
Object micrometer     Zeiss, Oberkochen 
Mastercycler® gradient    Eppendorf, Hamburg 
Multipipette® plus     Eppendorf, Hamburg 
MS1 minishaker vortexer    IKA®-Werke GmbH, Staufen 
Pipettes (1000 µl, 200 µl, 100 µl, 10 µl, 2 µl) Gilson Inc., USA 
Power Pac 300 gel electrophoresis unit  Bio Rad, Munich 
Shandon Citadel tissue processor 1000  Thermo Fisher Scientific, 
Schwerte 
Sony video graphic printer UP-895CE  Sony, USA 
TBS 88 paraffine embedding system   Medite, Burgdorf 
Tru Trak® 3900P pulse oximeter   Datex-Ohmeda, Finland 
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Centrifuges: 
Eppendorf Centrifuge 5430 R   Eppendorf, Hamburg 
Eppendorf Centrifuge 5810 R   Eppendorf, Hamburg 
Heraeus Sepatech Megafuge 1.0R   Heraeus, Munich 
Rotanta 460R      Hettich, Tuttlingen 
2.2. Consumables 
Adhesive tape      Tesa SE, Hamburg 
Adhesive tissue tape  Henry Schein® Vet GmbH, 
Hamburg 
Aluminium spray     CP – Pharma, Burgdorf 
BD Micro-Fine UltraTM pen needles   Becton Dickinson GmbH, 
(0.33 x 12.7 mm; 29 G)    Heidelberg 
Cavafix® Certo® central venous catheter  B. Braun, Melsungen 
Combitips® plus (1 ml, 10 ml)   Eppendorf, Hamburg 
Cover slips (24x40 mm)  VWR International GmbH, 
Darmstadt 
Disposable shaver     Wilkinson GmbH, Solingen 
Disposable syringes (2, 5, 10, 20 ml)  Henry Schein® Vet GmbH,  
       Hamburg 
Disposable tubes for γ-counter   Sarstedt, Nümbrecht 
Falcon® Centrifuge tubes (15 ml)   Becton Dickinson, Heidelberg 
Gazin® gauze swab     Lohmann + Rauscher,  
       Neuwied 
Glass cuvettes with rack insert   VWR GmbH, Darmstadt 
Hypodermic needles (18 G, 20 G)   Henry Schein® Vet GmbH, 
       Hamburg 
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Monovette® blood collection system   Sarstedt, Nümbrecht 
(Serum, EDTA) 
Omnican® 40 disposable insulin syringe  B. Braun, Melsungen 
OP-Cover (60 x 90 cm)    A. Albrecht, Aulendorf 
Parafilm® M  American Can Company, 
USA 
PCR reaction tubes (0.2 ml)    Braun, Wertheim 
Perfusor® cable (50 cm)    B. Braun, Melsungen 
Pipette tips      Eppendorf, Hamburg 
Pipette tips with filter     Axygen Inc., USA 
Safe-Lock reaction tubes (1.5 ml, 2 ml)  Eppendorf, Hamburg 
SafeGrip® latex gloves    SLG, Munich 
Scalpel blade sterile No.36    Medicon eG, Tuttlingen 
Sempermed® supreme latex OP gloves  Sempermed, USA 
Skin adhesive spray     A. Albrecht, Aulendorf 
3-way-stopcock Variostop®    Clinico GmbH, Bad Hersfeld 
Star Frost® microscope slides   Engelbrecht, Edermünde 
Surgicryl® suture material (USP 2-0)  SMI AG, Belgium 
Test tube peg wrack     Polylab, India 
TSK Supra sterile cannula (1.2 x 100 mm)  TSK, Japan 
Uni-Link embedding cassettes   Engelbrecht, Edermünde 
Vasofix® indwelling cannula (20 G, 22 G)  B. Braun, Melsungen 
Vasofix® mandrin (20 G, 22 G)   B. Braun, Melsungen 
2.3. Chemicals 
Comment: Chemicals were used in p.a. quality unless marked otherwise 
Acetic acid      Merck, Darmstadt 
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Agarose Universal     Bio Sell, Nürnberg  
Aprotinin (3.0 PEU/mg)    Roth, Karlsruhe 
Bromophenolblue     Roth, Karlsruhe 
DAB -3,3´diaminobenzidine tetrahydrochloride KemEnTec, Denmark 
Diprotin A      Sigma, Taufkirchen 
1.4-Dithiothreitol (DTT)    Biomol GmbH, Hamburg 
EDTA (Ethylenediaminetetraacetic acid)  Roth, Karlsruhe 
Ethanol      Roth, Karlsruhe 
Ethidiumbromide (1 mg/ml)    Merck KGaA, Darmstadt 
4% Formaldehyde     SAV LP, Flintsbach 
Glucose 50% solution    B. Braun, Melsungen 
Glycerol      Roth, Karlsruhe 
Hydrogen peroxide (30%)    NeoLab, Heidelberg 
Magnesium chloride     Merck, Darmstadt 
Magnesium chloride (25 mM)   Qiagen GmbH, Hilden 
Mayer´s Hemalum solution    Applichem GmbH, Darmstadt 
Rotipuran® benzyl alcohol    Roth, Karlsruhe 
Sodium chloride solution (0.9%)   B. Braun, Melsungen 
Sodium hydroxide (2 N)    Roth, Karlsruhe 
Tris-(hydroxymethyl)-aminomethane (TRIS) Roth, Karlsruhe 
Xylene      Applichem GmbH, Darmstadt 
2.4. Antibodies, drugs, enzymes, oligonucleotides 
2.4.1. Antibodies 
Primary antibody: 
Polyclonal guinea pig anti-porcine insulin  Dako Cytomation, Hamburg  
IV. Animals, materials and methods     43 
Secondary antibodies: 
AP-conjugated goat anti-guinea pig IgG  Southern Biotech, USA 
HRP-conjugated rabbit anti-guinea pig IgG  Dako Cytomation, Hamburg 
2.4.2. Drugs 
Azaperon (Stresnil®) Jansen Pharmaceutica,  
  Belgium   
Cefquinom (Cobactan® 2.5%)   Intervet, Unterschleißheim  
Embutramid, Mebezonium, Tetracain (T61®) Intervet, Unterschleißheim 
Heparin-Sodium (25,000 IU/5 ml)   B. Braun, Melsungen   
Isobar® Isoflurane     Intervet, Unterschleißheim 
Ketamine hydrochloride (Ursotamin®)  Serumwerke Bernburg 
       Bernburg 
Liraglutide (Victoza®)    Novo Nordisk, Denmark 
(6 mg/ml injection solution in pre-filled pen)   
Metamizol-Sodium (Vetalgin®)   Intervet, Unterschleißheim 
Meloxicam (Metacam®)    Boehringer Ingelheim, 
       Ingelheim 
Xylazine (Xylazin 2%)    WDT, Garbsen   
2.4.3. Enzymes 
Taq DNA Polymerase (5 U/ml)   Agrobiogen, Hilgertshausen 
2.4.4. Oligonucleotides 
RIP2 (sense):   5´-TAGTCGACCCCCAACCACTCCAAGTGGAG-3´ 
RIP2 (antisense): 5´-TAGGATCCCTCGAGTCTAGAGTTAGGGCTG-3´ 
ACTB (sense):  5´-TGGACTTCGAGCAGAGATGG-3´ 
ACTB (antisense): 5´-CACCGTGTTGGCGTAGAGG-3´ 
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2.5. Buffers, media and solutions 
Water deionized in a Millipore machine (Easypure® II, pure Aqua, Schnaitsee) 
was used as solvent and termed aqua bidest. unless indicated otherwise. All 
buffers, media or solutions were stored at room temperature unless otherwise 
noted. 
2.5.1. Aprotinin dilution for liraglutide profiling 
100 mg Aprotinin (3 PEU/mg) 
Add 19.82 ml sodium chloride solution (0.9%) 
Add 180 µl benzylalcohol 
Vortexed, aliquoted, stored at -80°C 
2.5.2. Buffers, media and solutions for PCR and agarose gels 
2.5.2.1. dNTP-mix 
2 mM dATP, dCTP, dGTP, dTTP  
mixed in aqua bidest. and stored at -20°C in aliquots 
2.5.2.2. Loading dye for DNA (6x) 
10% glycerol in aqua bidest. 
1 spatula tip of bromophenolblue 
Add 0.5 M NaOH until color turns blue 
Aliquoted, stored at -20°C 
2.5.2.3. TAE buffer (50x) 
242 g Tris 
100 ml 0.5 M EDTA (ph 8.0) 
57 ml AcOH 
Add 1000 ml aqua bidest. 
Buffer was diluted to single concentration before use. 
IV. Animals, materials and methods     45 
2.5.3. Buffers, media and solutions for immunohistochemistry 
2.5.3.1. DAB solution 
1 DAB tablet was dissolved in 10 ml aqua bidest. for 45 minutes under light 
protection, filtered, aliquoted and stored at -20°C. 
2.5.3.2. TBS buffer for immunohistochemistry (10x) 
90 g NaCl 
60.5 g Tris 
Ad 1000 ml aqua bidest. 
Buffer was adjusted to pH 7.6, autoclaved and diluted to single concentration 
before use. 
2.5.3.3. 100 mM Tris HCl (pH 8.5) 
12.114 g Tris 
Ad 1000 ml aqua bidest. 
Adjusted to pH 8.5, autoclaved 
2.6. Kits 
NexttecTM Genomic DNA Isolation Kit  Nexttec GmbH, Leverkusen 
OCTEIATM IGF-I ELISA Kit   Immunodiagnostic Systems  
       (IDS) Inc., USA 
Porcine Insulin RIA Kit    Millipore, USA 
Somatostatin (Human, Rat, Mouse, Porcine) Phoenix Pharmaceuticals Inc., 
RIA kit      USA 
Vector® Red Substrate Kit (AP)   Biozol, Eching 
2.7. Other reagents 
dNTPs (dATP, dCTP, dGTP, dATP)  MBI Fermentas, St. Leon Roth 
Braunol® solution      B. Braun, Melsungen   
Gene RulerTM (1 kb DNA ladder)   MBI Fermentas, St. Leon Roth 
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Goat serum      MP Biomedicals, France 
Histokitt  Glaswarenfabrik Hecht, 
 Sondheim / Röhn 
Kodan® Tinktur Forte    Schülke + Mayr GmbH, 
       Norderstedt 
10 x PCR buffer     Qiagen GmbH, Hilden 
Porcine serum      MP Biomedicals, France 
Puc Mix Marker 8     MBI Fermentas, St. Leon Roth 
Rabbit serum      MP Biomedicals, France 
Q-Solution      Qiagen GmbH, Hilden 
2.8. Software 
Endnote® version X6     Reuters, USA   
Graph Pad Prism® version 5.02   GraphPad Software Inc., USA 
Olympus VisiomorphTM image analysis  Visiopharm, Denmark 
SAS version 8.2     SAS Institute Inc., USA 
SPSS version 21.0     IBM, USA 
3. Methods 
3.1. Genotyping polymerase chain reaction (PCR) 
3.1.1.  DNA isolation 
Ear punches were obtained from 2-day-old piglets and stored at -20°C until 
further processing. For isolation of genomic DNA a NexttecTM Genomic DNA 
Isolation Kit (Nexttec GmbH, Leverkusen) was used according to the 
manufacturer´s instruction. In brief, ear punches (ca. 5 mm in diameter) were 
minced and transferred to 1.5 ml reaction tubes containing the following lysis 
buffer: 
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Lysis buffer:  265 µl G1 
   10 µl   G2 
    25 µl   G3 
   3 µl     DTT 
Samples were incubated over night at 60°C. The next day 120 µl lysate was 
transferred to equilibrated NexttecTM clean columns, incubated for three minutes 
at room temperature and centrifuged at 700 x g for one minute. The eluate 
containing the purified DNA was either immediately used for further genotyping 
PCR or stored at 4°C until further processing. 
3.1.2. PCR conditions 
The following transgene-specific primers were used to identify the GIPRdn 
transgene: 
RIP2 (sense):   5´-TAGTCGACCCCCAACCACTCCAAGTGGAG-3´ 
RIP2 (antisense): 5´-TAGGATCCCTCGAGTCTAGAGTTAGGGCTG-3´ 
To proof DNA integrity PCR was also carried out using beta-actin (ACTB)-
specific primers as listed below. ACTB is a house-keeping gene coding for a 
component of the cytoskeleton in eukaryotic cells and is thereby ubiquitously 
expressed.  
ACTB (sense):  5´-TGGACTTCGAGCAGAGATGG-3´ 
ACTB (antisense): 5´-CACCGTGTTGGCGTAGAGG-3´ 
PCR components were prepared on ice in 0.2 ml reaction tubes. Ingredients of 







IV. Animals, materials and methods     48 
Table 2: Reaction batch for RIP2-hGIPRdn PCR 
RIP2-hGIPRdn 
Aqua bidest.    15.5 µl 
10 x PCR buffer (Qiagen)  2.5 µl 
MgCl2 (15 mM)   2.5 µl 
dNTPs (2 mM)   2.5 µl 
Primer sense (10 µM)  0.4 µl 
Primer antisense (10 µM)  0.4 µl 
Taq DNA Polymerase (5 U/µl) 0.2 µl 
DNA Template   1 µl 
Total volume    25 µl 
 
Table 3: Reaction conditions RIP2-hGIPRdn PCR 
RIP2-hGIPRdn PCR 
Denaturation    95°C   4 min 
Denaturation    95°C   30 sec 
Annealing    62°C   30 sec              35 x 
Elongation     72°C    45 sec 
Termination     4°C   15 min 
 
 
Table 4: Reaction batch for ACTB PCR 
ACTB 
Aqua bidest.    8.75 µl 
Q-solution (Qiagen)   4 µl 
10 x PCR buffer (Qiagen)  2 µl 
MgCl2 (25 mM)   1.25 µl 
dNTPs (2 mM)   2 µl 
Primer sense (10 µM)  0.4 µl 
Primer antisense (10 µM)  0.4 µl 
Taq DNA Polymerase (5 U/µl) 0.2 µl 
DNA Template   1 µl 
Total volume    20 µl 
 
Table 5: Reaction conditions ACTB PCR 
ACTB PCR 
Denaturation    95°C   4 min 
Denaturation    95°C   30 sec 
Annealing    58°C   30 sec               35 x 
Elongation     72°C    45 sec 
Termination     4°C   15 min 
 
Genomic DNA of an already genotyped piglet was used as positive control and 
DNA of a wild-type pig served as negative control. Additionally, aqua bidest. was 
utilized as non-template control. 
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3.1.3. Agarose gel electrophoresis 
During agarose gel electrophoresis amplified DNA strands were separated 
according to their length. A 2% agarose gel was produced by heating a mixture of 
Universal Agarose and 1x TAE buffer in the microwave until solution was clear. 
After cooling to 55°C ethidiumbromide (0.5 µg/ml) was added because it 
intercalates in DNA and thereby allows visualization under UV-light. Gel 
solidified in a gel electrophoresis chamber that was additionally filled with 
1 x TAE buffer. Amplified DNA samples from PCR were mixed with 2.5 µl DNA 
loading dye (10x) and pipetted into gel slots. A Gene RulerTM 1 kb DNA 
molecular weight standard as well as a puc Mix Marker 8 were used to determine 
fragment size. By connecting chamber to an electric circuit (130 volt) for the time 
of approximately 1 hour DNA fragments were separated and visualized under 
UV-light. 
3.2. Clinical and metabolic analyses during the liraglutide/placebo 
treatment period 
3.2.1. Accomplishment of liraglutide/placebo administration 
Treatment period started at 2 months (67 days) of age in the prophylactic group 
and at 5 months (147 days) of age in the therapeutic group. Either liraglutide or 
placebo was administered subcutaneously to GIPRdn transgenic pigs once daily 
between 8 and 9 a.m. for a period of 90 days. Afterwards therapy was carried on 
for one week during the time of the post-treatment glucose tolerance tests and 
liraglutide profiling until necropsy. For liraglutide administration a prefilled pen 
(Victoza®, 6 mg/ml) was used. An equal volume of sodium chloride solution 
(0.9%) was filled in disposable insulin syringes and was subcutaneously injected 
as placebo. Victoza® pens and prepared placebo syringes were stored at 4°C until 
use. The lateral neck region behind the ear was chosen as injection site. Based on 
the recommended human dosage and pig body weight the following dose regimen 
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Table 6: Liraglutide/Placebo dose regimen 
Prophylactic group (n=18)  Liraglutide (n=9)  Placebo (n=9) 
Day of therapy 1-30   0.6 mg (100 µl)  100 µl 
Day of therapy 31-90  1.2 mg (200 µl)  200 µl 
Therapeutic group (n=11)   Liraglutide (n=5)  Placebo (n=6) 
Day of therapy 1-16   0.6 mg (100 µl)  100 µl 
Day of therapy 17-60  1.2 mg (200 µl)  200 µl 
Day of therapy 61-90  1.8 mg (300 µl)  300 µl 
 
3.2.2. Monitoring of body weight, food intake as well as clinical-chemical 
parameters 
Body weight of all GIPRdn transgenic pigs included in the study was measured to 
the nearest 0.5 kg once weekly using a standard large animal scale. Weighing was 
started during the pre-treatment period at an age of 32 days in the prophylactic 
group and at an age of 50 days in the therapeutic group and continued during the 
whole treatment period. To ensure an ad libitum food intake feeding devices were 
used that were continuously backfilled when necessary. During the treatment 
period food intake was determined every third day in the prophylactic group and 
once a week in the therapeutic group. Spilled food was collected daily, weighed 
and subtracted from food intake. Total body weight gain during the 90-day 
therapeutic period was divided by entire food intake to receive an index named 
feeding efficiency. Every pig included in the study was monitored daily by 
general examination for side effects like obvious signs of nausea, vomiting, 
diarrhea or obstipation. Additionally, blood samples were taken prior to the 
treatment period and subsequently once a month for evaluation of clinical-
chemical parameters. Therefore pigs were fixed with a restraining device after an 
18-hour overnight fasting period and blood was taken by puncture of the right 
Vena jugularis externa. Blood samples (serum, EDTA-plasma) were immediately 
stored on ice and centrifuged (1,500 x g, 15 min, 4°C). Supernatant was carefully 
separated and aliquoted. Serum parameters (glucose, bilirubin, urea, creatinine, 
total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, iron, 
magnesium, aspartate aminotransferase (AST), γ-glutamyltransferase (γGT), 
alkaline phosphatase (AP)) were determined using Autoanalyzer Hitachi 911® and 
adapted reagents from Roche Diagnostics GmbH, Unterhaching. Leucograms 
were compiled from EDTA-plasma samples using the fully automated blood cell 
counter Celltek®. 
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3.2.3. Determination of growth-regulating polypeptides 
3.2.3.1. Determination of plasma somatostatin levels by radioimmunoassay 
Somatostatin levels were determined in EDTA-plasma samples of liraglutide-
(n=4) and placebo-treated (n=4) GIPRdn transgenic  pigs from the prophylactic and 
the therapeutic group respectively, taken before the start and at the end of the 
treatment period, using a commercial somatostatin RIA kit (Phoenix 
Pharmaceuticals, Burlingame, USA). This assay is based on the competition 
between a radioactive-labeled somatostatin peptide and the not-labeled 
somatostatin peptide in the plasma sample for binding sites at a limited quantity of 
antibodies in each reaction mixture. As the concentration of somatostatin in the 
unknown sample increases, the amount of radioactive 125I-peptide able to bind to 
the antibody is decreased and vice versa. This was measured by separating 
antibody-bound from free radioactive tracer and counting the antibody-bound 
fraction in a γ-counter. Samples were measured in duplicates and only accepted 
with a coefficient of variance (CV) less than 10 %, otherwise measurement was 
repeated. Chemicals and buffers were diluted with aqua bidest. according to the 
manufacturer´s instructions. Using the provided somatostatin standard 
(12.8 µg/ml) eight serial dilutions were prepared for later set up of a standard 
curve. Tubes were labeled and filled according to the following assay flow chart: 
 
Table 7: Overview of somatostatin RIA assay set-up 
TC: total count tubes, NSB: non-specific binding tubes, Bo: reference/total 
binding tubes, AB: assay buffer, QC: quality control, SAB: somatostatin antibody 
Tube  AB  standard / QC / sample  SAB 
1, 2 (TC) ----   ----    ---- 
3, 4 (NSB) 200 µl   ----    ---- 
5, 6 (Bo) 100 µl   ----    100 µl 
7, 8  ----  100 µl of 10 pg/ml   100 µl 
9, 10  ----  100 µl of 20 pg/ml   100 µl 
11, 12  ----  100 µl of 40 pg/ml   100 µl  
13, 14  ----  100 µl of 80 pg/ml   100 µl 
15, 16  ----  100 µl of 160 pg/ml   100 µl    
17, 18  ----  100 µl of 320 pg/ml   100 µl    
19, 20  ----  100 µl of 640 pg/ml   100 µl    
21, 22  ----  100 µl of 1280 pg/ml   100 µl    
23, 24  ----  100 µl of QC    100 µl    
25-n  ----  100 µl of unknown sample    100 µl   
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After vortexing covered tubes were incubated for 20 hours at 4°C. Afterwards 50 
µl of 125I-tracer peptide were added to each sample, tubes were again vortexed, 
covered and incubated for 20 hours at 4°C. On day three, 100 µl of Goat Anti-
Rabbit IgG serum and 100 µl of Normal Rabbit Serum were added to each tube 
except total count tubes and after vortexing the mixture was incubated for 90 
minutes at room temperature. Subsequently 500 µl assay buffer were added, 
samples were centrifuged (1,900 x g, 30 min, 4°C), supernatant was carefully 
decanted and tubes stayed inverted for 45 seconds with the exception of the total 
count tubes. Remaining pellets were immediately measured for 1 minute in the γ-
counter. Prior to actual sample measurement linearity of concentrations was 
proven by sample dilution experiments. 
3.2.3.2. Determination of serum insulin-like growth factor binding protein-
2 and -3 (IGFBP-2 and -3) levels by Western ligand blot analysis 
Serum levels of IGFBP-2 and -3 were analyzed by quantitative Western ligand 
blotting as described before (Metzger et al. 2011) in cooperation with Dr. Andreas 
Hoeflich at the Leibniz Institute for Farm Animal Biology (FBN) in Dummerstorf, 
Germany. In brief, serum samples were diluted 1:3 with phosphate buffer (pH 7.4) 
and 1:2 with sample buffer containing 2% sodium dodecyl sulfate (SDS). Proteins 
were heat denatured for 5 minutes at 95°C and separated by SDS polyacrylamide 
gel electrophoresis. For quantitation diluted human recombinant IGFBPs were 
used as standards. After protein transfer to a polyvinyl fluoride membrane 
(Millipore, Schwalbach), blots were developed using a commercial Western 
ligand blotting kit containing biotinylated IGF-II and streptavidin-conjugated 
peroxidase (IBT, Binzwangen). IGFBPs were detected by the ECL Advance 
Western Blotting Detection kit (GE Healthcare, Freiburg) and a Kodak image 
station (Kodak, Berlin). Quantification of original IGFBP-2 and -3 levels was 
performed using the ImageQuant software package (Molecular Dynamics, USA). 
3.2.4. Determination of serum insulin-like growth factor-I (IGF-I) levels 
by enzyme linked immuno sorbent assay (ELISA) 
Serum IGF-I levels were kindly measured in cooperation with Dr. Maximilian 
Bielohuby at the Endocrine Research Unit, Medizinische Klinik und Poliklinik 
IV, LMU, Munich. A commercially available OCTEIATM Rat/Mouse IGF-I 
ELISA kit (Immunodiagnostic Systems (IDS) Inc., Boldon, UK) was used that has 
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been shown to also recognize porcine IGF-I (Tatara et al. 2007). As per 
manufacturer´s instruction, serum samples were pretreated with a release reagent 
and sample diluent to avoid interference from IGF-binding proteins. Accordingly, 
samples as well as kit controls were pipetted into slots of a microtiter plate coated 
with anti-IGF-I antibodies. Anti-rat IGF-I biotin conjugate was also given to slots 
and plate was allowed to incubate for 2 hours under constant shaking. After a 
washing step, Streptavidin-horseradish peroxidase conjugate was added and the 
plate was washed again after an incubation time of 30 minutes. Subsequently, 
tetramethylbenzidine was added as chromogen substrate. After 20 minutes 
incubation time the reaction was stopped by adding acidic stop solution. The IGF-
I concentration of the unknown samples was calculated by plotting the mean 
absorbance, measured at a wave length of 450 nm (reference wave length 
620 nm), of the unknown samples against the absorbance of a known calibration 
curve. The calibrators used in this assay were derived from human material and 
showed concentrations of 10, 22, 86, 261 and 892 ng/ml. 
3.3. Metabolic tests 
Metabolic tests included an intravenous glucose tolerance test (IVGTT) as well as 
an oral glucose tolerance test (OGTT). In the prophylactic as well as the 
therapeutic group these tests were performed prior to the liraglutide/placebo 
treatment and were repeated at the end of the treatment period. Every test was 
performed in freely moving animals in single pens after an 18-hour overnight 
fasting period. 
3.3.1. Surgical implantation of central venous catheters 
To ensure a stress-free frequent blood sampling in unrestrained animals during the 
glucose tolerance tests two central venous catheters were surgically inserted into 
the external jugular vein under general anesthesia. After a premedication of 
azaperone (0.5 ml per 10 kg body weight (BW) intra muscular (i.m.)) and 
ketamine hydrochloride (2 ml per 10 kg BW i.m.) anesthesia was initiated by 
inhalation of 5% isoflurane. After reaching the status of surgical tolerance 
anesthesia was maintained by an inhalation of 1% isoflurane. Metamizol (1 ml per 
10 kg BW) was administered through an indwelling venous catheter in the ear 
vein and meloxicam (0.2 ml per 10 kg BW) was given i.m. to assure peri- surgical 
analgesia. During surgery nasal septum as well as dew claws were regularly 
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stimulated to check the depth of anesthesia. Oxygen saturation and pulse rate were 
continuously monitored using a pulse oximeter. Animals were fixed in back 
position, hair was shaved around the neck and the surgical field was extensively 
cleaned and disinfected. A skin incision of about five centimeters length was 
made in the sulcus jugularis followed by careful preparation through 
subcutaneous tissue and cutaneous muscle. The external jugular vein was 
exposed, surrounding tissue was removed and two fixation sutures were set 
proximally and distally around the vein. After venotomy two central venous 
catheters were inserted 10 to 15 cm into the vein relative to pig size to reach the 
desired position near the heart base. A proximal ligature inhibited blood reflux 
and a distal ligature fixed catheters and saved them from slipping out of position. 
Subsequently, the operation wound was sutured in two layers. For further external 
fixation of the catheters they were attached with a single suture to the skin and 
covered with gauze swab and adhesive tape up to the ridge. Exterior catheter ends 
were connected to 3-way stopcocks and coiled in a pouch out of gauze to provide 
easy access for blood sampling (Figure 5). After surgery, cefquinom 2.5% was 
administered i.m. once daily for three days (2 ml per 25 kg BW) to prevent 
infections. Metamizol (1 ml per 10 kg BW) was administered intravenously to 
assure post-surgical analgesia. Both catheters were flushed once daily with 50 IU 
heparin/ml 0.9% isotonic sodium chloride solution. At the time of the metabolic 
tests all animals showed normal behavior and food intake, indicating full recovery 
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Figure 5: Surgical implantation of central venous catheters 
(A) Exposure of Vena jugularis externa, 
(B) Tensioning of the vein using two holding sutures 
(C) Placement of the first central venous catheter after venotomy 
(D) Placement of the second central venous catheter and fastening of the distal 
holding suture 
(E) Skin suture and external catheter fixation 
(F) Formed gauze pouch for easy access covered with adhesive tape 
 
(Pictures were kindly provided by Dr. Christiane Fehlings and Dr. Simone 
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3.3.2. Intravenous glucose tolerance test (IVGTT) 
After an 18-hour fasting period overnight a bolus injection of concentrated 50% 
glucose solution (0.5 g per kg BW) was administered as quickly as possible 
through one marked central venous catheter. The catheter was then cleared from 
residual glucose by flushing it with 20 ml of 0.9% isotonic NaCl solution. Blood 
samples were taken through the second catheter at -10, 0, 1, 3, 5, 7, 10, 15, 20, 30, 
40, 50, 60 and 90 minutes relative to the glucose load. Before obtaining each 
sample a small amount of blood was withdrawn through the catheter and 
discarded. After every blood collection the catheter was flushed with 3-4 ml of 
0.9% isotonic sodium chloride solution. Blood was drawn in EDTA monovettes 
and at once put on ice. After centrifugation (1,500 x g, 15 min, 4°C) and 
separation plasma was stored at -80°C until further processing. Plasma glucose 
levels were measured using an AU400 autoanalyzer (Olympus) and plasma 
insulin levels were determined in duplicate by a porcine insulin RIA kit 
(Millipore) as described in IV 3.3.4. 
3.3.3. Oral glucose tolerance test (OGTT) 
For OGTT pigs were offered a mixed meal consisting of 2 g glucose per kg BW 
(given as 50% glucose solution) mingled with commercial pig fodder (Deuka 
porfina U, for composition see Table 8) after an 18-hour fasting period. 
Table 8: Diet composition of Deuka porfina U 
Deuka porfina U 
MJ ME/kg    12.6 
Crude protein %  16.5 
Crude fat %   0.9 
Crude ash %    5.5 
Crude fiber %   6.0 
Calcium %   0.85 
Phosphorus %   0.55 
Sodium %   0.2 
 
The amount of chow used for the mixed meal was adapted to the amount of 
glucose solution dependent on body weight of the pigs. For the prophylactic group 
(treated from 2–5 months) 50 g pig fodder was used in the OGTT prior to the 
treatment and 200 g in the OGTT after the treatment. In the therapeutic group 
(treated from 5–8 months) 150 g chow was used in the pre-treatment OGTT and 
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300 g in the post-treatment OGTT. The mixed meal was given at time point 0 and 
was eaten from a bowl under supervision. Pigs had to eat the whole meal within 
15 minutes; otherwise the test was stopped and repeated one day later. Blood 
samples were taken at -10, 0, 15, 30, 45, 60, 90 and 120 minutes relative to the 
beginning of glucose feeding and further processed as explained in IV 3.3.2. 
3.3.4. Measurement of plasma insulin levels by radioimmunoassay 
Plasma insulin levels of samples taken during glucose tolerance tests were 
measured in duplicates using a porcine insulin RIA kit (Millipore) according to 
the manufacturer´s instructions. Like the RIA for somatostatin, this is a 
competitive radioimmunoassay and is based on the same principle (see IV 
3.2.3.1). With the help of six standard reaction mixtures it was possible to set up a 
standard curve with increasing concentrations of unlabeled antigen and from this 
curve the amount of antigen in the unknown samples could be calculated. Values 
were only accepted when the CV of duplicate measurements was less than 10%; 
otherwise the measurement was repeated. 
3.3.4.1. Standard preparation 
After 1.0 ml of assay buffer was added to six labeled tubes serial dilutions were 
prepared using the provided 200 µU/ml standard according to the following 
schedule: 
Table 9: Overview of standard preparation for insulin RIA 
Tube  Standard Concentration            Volume of Standard to add  
1   100 µU/ml   1.0 ml of 200 µU/ml  
2   50 µU/ml   1.0 ml of 100 µU/ml 
3   25 µU/ml   1.0 ml of 50 µU/ml  
4   12.5 µU/ml   1.0 ml of 25 µU/ml 
5   6.25 µU/ml   1.0 ml of 12.5 µU/ml 
6   3.125 µU/ml   1.0 ml of 6.25 µU/ml 
Standards were stored at -20°C. 
3.3.4.2. Assay set-up  
Samples were thawed, vortexed and centrifuged at full speed for 10 minutes at 
4°C. Disposable tubes for γ-counter were labeled and filled according to the 
following assay flow chart:  
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Table 10: Overview of insulin RIA assay set-up  
AB: assay buffer, QC: quality control, IT: insulin tracer, AB: insulin antibody, 
TC: total count tubes, NSB: non-specific binding tubes, Bo: reference / total 
binding tubes 
Tube  AB  Standard/QC/sample  125 I-IT  AB 
1, 2 (TC) ----   ----   50 µl  ---- 
3, 4 (NSB) 150 µl   ----   50 µl  ---- 
5, 6 (Bo) 100 µl   ----   50 µl  ---- 
7, 8  50 µl                   50 µl of 3.125 µU/ml 50 µl  50 µl  
9, 10  50 µl                   50 µl of 6.25 µU/ml 50 µl  50 µl  
11, 12  50 µl                   50 µl of 12.5 µU/ml 50 µl  50 µl  
13, 14  50 µl                   50 µl of 25 µU/ml  50 µl  50 µl  
15, 16  50 µl                   50 µl of 50 µU/ml  50 µl  50 µl 
17, 18  50 µl                   50 µl of 100 µU/ml 50 µl  50 µl  
19, 20  50 µl                   50 µl of 200 µU/ml 50 µl  50 µl  
21, 22  50 µl                   50 µl of QC 1  50 µl  50 µl 
23, 24  50 µl                   50 µl of QC 2  50 µl  50 µl 
25-n  50 µl                   50 µl of unknown sample 50 µl  50 µl  
 
Tubes were vortexed, covered with parafilm and incubated for 22 hours at 4°C. 
On day two 500 µl of cold precipitating reagent were added to every tube except 
total count tubes. Mixture was vortexed, incubated for 20 minutes at 4°C and 
centrifuged (2,700 x g, 30 min, 4°C). All tubes except total count tubes were at 
once inversed for 45 seconds to decant supernatant and excess liquid was blotted 
from lip of the tubes. The remaining pellet was counted in a γ-counter for one 
minute. 
3.3.5. Calculation of insulin sensitivity indices 
For assessment of insulin sensitivity in GIPRdn transgenic pigs prior to and after 
liraglutide/placebo therapy different insulin sensitivity/resistance indices were 
calculated. 
3.3.5.1. Homeostasis model assessment (HOMA) 
The index homeostasis model assessment (HOMA) was calculated according to 
Matthews et al. using fasting plasma glucose and insulin values to determine the 
degree of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) 
(Matthews et al. 1985). The following formula was used: 
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HOMA-IR = (I0 x G0) / 22.5 
HOMA-β = 20 * I0  / (G0 – 3.5) 
I0 =  Fasting plasma insulin (µU/ml) 
G0 = Fasting plasma glucose (mmol/l) 
3.3.5.2. Quantitative insulin sensitivity check index (QUICKI) 
This insulin sensitivity index proposed by Katz et al. was also calculated using 
fasting plasma glucose/insulin values (Katz et al. 2000). 
QUICKI = 1 / (log I0 + log G0) 
I0 =  Fasting plasma insulin (µU/ml) 
G0 = Fasting plasma glucose (mg/dl) 
3.3.5.3. Matsuda Index (ISI (Matsuda)) 
For this index not only fasting plasma glucose/insulin values but also mean values 
during OGTT (time points 0, 15, 30, 45, 60, 90, 120 minutes relative to glucose 
mixed meal) were used.(Matsuda et al. 1999). 
ISI(Matsuda) = 10000 / √(G0 * I0 * Gmean * Imean) 
I0 =  Fasting plasma insulin (µU/l) 
G0 = Fasting plasma glucose (mg/dl) 
Imean = mean plasma insulin concentration during OGTT (µU/l) 
Gmean = mean plasma glucose concentration during OGTT (mg/dl) 
3.4. Liraglutide profiling 
At the end of the 90-day treatment period plasma liraglutide levels were 
determined over a period of 16 hours. Therefore, all liraglutide-treated GIPRdn 
transgenic pigs from the prophylactic and the therapeutic group were investigated. 
During profiling pigs had access to an ad libitum chow and were not fasted. For 
blood collection central intravenous catheters were used that pigs still had from 
the post-treatment glucose tolerance tests (see IV 3.3.1). Before obtaining each 
sample a small amount of blood was withdrawn through the catheter and 
discarded. After every blood collection catheter was flushed with 3-4 ml 0.9% 
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isotonic sodium chloride solution. Animals of the prophylactic group received 
1.2 mg liraglutide, while pigs of the therapeutic group received 1.8 mg liraglutide. 
Victoza® was injected as usual into the lateral side of the neck at 8 a.m. One blood 
sample was taken prior to injection (t=0 minutes), thereby representing a value 
where the last liraglutide injection the day before was 24 hours ago. Subsequently 
blood samples were taken at 4, 8, 12 and 16 hours relative to the Victoza® 
injection. EDTA monovettes were prepared with DPP-4 inhibitor diprotin A 
(3 mM, 50 µl/ml blood sample) and protease inhibitor aprotinin (0.6 TIU/ml 
blood sample). After centrifugation (1,500 x g, 15 min, 4°C) plasma was 
separated, aliquoted and stored at -80°C until further processing. Plasma 
liraglutide levels were measured by Novo Nordisk A/S using an in-house 
luminescence oxygen channeling immunoassay validated for pig plasma. 
3.5. Morphological evaluation of GIPRdn transgenic pigs at the end of 
the treatment period 
3.5.1.  Necropsy 
Anesthesia was induced by intramuscular injection of ketamine hydrochloride 
(2 ml per 10 kg BW) and azaperone (0.5 ml per 10 kg BW) followed by insertion 
of an indwelling cannula into the ear vein. The animals were euthanized by 
intravenous injection of T61 (1 ml per 10 kg BW). During general pathologic 
examination pancreas, lung, heart, kidney, liver, spleen and stomach were 
weighed for further calculation of absolute and relative organ weights. 
3.5.2. Pancreas preparation and sampling 
The whole pancreas was taken out of the abdominal cavity as quick as possible 
after euthanasia of the animals. Fat tissue, connective tissue and vessels were 
removed and the organ was weighed. The pancreas was cut through between the 
lobus pancreatis sinister and the connective lobe to the lobus pancreatis dexter 
(Figure 6) and brought into straight position. For subsampling the length of the 
organ was determined and tissue slides of 0.5 cm thickness were cut out every 2.5 
cm over the whole pancreas and prefixed in 4% neutral buffered formalin for 8 
hours. Subsequently slides were turned to their left side and covered by a 1 cm2 
point-counting grip. Every point that encountered pancreatic tissue was marked, 
counted and the sum of hitting points was divided by the number 20 and called 
quotient Y. A random number X between one and quotient Y was chosen and 
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samples of about 1 cm2 were taken out of the tissue slides at position X, X+Y, 
X+2*Y, X+3*Y until X+20*Y. Excised samples were placed in an embedding 
cassette right cut surface downwards, fixed in 4% neutral buffered formalin 
overnight and further routinely processed for paraffin embedding. Sections of 
about 4 µm thickness were cut from every paraffin block using a HM 315 
microtome, put in aqua bidest., mounted on 3-aminopropyltriethoxy-silane-treated 










3.5.3. Immunohistochemical staining for insulin 
The indirect alkaline phosphatase (AP) method was used for the detection of 
insulin containing cells in paraffin sections of all pigs included in this study for 
further quantitative-stereological analyses. Pancreatic tissue sections on 
microscope slides (see IV 3.5.2) were deparaffinized in xylene for 15 minutes and 
rehydrated in descending alcohol concentrations (99%, 96%, 70% alcohol, aqua 
bidest.). Then sections were further processed as indicated in Table 11. 
 
 
Figure 6: Pancreas preparation for quantitative-stereological analyses 
Red arrow indicates the separation site between lobus pancreatis sinister and the 
connective lobe to the lobus pancreatis dexter. 
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Table 11: Flow chart of immunohistochemistry for evaluation of the beta-cell 
volume 
  Chemical      Incubation  
STEP 1 Hydrogen peroxide solution 1%   15 minutes 
STEP 2 TBS buffer       10 minutes 
STEP 3 Goat serum diluted 1:10 in TBS buffer  30 minutes 
STEP 4 Primary antibody diluted 1:1000 in TBS buffer 60 minutes 
  (Polyclonal guinea pig anti-porcine insulin) 
STEP 5 TBS buffer      10 minutes 
STEP 6 Secondary antibody diluted 1:100 in TBS buffer 60 minutes 
  (AP-conjugated goat anti-guinea pig IgG)     
  + 5% porcine serum 
STEP 7 TBS buffer      10 minutes 
STEP 8 Vector® Red chromogen diluted   20 minutes 
  in 100 mM Tris HCl (pH 8.5) 
STEP 9 Floating distilled water    5 minutes 
STEP 10 Mayer´s haemalum solution    10 seconds 
STEP 11 Floating distilled water    5 minutes 
 
 
Afterwards, slides were dehydrated in ascending alcohol concentrations (aqua 
bidest., 70%, 96%, 99% alcohol), cleared in xylene and mounted under cover slips 
using quick-hardening mounting medium histokitt. This method was used for all 
pancreatic tissue sections used for quantitative-stereological analyses. For nuclear 
profile counting sections were processed similarly using a slightly different flow 
chart as follows:  
Table 12: Flow chart of immunohistochemistry for nuclear profile count 
  Chemical      Incubation  
STEP 1 Hydrogen peroxide solution 1%   15 minutes 
STEP 2 TBS buffer      10 minutes 
STEP 3 Rabbit serum diluted 1:10 in TBS buffer  30 minutes 
STEP 4 Primary antibody diluted 1:1000 in TBS buffer 60 minutes 
  (Polyclonal guinea pig anti-porcine insulin) 
STEP 5 TBS buffer      10 minutes 
STEP 6 Secondary antibody diluted 1:50 in TBS buffer 60 minutes 
  (HRP-conjugated rabbit anti-guinea pig IgG) 
   + 5% porcine serum 
STEP 7 TBS buffer      10 minutes 
STEP 8 DAB chromogen activated with 1 µl   3 minutes 
  30% hydrogen peroxide solution per 1 ml 
STEP 9 Floating distilled water    5 minutes 
STEP 10 Mayer´s haemalum solution    4 minutes 
STEP 11 Floating distilled water    5 minutes 
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3.5.4. Quantitative-stereological analyses of pancreata 
During pancreas sampling 20 tissue specimens were obtained from each animal 
included in the study and immunostained for insulin using Vector® Red as 
chromogen (see IV 3.5.3). Quantitative-stereological analyses were carried out 
using the computer-assisted Olympus VisiomorphTM image analysis system 
coupled to a light microscope and a color video camera. In 50% of every tissue 
slide area of insulin-positive cells as well as of total pancreatic area was 
determined in 400 x final magnification on a color monitor displaying images of 
stained samples with the help of the semiautomatic stereological software 
VisiomorphTM. This software can differentiate between colors and thereby 
measured areas of red stained insulin-positive beta cells and additionally of the 
blue casted surrounding pancreatic tissue. Isolated beta-cells were not manually 
counted; they were also recognized by the system by definition of insulin-positive 
red stained cells covering an area smaller than 250 µm2. Total beta-cell areas and 
total pancreatic section areas on every slide of one pig where summed up and 
named A (isoβ-cell,50%), A (β-cell,50%) and A (Pan,50%), whereas total area of isolated beta-
cells was also included into A (β-cell,50%), and area of A (β-cell,50%) was also included 
into A (Pan,50%). To avoid impreciseness due to tissue shrink during histological 
processing, total pancreas volume (V (Pan)) before paraffin embedding was 
calculated by the quotient of pancreas weight at necropsy (W (Pan)) and the specific 
weight of the pig pancreas (sp. W (Pan), 1.07 g/cm3). This specific weight was 
determined by the submersion method in which a displacement of isotonic 
hydroxide solution caused by the pancreas volume was investigated by weighing 
(Scherle 1970). V (Pan) as well as pancreatic volume density of beta-cells (Vv (β-
cells/Pan)) and isolated beta-cells (Vv (isoβ-cell/Pan)) as well as pancreatic total beta-cell 
volume (V (β-cell,Pan)) and isolated beta-cell volume (V (isoβ-cell,Pan)) were computed 
according to the following formulae: 
V (Pan) = W (Pan) / sp. W (Pan) 
Vv (β-cell/Pan) = A (β-cell,50%) / A (Pan,50%) 
V (β-cell,Pan) = Vv (β-cells/Pan) * V (Pan) 
Vv (isoβ-cell/Pan) = A (isoβ-cell,50%) / A (Pan,50%) 
V (isoβ-cell,Pan) = Vv (isoβ-cells/Pan) * V (Pan) 
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Total beta-cell volume referred to body weight (V (β-cell,Pan) / BW) was calculated 
by dividing the total beta-cell volume (V (β-cell,Pan)) by the individual body weight 
of the pigs at the day of necropsy. Images were taken from representative tissue 
slides of each animal group and treatment type under equal conditions. For 
illustration of dimensions an object micrometer was photographed in the same 
magnification as slides to design accurate scale bars. 
3.5.5. Counting of nuclear profiles 
Within the prophylactic group, 4 liraglutide-treated and 4 placebo-treated animals 
were randomly chosen for nuclear profile counting within a defined insulin-
positive stained area. From each animal 4 tissue slides also used for the evaluation 
of beta-cell volume were randomly selected, stained for insulin using DAB as 
chromogen and additionally with haemalum for a strong nuclei staining (see 
3.5.3) and randomly sampled until 25 islets per slide were detected. Thus, in total 
100 islets per animal were evaluated. Per islet the insulin-positive stained area 
was measured at 400 x final magnification using the semiautomatic stereological 
software VisiomorphTM and within this area nuclear profiles were manually 
counted. The nuclear profile count was expressed as the number of nuclear 
profiles per insulin-positive stained area of 105 µm2. 
3.6. Statistics 
All data are presented as means ± standard error of means (SEM). The results of 
oral and intravenous glucose tolerance tests were statistically evaluated by 
analysis of variance (Linear Mixed Models; SAS 8.2) taking the fixed effects of 
Group (liraglutide/placebo-treated), Time (relative to glucose administration), 
interaction of Group*Time as well as random effect of animal into account. The 
same analysis of variance was used for the evaluation of body weight and food 
intake taking the fixed effects of Group (liraglutide/placebo-treated), duration of 
treatment/Age and the interaction Group*duration of treatment/Age into account. 
Statistical differences regarding clinical-chemical parameters were evaluated by 
analysis of variance (General Linear Models; SAS 8.2) taking the fixed effects of 
Group (liraglutide/placebo-treated), Age (before/during different time points of 
the treatment period) and the interaction Group*Age into account. Absolute and 
relative organ weights were statistically evaluated by analysis of variance 
(General Linear Model, SPSS 21.0) taking the fixed effect of Group 
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(liraglutide/placebo-treated) into account. Statistical significance between 
liraglutide- and placebo-treated GIPRdn transgenic pigs regarding quantitative-
stereological analyses, nuclear profile counting as well as ratios of somatostatin, 
IGF-I, IGFBP-2 and -3 were evaluated by Mann-Whitney-U test in combination 
with an exact test procedure (SPSS 21.0). Areas under the curve for insulin and 
glucose were created using Graph Pad Prism® software (version 5.02) and 
statistical significance between liraglutide- and placebo-treated GIPRdn transgenic 
pigs was also evaluated by Mann-Whitney-U test in combination with an exact 
test procedure (SPSS 21.0). P values less than 0.05 were considered to be 
significant. 
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V. RESULTS 
1. Genotyping of GIPRdn transgenic pigs by PCR 
Pigs used in this study were hemizygous F4-generation GIPRdn transgenic pigs. 
They were bred by naturally mating one GIPRdn transgenic boar to overall 8 non-
transgenic sows. Altogether, 82 piglets were born of which 43 were identified as 
transgenic by evaluation of isolated DNA from ear punches using PCR. PCR of 
DNA samples from GIPRdn transgenic pigs resulted in a 720-bp RIP2-specific 
band, while there was no band visible in DNA of non-transgenic littermates. To 
avoid false-negative results DNA integrity was proven by simultaneous PCR 
using ACTB-specific primers, resulting in a band of 331 bp if the DNA sample 
was intact (Figure 7). Among the GIPRdn transgenic animals, 18 pigs were 
included in the prophylactic group and 11 pigs in the therapeutic group. 
Figure 7:  Genotyping of GIPRdn transgenic pigs and non-transgenic 
littermates by PCR analysis 
(A) Specific PCR analysis for GIPRdn transgene using RIP2 primers; (B) Control 
of DNA integrity using ACTB primers; (A/B) tg: GIPRdn transgenic pig; wt: non-
transgenic littermate; +: genomic DNA of already genotyped GIPRdn transgenic 
pig as positive control; wt -: genomic DNA of non-transgenic pig as negative 
control; -: aqua bidest. as non-template control; M1: puc Mix Marker 8; M2: 
Gene rulerTM 1 kb DNA ladder. 
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2. Plasma liraglutide levels in GIPRdn transgenic pigs  
To determine the amount of subcutaneously injected liraglutide that is actually 
arriving in the blood, liraglutide plasma levels were evaluated by Novo Nordisk 
A/S, Denmark at the end of the treatment period, using an in-house luminescence 
oxygen channeling immunoassay. All GIPRdn transgenic pigs from both groups 
that were treated with liraglutide were included (prophylactic group: n=9, 
therapeutic group: n=5). While the course of liraglutide levels in the therapeutic 
group was similar, 3 out of 9 pigs included in the prophylactic group showed 
distinctly lower liraglutide levels than the remaining six pigs. This was not 
correlated with the body weight of the animals. Right before administration of 1.2 
mg liraglutide at time point 0 minutes the prophylactic group showed mean steady 
state concentration of 24,522.2 ± 1,332.3 pmol/l (mean ± SEM) while pigs of the 
therapeutic group that got the last subcutaneous injection of 1.8 mg liraglutide 24 
hours ago exhibited mean concentrations of 29,820 ± 2,069.88 pmol/l. Within the 
5 defined time-points where blood samples were taken the highest plasma 
liraglutide levels were determined in both groups 8 hours after dosing with the 
therapeutic group showing 52,260 ± 2,163.24 pmol/l and the prophylactic group 
showing 43,233.3 ± 2,959.35 pmol/l. During the whole profile both groups 
showed relatively constant plasma liraglutide levels with the therapeutic group 
revealing between 11-18% higher concentrations compared to the prophylactic 
































Figure 8: Individual and mean liraglutide plasma levels in GIPRdn 
transgenic pigs 
Individual curves of each liraglutide-treated GIPRdn transgenic pig included in 
the prophylactic (A) or therapeutic (B) group and mean plasma liraglutide 
concentrations (C) in the prophylactic (red) and therapeutic (orange) group; 0 
hours = point of liraglutide administration; n = number of animals investigated. 
Data are means ± SEM. 
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3. Monitoring of clinical, metabolic and clinical-chemical 
parameters during liraglutide therapy 
3.1. Clinical-chemical parameters and unchanged health status in 
liraglutide-treated GIPRdn transgenic pigs 
During the treatment period GIPRdn transgenic pigs of the prophylactic and the 
therapeutic group were regularly examined. At all times animals showed normal 
behavior and undisturbed general condition, even when being treated with the 
maximum dosage of liraglutide recommended for the treatment of human patients 
(1.8 mg per day). Adverse effects including gastrointestinal symptoms like 
vomiting, obstipation, diarrhea or noticeable signs of nausea were not obvious. To 
further check health status blood samples were taken from all animals after an 18-
hour fasting period before the beginning of the treatment (prophylactic group: 8 
weeks of age, therapeutic group: 20 weeks of age) and subsequently every four 
weeks until the end of the treatment period. Significant differences between the 
different time points of blood sampling were frequently seen, independent of the 
treatment type of the pigs, indicating changes of these parameters with age and 
growth. Most clinical-chemical parameters including leucocytes, bilirubin, urea, 
sodium, potassium, chloride, magnesium, AST and µGT did not significantly 
differ between liraglutide- and placebo-treated GIPRdn transgenic pigs 
(Table 13+14). This is also true for serum blood glucose that stayed in 
normoglycemic ranges (70-115 mg/dl) (Kraft 2005; Plonait 1988; Waldmann 
2001) during the whole treatment period in liraglutide-treated as well as in 
placebo-treated GIPRdn transgenic pigs. However, total protein, albumin as well 
as phosphorus were significantly lower in liraglutide-treated compared to placebo-
treated GIPRdn transgenic pigs in both groups. Furthermore, liraglutide-treated 
animals of the therapeutic group showed significant lower levels of creatinine, 
calcium and iron compared to placebo-treated pigs. Within the prophylactic group 
a significant increase of AP was detected in liraglutide-treated GIPRdn transgenic 
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Table 13: Clinical-chemical parameters in GIPRdn transgenic pigs of the 
prophylactic group 
Clinical-chemical parameters in liraglutide- (L, n=9) and placebo-treated (P, n=9)   
GIPRdn transgenic pigs of the prophylactic group prior to (8 weeks of age) and 
during the treatment period. 
 




Table 14: Clinical-chemical parameters in GIPRdn transgenic pigs of the 
therapeutic group 
Clinical-chemical parameters in liraglutide- (L, n=5) and placebo-treated (P, n=6) 
GIPRdn transgenic pigs of the therapeutic group prior to (20 weeks of age) and 
during the treatment period. 
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3.2. Reduced food intake and feeding efficiency in liraglutide-treated 
GIPRdn transgenic pigs 
Food intake was determined every third day (prophylactic group) or every week 
(therapeutic group) during the whole treatment period. In this time animals had 
constantly access to an ad libitum chow. Generally, all pigs of the prophylactic 
group that were treated from two until five months of age (n=18) showed food 
intake that was steadily increasing with age, while older pigs included in the 
therapeutic group treated from five to eight months of age (n=11) revealed a more 
constant food intake. For both groups, the effect of liraglutide treatment was 
consistent: Straight from the beginning of the treatment period liraglutide-treated 
animals showed significant decreases in food intake in comparison to placebo-
treated pigs, with differences of 20-35% determined in the prophylactic group and 
40-50% in the therapeutic group (Figure 9). This distinction was assessed steadily 
over the whole treatment period and did not change by an increase of the 
liraglutide dosage. Additionally, feeding efficiency (body weight gain per food 
intake) was significantly reduced in liraglutide-treated pigs both in the 
prophylactic group (0.27 ± 0.01 vs. 0.31 ± 0.01, p<0.05) and the therapeutic group 
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3.3. Reduced body weight gain in liraglutide-treated GIPRdn transgenic 
pigs 
Regular weekly body weight control was already started during the pre-treatment 
period at the age of 32 days (prophylactic group, n=18) or 50 days (therapeutic 
group, n=11) and continued over the whole treatment period until necropsy. 
Effects of liraglutide treatment on body weight were in accordance with the 
observed effects on food intake and feeding efficiency. GIPRdn transgenic animals 
of the prophylactic group gained weight consistently during pre-treatment time. 
However, a rapid change was observed at the start of therapy: Liraglutide-treated 
pigs distinctly gained less weight compared to placebo-treated animals. This 
finding was progressive throughout the whole treatment period and finally 
Figure 9: Reduced food intake and feeding efficiency in liraglutide-treated 
GIPRdn transgenic pigs 
Mean food intake (left) and feeding efficiency (right) in the prophylactic (A) and the  
therapeutic group (B) during the treatment period in liraglutide- (L) and placebo-
treated (P) GIPRdn transgenic pigs; n = number of animals investigated. Data are 
means ± SEM; *: p<0.05; **: p<0.01; ***: p<0.001. 
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resulted in a body weight difference of 31% (63.7 ± 2.4 kg vs. 91.6 ± 3.7 kg) 
compared to placebo-treated pigs at the day of necropsy (Figure 10 A). Animals 
of the therapeutic group were chosen randomly by lot and raised equally, yet they 
showed – by chance – already slight, but significant differences in body weight 
before the start of the treatment. But also in this group liraglutide treatment 
impaired body weight gain, reflected in a final body weight difference of 41% 
(79.9 ± 4.3 kg vs. 134.2 ± 5.9 kg) in liraglutide-treated pigs in comparison to the 
placebo-treated pigs (Figure 10 B). Differences in body weight were already 
clearly visible by looking at the physical appearance of the pigs, whereby 
liraglutide-treated animals showed distinct smaller shape and size in comparison 
to placebo-treated pigs. 
Figure 10: Reduced body weight gain of liraglutide-treated GIPRdn 
transgenic pigs 
Mean body weight gain of the prophylactic (A) and the therapeutic (B) group during 
pre-treatment and treatment period; n = number of animals investigated; black 
arrows indicate the start and the end of the treatment period; data are means ± SEM; 
*: p<0.05; **: p<0.01; ***: p<0.001; representative physical appearance of 
liraglutide-treated pig (right side) and placebo-treated pig (left side) in the last third 
of therapy in the prophylactic (C) and therapeutic (D) group. 
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3.4. Influence of liraglutide treatment on levels of growth-regulating 
polypeptides 
Due to the distinctly reduced body weight gain of liraglutide-treated GIPRdn 
transgenic pigs in both the prophylactic and the therapeutic trial, it was interesting 
to evaluate if blood levels of polypeptides involved in growth regulation were 
altered. Therefore, levels of somatostatin, insulin-like growth factor-I (IGF-I) and 
insulin-like growth factor binding protein (IGFBP) -2 and -3 were determined in 
blood samples of 18-hours fasted animals of the prophylactic and the therapeutic 
group right before the start and at the end of the treatment period respectively. 
Due to a large variation between individual animals, the peptide concentrations 
after the treatment period were divided by the concentrations before the treatment 
period and this ratio representative for the degree of concentration changes was 
compared between liraglutide- and placebo-treated GIPRdn transgenic pigs.  
3.4.1. Changes in somatostatin levels in liraglutide- and placebo-treated 
GIPRdn transgenic pigs 
Somatostatin levels were determined in plasma samples in randomly chosen 
liraglutide- (n=4) and placebo-treated pigs (n=4) of the prophylactic group as well 
as the therapeutic group using RIA. The ratio of the mean somatostatin 
concentration after the treatment to the concentration prior to the treatment 
showed no significant differences in pigs of the prophylactic group, but was 
significantly elevated (p<0.05) in liraglutide-treated compared to placebo-treated 
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3.4.2. Changes in IGF-I, IGFBP-2 and-3 levels in liraglutide- and placebo-
treated GIPRdn transgenic pigs  
IGF-I levels were measured in serum samples using an ELISA kit, while IGFBP-2 
and -3 levels  were determined also in serum samples by quantitative Western 
ligand blot analysis. Samples of all animals of the therapeutic group were 
included (n=11) while 7 liraglutide-treated and 7 placebo-treated pigs were 
randomly chosen within the prophylactic group. The post-treatment/pre-treatment 
ratios for IGF-I did not differ between liraglutide- and placebo-treated GIPRdn 
transgenic pigs in both groups. Additionally, no major effect of liraglutide 
treatment on IGFBP-2 and -3 was detected as there were also no significant 
differences seen for IGFBP-2 and -3 post-treatment/pre-treatment ratios compared 
between liraglutide- and placebo-treated GIPRdn transgenic pigs (Figure 12). 
 
Figure 11: Somatostatin ratio in GIPRdn transgenic pigs  
Mean post-treatment/pre-treatment somatostatin ratio in liraglutide- (L) and 
placebo-treated (P) pigs of the prophylactic (A) and the therapeutic (B) 
group; n = number of animals investigated. Data are means ± SEM, *: 
p<0.05. 
 




















Figure 12: Unchanged IGF-I, IGFBP-2 and -3 ratios in liraglutide-
treated GIPRdn transgenic pigs 
Mean post-treatment/pre-treatment ratio of IGFBP-2 (A, B), IGFBP-3 (C, D) 
and IGF-I (E, F) in liraglutide- (L) and placebo-treated (P) GIPRdn transgenic 
pigs of the prophylactic group (A, C, E) and the therapeutic group (B, D, F); n = 
number of animal investigated. Data are means ± SEM. 
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4. Effect of liraglutide treatment on glucose control 
Intravenous and oral glucose tolerance tests were performed in all animals 
included in the study prior to liraglutide/placebo treatment and additionally at the 
end of the treatment period. Liraglutide/placebo treatment was carried on during 
the post-treatment glucose tolerance tests. Thus, 3 hours before the start of the 
post-treatment glucose tolerance tests pigs received their usual dosage of 
liraglutide (prophylactic group: 1.2 mg, therapeutic group: 1.8 mg) or placebo. 
Intravenous and oral glucose tolerance tests were performed on consecutive days 
while pigs showed the following ages and body weights: Pigs of the prophylactic 
group (n=18) underwent the first glucose tolerance test at 60 ± 1 days of age prior 
to the start of therapy at 67 days of age, while showing similar body weights of 
15 ± 1.0 kg (placebo-treated subgroup, n=9) and 16.1 ± 0.73 kg (liraglutide-
treated subgroup, n=9). The post-treatment glucose tolerance tests were conducted 
at 158 ± 1 days of age and body weight at this time point already showed 
significant differences with mean values of 87.7 ± 3.84 kg (placebo-treated 
subgroup) and 59.78 ± 2.32 kg (liraglutide-treated subgroup). The first glucose 
tolerance test in pigs of the therapeutic group (n=11) was performed at an age of 
135 ± 5 days. At this time point animals of the later liraglutide-treated subgroup 
(n=5) showed mean body weight of 50.7 ± 4.10 kg while the later placebo-treated 
subgroup (n=6) had mean body weight of 58.6 ± 2.71 kg. Therapy was started in 
all animals at an age of 147 days and accordingly post-treatment glucose tolerance 
tests were conducted at an age of 238 ± 2 days. At this age liraglutide-treated pigs 
showed clearly less body weight compared to placebo-treated animals (78.8 ± 
4.10 kg (liraglutide) vs. 132.3 ± 5.94 kg (placebo)). 
4.1. Improved oral glucose tolerance and decreased insulin secretion in 
liraglutide-treated GIPRdn transgenic pigs 
4.1.1. Prophylactic group: Results of oral glucose tolerance tests  
There was no significant difference seen during the pre-treatment OGTT between 
GIPRdn transgenic pigs concerning elevation and decline of blood glucose levels 
after oral stimulation and AUC for glucose was similar (18,375 ± 881 (liraglutide-
treated subgroup) vs. 17,839 ± 682 (placebo-treated subgroup), p=0.80) 
(Figure 13 A). However, treatment with liraglutide led to significant changes in 
blood glucose levels during the post-treatment OGTT: Liraglutide-treated pigs 
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showed slower and distinctly less glucose elevation in comparison to placebo-
treated pigs. AUC for glucose was reduced by 22.5% (14,018 ± 447 vs. 18,094 ± 
659, p<0.001), indicating an improvement in oral glucose tolerance by liraglutide 
treatment (Figure 13 B). 
 
Figure 13: Improved oral glucose tolerance in liraglutide-treated GIPRdn 
transgenic pigs of the prophylactic group 
Similar glucose levels during pre-treatment OGTT (A), but significantly reduced 
glucose levels and AUC glucose during post-treatment OGTT (B) of liraglutide-
treated (L) compared to placebo-treated (P) GIPRdn transgenic pig, 0 minutes = 
point of glucose administration; n = number of animals investigated; AUC 
glucose = area under the glucose curve. Data are means ± SEM, *: p<0.05, **: 
p<0.01, ***: p<0.001. 
 
Although plasma insulin levels in animals of the liraglutide-treated subgroup 
showed a significant increase (p<0.05) 30 minutes after glucose administration 
during the pre-treatment OGTT, the course of the insulin curve seemed similar 
and AUC for insulin was not significantly different (3,296 ± 261 (liraglutide- 
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treated subgroup) vs. 2,956 ± 187 (placebo-treated subgroup), p=0.30) 
(Figure 14 A). Though, insulin levels of liraglutide-treated animals in response to 
oral stimulation after the treatment period were significantly decreased in 
comparison to placebo-treated pigs. Additionally, AUC for insulin in liraglutide-
treated animals was reduced by 36% (2,865 ± 283 vs. 4,474 ± 619, p<0.05) 
(Figure 14 B). 
 
Figure 14: Reduced insulin secretion in liraglutide-treated GIPRdn 
transgenic pigs of the prophylactic group 
Similar insulin level during pre-treatment OGTT (A) but significantly reduced 
insulin levels and AUC insulin during post-treatment OGTT (B) in liraglutide-
treated (L) compared to placebo-treated (P) GIPRdn transgenic pigs, 0 minutes = 
point of glucose administration; n = number of animals investigated; AUC insulin 
= area under the insulin curve. Data are means ± SEM, *: p< 0.05, ***: p<0.001. 
4.1.2. Therapeutic group: Results of oral glucose tolerance tests 
Generally, results seen during OGTTs in the therapeutic group resembled those 
determined in the prophylactic group regarding changes in blood glucose and 
insulin levels: There was no significant difference seen in elevation or decline of 
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blood glucose levels after oral stimulation during pre-treatment OGTT going 
along with similar AUC for glucose (16,223 ± 1,612 (liraglutide-treated subgroup) 
vs. 15,258 ± 647 (placebo-treated subgroup), p=0.93) (Figure 15 A). However, 
liraglutide treatment led to significantly lower blood glucose elevations only 
reaching maximum concentrations of 124 mg/dl and AUC for glucose was 
reduced by 28% (14,561 ± 942 vs. 20,025 ± 1,707, p<0.05). In contrast, placebo-
treated pigs showed a peak glucose concentration of 194 mg/dl during the post-
treatment OGTT (Figure 15 B). Thus, oral glucose tolerance in GIPRdn transgenic 
pigs included in the therapeutic group was improved by liraglutide treatment.  
 
Figure 15: Improved oral glucose tolerance in liraglutide-treated GIPRdn 
transgenic pigs of the therapeutic group  
Unchanged glucose levels during pre-treatment OGTT (A), but significantly 
reduced glucose levels and AUC glucose during post-treatment OGTT (B) of 
liraglutide-treated (L) compared to placebo-treated (P) GIPRdn transgenic pigs, 0 
minutes = point of glucose administration; n = number of animals investigated; 
AUC glucose = area under the glucose curve. Data are means ± SEM, *: p<0.05, 
**: p<0.01, ***: p<0.001. 
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Although insulin secretion in animals of the liraglutide-treated subgroup during 
the pre-treatment OGTT was lower compared to the placebo-treated subgroup, 
significance was only reached at time point 45 minutes after glucose 
administration (p<0.05). Likewise the AUC for insulin showed no significant 
difference (3,268 ± 360 (liraglutide-treated subgroup) vs. 4,671 ± 869 (placebo-
treated subgroup), p=0.25) (Figure 16 A). However, results of the post-treatment 
OGTT were different: Insulin levels of placebo-treated pigs showed a distinct 
increase and a peak insulin concentration of 111.3 µU/ml was reached 60 minutes 
after glucose administration, thereby being approximately twice as high as 
maximum concentrations reached during pre-treatment OGTT. In contrast, 
liraglutide-treated animals only showed a slight rise in insulin levels with low 
peak concentrations of 37 µU/ml. The difference of insulin secretion between 
liraglutide- and placebo-treated pigs was significant throughout the whole post-
treatment OGTT. Accordingly, AUC for insulin in liraglutide-treated animals was 
reduced by 71% in comparison to placebo-treated pigs (2,685 ± 103 vs. 9,138 ± 
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Figure 16: Reduced insulin secretion in liraglutide-treated GIPRdn 
transgenic pigs of the therapeutic group 
Similar insulin level during pre-treatment OGTT (A) but significantly reduced 
insulin levels and AUC insulin during post-treatment OGTT (B) in liraglutide-
treated (L) compared to placebo-treated (P) GIPRdn transgenic pigs, 0 minutes = 
point of glucose administration; n = number of animals investigated; AUC insulin 
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4.2. Improved insulin sensitivity in liraglutide-treated GIPRdn 
transgenic pigs 
Extensive clinical trials with type 2 diabetic patients proposed the ability of 
liraglutide to improve insulin sensitivity and beta-cell function, indicated by the 
calculation of different parameters (Blonde et al. 2009; Buse et al. 2009). For 
evaluation of changes in insulin sensitivity of GIPRdn transgenic pigs prior to and 
after the treatment with the GLP-1R agonist liraglutide indices were calculated 
that show good correlation to the euglycemic hyperinsulinemic clamp, which is 
widely accepted being the gold standard for the validation of insulin sensitivity 
(Katz et al. 2000; Matsuda et al. 1999; Matthews et al. 1985; Radikova 2003). 
Basal plasma insulin and glucose values of animals after an 18-hour fasting period 
were used for calculation of HOMA-IR, HOMA-β and QUICKI. As these indices 
mainly reflect hepatic insulin sensitivity and basal hepatic glucose production, 
additionally ISI (Matsuda)) was calculated. ISI (Matsuda) includes glucose and insulin 
levels in the fasting state as well as during OGTT. Thus, not only hepatic but also 
insulin sensitivity of peripheral tissues can be assessed (Radikova 2003). Results 
of insulin sensitivity evaluation were similar for the prophylactic group as well as 
for the therapeutic group: HOMA-IR showed similar values before the start of 
therapy in all GIPRdn transgenic pigs (prophylactic group: 0.72 ± 0.09 vs. 0.85 ± 
0.12, p=0.43, therapeutic group: 0.77 ± 0.07 vs. 0.83 ± 0.16, p=0.58). After the 
treatment period HOMA-IR of liraglutide-treated pigs had not changed or just 
slightly increased whereas placebo-treated pigs showed a distinct rise in HOMA-
IR, leading to significant differences between HOMA-IR of liraglutide-treated 
compared to placebo-treated pigs after the therapy (prophylactic group: 0.89 ± 
0.10 vs. 1.26 ± 0.11, p<0.05; therapeutic group: 0.87 ± 0.12 vs. 1.87 ± 0.21, 
p<0.05). This indicates decreased insulin sensitivity in placebo-treated pigs. 
Although a trend of lower levels of HOMA-β as an index for beta-cell function 
was detected in liraglutide-treated pigs after therapy, no significance was reached 
in comparison to the placebo-treated pigs (prophylactic group: 83.98 ± 7.88 vs. 
100.95 ± 13.42, p=0.34; therapeutic group: 67.53 ± 11.21 vs. 112.72 ± 18.14, 
p=0.18). QUICKI showed similar values prior to the start of the therapy 
(prophylactic group: 1.17 ± 0.11 vs. 1.03 ± 0.10, p=0.44, therapeutic group: 0.90 
± 0.06 vs. 0.98 ± 0.11, p=0.54). However, values of QUICKI were significantly 
higher in liraglutide-treated pigs after the therapy in comparison to placebo-
treated animals (prophylactic group: 0.87 ± 0.05 vs. 0.69 ± 0.03, p<0.05; 
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therapeutic group: 0.89 ± 0.09 vs. 0.58 ± 0.04, p<0.05), indicating an improved 
insulin sensitivity in liraglutide-treated pigs. The greatest difference between 
liraglutide- and placebo-treated pigs was seen when glucose and insulin values of 
OGTTs were additionally included for the calculation of ISI (Matsuda). Before the 
start of the therapy this index did not differ between the two groups (prophylactic 
group: 10.24 ± 0.90 vs. 10.00 ± 0.83, p=0.87; therapeutic group: 10.78 ± 0.84 vs. 
9.82 ± 1.34, p=0.93). After the treatment, ISI (Matsuda) of liraglutide-treated animals 
had hardly changed, while placebo-treated ones showed a distinct decrease of 
insulin sensitivity in comparison to the pre-treatment values. Thereby, treatment 
with liraglutide led to a significant increase in ISI (Matsuda) in comparison to 
placebo treatment (prophylactic group: 12.10 ± 1.28 vs. 7.24 ± 0.72, p<0.01; 
therapeutic group: 11.68 ± 0.74 vs. 3.95 ± 0.57, p<0.01). Altogether, calculation 
of different insulin sensitivity indices showed a significant improvement of insulin 
sensitivity by a 90-day liraglutide therapy in comparison to placebo treatment, but 





































Figure 17: Improved insulin sensitivity in liraglutide-treated GIPRdn 
transgenic pigs 
Different insulin indices representing prophylactic group (A, C, E, G) and 
therapeutic group (B, D, F, H) before and at the end of the treatment period 
respectively; n = number of animals investigated; mo = months of age; L = 
liraglutide-treated animals (red), P = placebo-treated animals (green). Data are 
means ± SEM; *: p<0.05, **: p<0.01. 
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4.3. Improved intravenous glucose tolerance in liraglutide-treated 
GIPRdn transgenic pigs 
4.3.1. Prophylactic group: Results of intravenous glucose tolerance tests 
GIPRdn transgenic pigs of the liraglutide-treated subgroup (n=9) showed higher 
blood glucose concentrations one minute after glucose administration in 
comparison to the placebo-treated subgroup (n=9) during pre-treatment IVGTT 
(p<0.01). However, further course of the glucose curves was similar and AUC for 
glucose showed no significant differences (12,821 ± 458 (liraglutide-treated 
subgroup) vs. 13,015 ± 592 (placebo-treated subgroup), p=0.86) (Figure 18 A). In 
contrast to these findings, the post-treatment IVGTT revealed a significant 
improvement in intravenous glucose tolerance by liraglutide treatment in 
comparison to placebo treatment: AUC for glucose in liraglutide-treated animals 
was reduced by 15% (12,259 ± 446 vs. 14,445 ± 386, p<0.01) compared to 
placebo-treated ones and although the initial rise in blood glucose levels as well as 
maximum glucose concentrations were similar in all pigs included in this group, 
liraglutide-treated pigs showed significantly faster decline of glucose in the 
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Before the start of the treatment period, animals of the liraglutide treatment group 
revealed significantly higher insulin concentrations 15 minutes after intravenous 
glucose bolus (p<0.01), while no significant differences were seen at all other 
time points in comparison to the placebo treatment group. AUC for insulin 
revealed a tendency to be higher in the liraglutide-treated animals (862 ± 75 
(liraglutide-treated subgroup) vs. 719 ± 69 (placebo-treated subgroup), p = 0.07) 
(Figure 19 A). Insulin secretion during post-treatment IVGTT showed a higher 
increase in liraglutide-treated animals reaching significance 20 minutes after 
Figure 18: Improved intravenous glucose tolerance in liraglutide-treated 
GIPRdn transgenic pigs of the prophylactic group 
Similar course of glucose curves during pre-treatment IVGTT (A), but 
significantly faster decline of blood glucose and reduced AUC for glucose during 
post-treatment IVGTT (B) of liraglutide-treated (L) compared to placebo-treated 
(P) GIPRdn transgenic pigs; 0 minutes = point of glucose administration; n = 
number of animals investigated; AUC = area under the glucose curve. Data are 
means ± SEM; *: p<0.05, **: p<0.01. 
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glucose administration (p<0.05) and also slightly faster decline, but AUC for 
insulin was not different in comparison to placebo-treated pigs (1,322 ± 123 
(liraglutide-treated subgroup) vs. 1,387 ± 101 (placebo-treated subgroup), p = 
0.74) (Figure 19 B). 
 
4.3.2. Therapeutic group: Results of intravenous glucose tolerance tests 
Results of the intravenous glucose tolerance tests observed in the therapeutic 
group regarding blood glucose generally reflect the findings determined in the 
prophylactic group: Prior to the treatment period blood glucose concentration one 
minute after glucose administration was significantly higher in the liraglutide-
Figure 19: Insulin secretion and AUC for insulin during IVGTT in the 
prophylactic group 
Insulin secretion in liraglutide-treated (L) compared to placebo-treated (P) GIPRdn 
transgenic pigs during pre-treatment IVGTT (A) and post-treatment IVGTT (B); 0 
minutes = point of glucose administration; n = number of animals investigated; 
AUC = area under the insulin curve. Data are means ± SEM; *: p<0.05, **: 
p<0.01. 
 
V. Results     90 
treated subgroup (n=5) compared to the placebo-treated subgroup (n=6) (p<0.05), 
but AUCs for glucose were similar in both subgroups (13,142 ± 918 (liraglutide-
treated subgroup) vs. 13,557 ± 359 (placebo-treated subgroup), p=0.80) 
(Figure 20 A). The post-treatment IVGTT also mirrored results seen in the 
prophylactic group, but to a greater extent: AUC for glucose was reduced by 23% 
(14,900 ± 614 vs. 19,148 ± 914, p<0.01) and glucose levels were generally lower 
in liraglutide-treated pigs over the whole period of time (90 minutes) following 
intravenous glucose load compared to placebo-treated pigs (Figure 20 B). 
Figure 20: Improved intravenous glucose tolerance in liraglutide-
treated GIPRdn transgenic pigs of the therapeutic group 
Similar course of glucose curves during pre-treatment IVGTT (A), but 
significantly lower rise and faster decline of blood glucose concentration as 
well as reduced AUC for glucose during post-treatment IVGTT (B) in 
liraglutide-treated (L) compared to placebo-treated (P) GIPRdn transgenic pigs; 
0 minutes = point of glucose administration; n = number of animals 
investigated; AUC = area under the glucose curve. Data are means ± SEM; *: 
p<0.05, **: p<0.01; ***: p<0.001. 
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Liraglutide-treated pigs of the therapeutic group showed lower insulin secretion 
both during the pre-treatment and the post-treatment IVGTT. Prior to the start of 
the therapy, at a time point where pigs were still untreated but yet showed 
differences in body weight of 13.5%, pigs of the liraglutide-treated subgroup 
showed significantly lower insulin secretion 7 to 20 minutes after intravenous 
glucose administration and also lower but not significantly different AUC for 
insulin compared to the placebo-treated subgroup (1,022 ± 178 (liraglutide) vs. 
1,474 ± 243 (placebo), p=0.34) (Figure 21 A). During post-treatment IVGTT 
insulin secretion in liraglutide-treated pigs was even more decreased, reaching 
significance from 1 to 50 minutes after glucose bolus, and this was accompanied 
by significantly lower AUC for insulin in comparison to the placebo-treated 
animals (1,605 ± 146 vs. 2,991 ± 355, p<0.01) (Figure 21 B). 
Figure 21: Insulin secretion and AUC for insulin during IVGTT in the 
therapeutic group 
Insulin secretion in liraglutide-treated (L) and placebo-treated GIPRdn transgenic 
pigs (P) during pre-treatment IVGTT (A) and post-treatment IVGTT (B); 0 
minutes = point of glucose administration; n = number of animals investigated; 
AUC = area under the insulin curve. Data are means ± SEM; *: p<0.05, **: 
p<0.01, ***: p<0.001 
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5. Effects of liraglutide treatment on the beta-cell volume of 
GIPRdn transgenic pigs 
5.1. Pancreas histology of liraglutide- and placebo-treated GIPRdn 
transgenic pigs 
Pancreatic tissue slides immunohistochemically stained for insulin did not show 
histological differences, neither between liraglutide- and placebo-treated animals, 
nor between the prophylactic and the therapeutic group. Insulin staining pattern 
and intensity were very similar in all animals included in the study and there was 
no visible difference in size or number of pancreatic islets. Pancreas morphology 
appeared to be conserved with normal structure of exocrine and endocrine 
pancreatic tissue (Figure 22).  
Figure 22: Unaltered insulin staining pattern and islet size in liraglutide-
treated GIPRdn transgenic pigs 
Representative histological pancreas sections immunohistochemically stained for 
insulin of liraglutide-treated pigs of the prophylactic (A) and the therapeutic group 
(C) in comparison to placebo-treated pigs of the prophylactic (B) and the 
therapeutic group (D), scale bar represents a length of 100 µm. 
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5.2. Effect of liraglutide treatment on the total beta-cell volume 
For evaluation of the effect of liraglutide treatment on the total beta-cell volume 
quantitative-stereological analyses were performed in specimens obtained by 
random systematic sampling of pancreata from all GIPRdn transgenic pigs 
included in the study. The volume density of beta-cells (Vv (β-cell/Pan)) as well as 
isolated beta-cells in the pancreas (Vv (isoβ-cell/Pan)) was determined and the total 
volume of beta-cells (V (β-cell, Pan)) as well as isolated beta-cells (V (isoβ-cell,Pan)) was 
calculated. Isolated beta-cells were not determined manually, but recognized by 
the software VisiomorphTM as red stained insulin-positive cells covering an area 
smaller than 250 µm2. Thereby it is possible that not only single cells were 
counted, but also small cell clusters of approximately up to five insulin-positive 
stained cells. As liraglutide- and placebo-treated pigs of both groups showed 
distinct differences in total body weight at the time of the morphological 
evaluation, total beta-cell volume was also related to body weight ((V (β-cell, Pan)) / 
BW). 
5.2.1. Evaluation of the beta-cell volume in the prophylactic group 
Neither volume density of beta-cells in the pancreas (Vv (β-cell/Pan), p=0.11) nor the 
total beta-cell volume (V (β-cell, Pan), p=0.07) showed significant differences 
between liraglutide- (n=9) and placebo-treated pigs (n=9) in the prophylactic 
group at an age of 5 months. However, these parameters revealed a tendency to be 
decreased in liraglutide-treated pigs with a 14% lower volume density (Vv (β-
cell/Pan)) and 22% lower total beta-cell volume (V (β-cell, Pan)) compared to placebo-
treated pigs. Also, no differences were observed regarding volume density (Vv 
(isoβ-cell/Pan), p=0.55) and total volume of isolated beta-cells in the pancreas (V (isoβ-
cell,Pan), p=0.61). The absolute weight of pancreata revealed no significant 
differences between liraglutide- and placebo-treated pigs (p=0.26). However, at 
the time of necropsy liraglutide-treated pigs showed a body weight reduction of 
31% compared to the placebo-treated ones. Therefore, the total beta-cell volume 
related to body weight ((V (β-cell, Pan)) / BW) was additionally calculated. Individual 
body weights of the pigs at the day of necropsy were used for the calculation. The 
parameter V (β-cell, Pan) / BW was not different between liraglutide- and placebo-
treated pigs (p=0.34) (Figure 23).  


















Figure 23: Quantitative-stereological analyses of pancreata from GIPRdn 
transgenic pigs of the prophylactic group 
(A/B) Volume density (Vv (β-cell/Pan)) and total volume (V (β-cell, Pan)) of beta-cells in 
the pancreas; (C/D) volume density (Vv (isoβ-cell/Pan)) and total volume (V (isoβ-cell, 
Pan)) of isolated beta-cells in the pancreas; (E) mean absolute pancreas weight; (F) 
total beta-cell volume related to body weight (V (β-cell, Pan) / BW); L = liraglutide-
treated animals, P = placebo-treated animals, n = number of animals investigated. 
Data are means ± SEM. 
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5.2.2. Evaluation of the beta-cell volume in the therapeutic group 
The trend for lower volume density and total volume of beta-cells in the pancreas 
of liraglutide-treated pigs observed in the prophylactic group at five months of age 
did reach significance in the therapeutic group at eight months of age: Eight-
month-old liraglutide-treated animals (n=5) showed a 32% (p<0.01) reduction in 
Vv (β-cell/Pan) and a 44% (p<0.01) reduction of V (β-cell, Pan) in comparison to 
placebo-treated pigs (n=6). In accordance with the findings in the prophylactic 
group there was no significant difference of Vv (isoβ-cell/Pan) (p=0.44) and V (isoβ-
cell,Pan) (p=0.67) between liraglutide- and placebo-treated pigs. At the day of 
necropsy liraglutide-treated pigs in the therapeutic group also showed distinct less 
body weight (-41%) than placebo-treated animals. Therefore also in this group the 
total beta cell volume was related to body weight (V (β-cell, Pan) / BW), which 
resulted in the loss of significant differences between liraglutide- and placebo-


































Figure 24: Quantitative-stereological analyses of pancreata from GIPRdn 
transgenic pigs of the therapeutic group 
(A/B) Volume density (Vv (β-cell/Pan)) and total volume (V (β-cell, Pan)) of beta cells in 
the pancreas; (C/D) volume density (Vv (isoβ-cell/Pan)) and total volume (V (isoβ-cell, Pan)) 
of isolated beta cells in the pancreas; (E) mean absolute pancreas weight; (F) total 
beta-cell volume related to body weight (V (β-cell, Pan) / BW); L = liraglutide-treated 
animals, P = placebo-treated animals; n = number of animals investigated. Data are 
means ± SEM; **: p<0.01. 
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5.3. Unchanged nuclear profile count in liraglutide- and placebo-treated 
GIPRdn transgenic pigs  
Due to the knowledge that liraglutide-treated pigs of the prophylactic group 
showed a strong tendency of decreased total beta-cell volume (V (β-cell, Pan)) that 
even got significant in the therapeutic group, nuclear profile counting was carried 
out to get an idea whether augmented cell division (hyperplasia) or rather 
enlargement of the cells (hypertrophy) can be detected in placebo-treated animals. 
Therefore, tissue slides of randomly chosen liraglutide- (n=4) and placebo-treated 
animals (n=4) of the prophylactic group were immunohistochemically stained for 
insulin using DAB as chromogen combined with strong nuclear staining using 
haemalum and subsequently beta-cell nuclei were manually counted within 
insulin-positive stained area of 100 islets per animal. Nuclear profile counting 
revealed no significant differences between liraglutide- and placebo-treated 












Figure 25: Unchanged nuclear profile count in GIPRdn transgenic  pigs 
of the prophylactic group 
Nuclear profile count of liraglutide-treated (L) in comparison to placebo-treated 
(P) GIPRdn transgenic pigs, n = number of animals investigated, Data are means 
± SEM 
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5.4. Influence of liraglutide treatment on gastric emptying in GIPRdn 
transgenic pigs 
Prior to necropsy, five liraglutide-treated and four placebo-treated pigs of the 
prophylactic as well as the therapeutic group were fasted for 6 hours, then 1 kg of 
food was offered for one hour, followed by another 12-hour fasting period until 
pigs were euthanized. Two hours before necropsy, daily liraglutide and placebo 
treatment was accomplished, i.e. 1.2 mg (prophylactic group) and 1.8 mg 
liraglutide (therapeutic group) or the corresponding volume of placebo was 
subcutaneously injected. After euthanasia, the stomach was opened and content 
was examined. Differences between the two treatment types were clearly visible: 
While stomach of placebo-treated pigs was empty or only filled with liquid, 
stomach content of liraglutide-treated pigs still contained large amounts of 
remaining food as well as small amounts of liquid.  
5.5. Organ weights of liraglutide- and placebo-treated GIPRdn 
transgenic pigs 
With the knowledge that liraglutide-treated pigs of both groups showed distinctly 
less body weight compared to placebo-treated animals at the end of treatment 
period, organs were weighed during necropsy for the calculation of absolute and 
relative organ weights. In the prophylactic group significantly lower absolute 
organ weights in liraglutide-treated pigs (n=9) could be detected for the kidneys 
(p<0.001), heart (p<0.001), spleen (p<0.01) and liver (p<0.01) in comparison to 
placebo-treated animals (n=9). Pancreas, stomach and lung also showed this 
tendency but without reaching significance. When related to body weight, 
liraglutide-treated pigs in this group showed significantly higher relative organ 
weights for pancreas (p<0.001), stomach (p<0.05) and spleen (p<0.05), while the 
remaining organs showed no significant differences. In the therapeutic group 
liraglutide-treated pigs (n=5) also showed lower absolute organ weights compared 
to placebo-treated animals (n=6) getting significant for the kidneys (p<0.01), heart 
(p<0.01), stomach (p<0.05) and liver (p<0.05). Regarding relative organ weights 
liraglutide-treated pigs showed a tendency of higher values. However, no 
significant differences could be detected compared to placebo-treated pigs 
(Figure 26).  
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Figure 26: Organ weights of liraglutide- and placebo-treated GIPRdn 
transgenic pigs 
Absolute (A,C) and relative (B,D) organ weights determined in liraglutide- and 
placebo-treated GIPRdn transgenic pigs of the prophylactic group (A,B) and the  
therapeutic group (C,D); n =  number of animals investigated; n.s. = not 
significant. Data are means ± SEM; *: p<0.05, **: p<0.01, ***: p<0.001. 
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VI. DISCUSSION 
The present study evaluated the effect of a 90-day treatment with the long-acting 
GLP-1R agonist liraglutide on glycemic control, body weight, food intake and the 
total beta-cell volume in adolescent GIPRdn transgenic pigs. This pig model shows 
key characteristics of a prediabetic state including an impaired function of the 
incretin hormone GIP, reduced glucose tolerance and insulin secretion as well as a 
progressive decline of the total beta-cell volume (Renner et al. 2010). Two 
different age groups were investigated during this study: The prophylactic group 
(n=18) was treated with liraglutide/placebo from 2 months (unaltered beta-cell 
volume) to 5 months of age to investigate if liraglutide would be able to cause a 
cessation of the beta-cell volume reduction or if it can even prophylactically 
prevent it. A second group (therapeutic group, n=11) was treated with 
liraglutide/placebo from 5 months (35% reduced beta-cell volume) to 8 months of 
age to see if liraglutide treatment can slow down the progressive reduction of the 
beta-cell volume or if it is even able to restore it. 
1. Plasma liraglutide levels in GIPRdn transgenic pigs 
Among the approved GLP-1R agonists on the market liraglutide under the brand 
name Victoza® was the drug of choice for this study because it seems to have the 
highest pharmacodynamic potency: Compared to exenatide twice daily (Byetta®) 
the pharmacokinetic profile of liraglutide makes it suitable for once daily 
administration and it maintains stable steady state concentrations over a time 
range of 24 hours leading to long-term blood glucose lowering effects with low 
rates of hypoglycemia in diabetic subjects (Blonde et al. 2009; Knudsen et al. 
2000; Rosenstock 2009). In direct comparison to the maximum recommended 
dosage of exenatide (10 µg twice daily) the maximum recommended dosage of 
liraglutide (1.8 mg once daily) was able to decrease HbA1c more effective in type 
2 diabetic subjects over a treatment period of 26 weeks. Additionally, liraglutide 
caused less hypoglycemia as well as less persistent nausea and increased HOMA-
β to a higher extent than exenatide, indicating greater improvement in beta-cell 
function (Buse et al. 2009). During an extension of this study the treatment of 
some patients was switched from exenatide to liraglutide, resulting in further 
improvement of glucose control (Buse et al. 2010). In a head-to-head trial over a 
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26 weeks treatment period liraglutide (1.8 mg once daily) also caused a greater 
decrease in HbA1c compared to the long-acting exenatide formulation Bydureon® 
(2 mg once weekly) that was recently approved (Buse et al. 2013). These findings 
further demonstrate the great potential of liraglutide and underline the reasons for 
its use in the present study. To determine effective plasma liraglutide levels in the 
liraglutide-treated GIPRdn transgenic pigs included in this study a profile was 
performed at the end of the 90-day treatment period. Within the five time-points 
where blood samples were taken (0, 4, 8, 12, 16 hours relative to liraglutide 
administration) the animals showed relatively constant course of liraglutide 
plasma level. The highest mean liraglutide plasma levels were 52.3 nmol/l after 
dosing of 1.8 mg liraglutide (therapeutic group) and 43.2 nmol/l after dosing of 
1.2 mg liraglutide (prophylactic group). Although blood sampling during the 
profile was insufficiently frequent to determine a real peak concentration, the 
highest liraglutide plasma concentrations were measured in the blood sample 8 
hours after dosing. This is similar to the findings in human clinical trials, where 
liraglutide concentrations peaked within 9-14 hours after dosing (Agerso et al. 
2002; Elbrond et al. 2002). In humans it was reported that an injection of 0.6 mg 
liraglutide causes peak concentrations of about 9.4 nmol/l that seem to increase 
proportionally with dose in the therapeutic range of 0.6 mg to 1.8 mg liraglutide 
(Agerso et al. 2002; EMEA 2009b). Although Rosenstock et al. measured 
maximum concentrations of only 17 nmol/l after subcutaneous administration of 
1.8 mg liraglutide in humans, the European Medicine Agency assessed maximum 
concentrations of 44.7 nmol/l (EMEA 2009a; Rosenstock et al. 2009). Average 
steady state concentrations over 24 hours after 1.8 mg liraglutide administration 
were reported to be approximately 34 nmol/l (EMEA 2009b; Novo Nordisk 
2010). Compared with the data from humans, pigs included in this study showed 
higher effective plasma levels of liraglutide after administration of similar 
dosages. This may partly be explained by the higher overall bioavailability of 
76% in pigs compared to the human (55%). The upper tolerance limit of 
liraglutide dosage is not known for pigs, but during chronic repeat-dose toxicity 
studies in rats or monkeys liraglutide was still well tolerated when reaching 8- or 
70-fold higher plasma levels compared to the clinical exposure (EMEA 2009a). In 
previous studies with porcine models lower dosages of liraglutide (3.3 µg/kg and 
7 µg/kg) were used compared to the present study (Raun et al. 2007b; Ribel et al. 
2002). One study reported that Yucutan miniature pigs seem to be particularly 
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sensitive to liraglutide (Emamaullee et al. 2009). However, the higher liraglutide 
dosage that is also recommended for humans and the following greater liraglutide 
plasma levels did not seem to influence the general health status of the pigs 
included in this study as they showed normal behavior and undisturbed condition 
throughout the whole treatment period. Furthermore, no adverse effects like 
vomiting, obstipation and diarrhea were obvious. No signs of nausea were 
observed, although it has to be mentioned that the assessment of malaise in a pig 
model is difficult and may be overlooked. Most serum parameters (except total 
protein, albumin, phosphorus, calcium, AP; see below) were not significantly 
different between liraglutide- and placebo-treated GIPRdn transgenic pigs and 
additionally stayed within reference ranges (Kixmöller 2004; Kraft 2005). 
2. Dramatic food intake and body weight gain reducing 
effects due to liraglutide treatment 
2.1. Reduced food intake and feeding efficiency in liraglutide-treated 
GIPRdn transgenic pigs 
Liraglutide treatment had a strong and sustained effect on ad libitum feeding 
behavior: Straight from the beginning of the therapy food intake was significantly 
decreased in liraglutide-treated GIPRdn transgenic pigs with reductions of 20-35% 
in the prophylactic group and even 40-50% in the therapeutic group compared to 
placebo-treated GIPRdn transgenic animals. This chronic reduction of nutrient 
intake may also serve as an explanation for the significant reduction of total serum 
protein and serum albumin observed in liraglutide-treated GIPRdn transgenic pigs 
compared to placebo-treated ones. A food intake reducing effect during liraglutide 
treatment was also shown in studies with normal, obese and diabetic rodents 
(Larsen et al. 2001b; Larsen et al. 2008; Raun et al. 2007a; Sturis et al. 2003) as 
well as in hyperphagic adult Göttingen minipigs. These minipigs even showed a 
sustained decrease in food intake of approximately 60% although they were 
treated with a lower dosage of liraglutide (7 µg/kg) compared to this study (Raun 
et al. 2007b). Furthermore clinical studies with type 2 diabetic human patients 
also showed that liraglutide treatment provoked improved eating behavior going 
along with less energy intake with one study reporting an ad libitum energy intake 
reduction between 9% to 15% after liraglutide treatment (Fujishima et al. 2012; 
Horowitz et al. 2012; Horowitz 2008). One of the underlying mechanisms for this 
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effect on feeding behavior is certainly the ability of liraglutide as a GLP-1R 
agonist to delay gastric emptying and thereby increase the feeling of fullness and 
satiety (Horowitz et al. 2012; Ribel et al. 2002). A recent study showed that the 
effect of delayed gastric emptying was clearly reduced in rats after 14 days of 
liraglutide treatment compared to treatment day 1, maybe due to tachyphylaxis or 
GLP-1R desensitization, suggesting that reduced gastric emptying only mediates 
acute effects on food intake and body weight while other factors mainly seem to 
contribute to further chronic effects (Jelsing et al. 2012a). In the present study it 
was observed at the end of the 90-day treatment period that the stomach of 
liraglutide-treated GIPRdn transgenic pigs still contained large amounts of 
remaining food after a fasting period of 12 hours. In comparison, the stomach of 
placebo-treated GIPRdn transgenic pigs was empty or only fluid filled. Although 
these observations were not quantified, they clearly argue for a delayed gastric 
emptying in liraglutide-treated GIPRdn transgenic pigs. A similar finding was also 
reported in a study with Göttingen minipigs after 4 weeks of liraglutide treatment 
(Ribel et al. 2002). However, it is still likely that further factors like stimulation of 
GLP-1R within energy-intake regulating regions of the central nervous system 
(e.g. in the brainstem or hypothalamus) and the occurrence of nausea as adverse 
effect also contribute to the food intake reducing effects of liraglutide (Flint et al. 
1998; Jelsing et al. 2012a; Meece 2009). Liraglutide-treated GIPRdn transgenic 
pigs also showed significant decreases in feeding efficiency by 12%-32% 
compared to placebo-treated GIPRdn transgenic pigs, indicating a lower body 
weight gain per food intake. This could be indicative for an increase in energy 
expenditure by liraglutide treatment which was also seen in candy-fed obese rats 
and human type 2 diabetic subjects, although it did not reach significance in these 
two studies (Horowitz et al. 2012; Raun et al. 2007a). An increase of energy 
expenditure in liraglutide-treated rats was also suggested as it was observed that 
liraglutide-treated animals developed similar body weights compared to a 
restricted-fed control group with significant lower food intake (Cummings et al. 
2010). However, no effects on 24-hour energy expenditure where detected in a 
study with type 2 diabetic patients but it has to be mentioned that only the lowest 
recommended dosage of liraglutide (0.6 mg) was used for treatment in this case 
(Harder et al. 2004). 
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2.2. Reduced body weight gain in liraglutide-treated GIPRdn transgenic 
pigs 
Liraglutide-treated GIPRdn transgenic pigs gained significantly less weight 
compared to placebo-treated ones during the whole 90-day treatment period. This 
finding was progressive and resulted in a body weight decrease by 31% in the 
prophylactic group and even 41% in the therapeutic group compared to placebo-
treated pigs at the end of liraglutide therapy. Body composition of the pigs was 
not determined in the present study so that no statement can be made about what 
tissues were reduced the most. Absolute organ weights of liraglutide-treated 
GIPRdn transgenic pigs were decreased compared to their placebo-treated 
counterparts, while relative organ weights mainly did not show significant 
differences. This fact suggests that liraglutide had a generalized inhibitory effect 
on whole body and organ growth. Furthermore, liraglutide-treated GIPRdn 
transgenic pigs of both groups showed significantly reduced serum levels of 
phosphorus going along with significantly reduced calcium levels in the 
therapeutic group and increased levels of AP in the prophylactic group. Calcium 
and phosphorus are major constituents of bone and it is known that an insufficient 
mineralization of the organic bone matrix, as for example seen during 
osteomalacia/rachitis, can go along with increased activity of AP in the blood 
(Kixmöller 2004; Kraft 2005; Plonait 1980). These findings could suggest a 
liraglutide associated disturbance of bone metabolism, but it has to be mentioned 
that AP is an enzyme that is influenced by age, nutrition as well as other organ 
systems like the liver (Kraft 2005; Plonait 1980). Furthermore, the parameters 
calcium, phosphorus and AP were significantly different between liraglutide- and 
placebo-treated GIPRdn transgenic pigs, but they were within reference ranges for 
pigs (Kixmöller 2004; Kraft 2005). Nevertheless future studies on the effects of 
liraglutide in adolescents should include a detailed analysis of bone growth and 
structural characteristics. Body weight lowering effects caused by liraglutide 
treatment are a consistent finding both during studies in animal models as well as 
in clinical human trials with type 2 diabetic subjects like the extensive LEAD 
studies 2-6 (Blonde et al. 2009; Larsen et al. 2001b; Larsen et al. 2008; Raun et al. 
2007a; Raun et al. 2007b). An exception was the study LEAD-1 where liraglutide 
in combination with glimepiride showed weight neutral effects (Marre et al. 
2009). A big part of this body weight reducing effect is definitely mediated by the 
lower food intake caused by liraglutide treatment (see VI 2.1). However, studies 
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with rats showed that chronic liraglutide treatment over 12 weeks only caused 
short-term food intake reducing effects, while the body weight reducing effect 
was nevertheless sustained, indicating that other mechanisms might also be 
responsible for the weight loss (Guo et al. 2013). Although the reduction of food 
intake in the present study was sustained, further reasons for the differences in 
body weight also have to be considered regarding that body weight was so 
dramatically diverging by 31% (prophylactic group) and 41% (therapeutic group) 
in liraglutide-treated GIPRdn transgenic pigs compared to placebo treatment. In 
comparison, liraglutide monotherapy with similar dosages as used in this study 
(1.2 mg or 1.8 mg) over 52 weeks in type 2 diabetic subjects caused mean weight 
loss of 2.1 kg to 2.5 kg compared to the beginning of treatment from a baseline 
that was about 92 kg. Therefore, this means a body weight reduction of only about 
2.2% to 2.5% (Garber et al. 2009). Compared with this data the inhibition of body 
weight gain in liraglutide-treated GIPRdn transgenic pigs included in this study 
was much higher. This may at least in part be related to the fact that treated 
patients were adult, while the treated GIPRdn transgenic pigs in the present study 
were adolescent. A number of hypotheses about the potentially involved 
mechanisms are discussed below. 
2.2.1. Reduced secretion of the anabolic hormone insulin 
Liraglutide treatment caused a significant reduction of insulin secretion during a 
mixed meal oral glucose tolerance test in GIPRdn transgenic pigs compared to 
placebo treatment. AUC insulin was reduced by 36% in liraglutide-treated GIPRdn 
transgenic pigs in the prophylactic group (5 months of age) and by 70% in the 
therapeutic group (8 months of age) as compared to age-matched placebo-treated 
GIPRdn transgenic pigs. As a mixed meal oral glucose tolerance test mimics 
normal food intake very well, it can be assumed that liraglutide-treated GIPRdn 
transgenic pigs in the present study generally show much lower insulin secretion 
without real peaks during their normal feeding behavior when compared to 
placebo-treated animals. Insulin is known to be a hormone with strong anabolic 
and growth-promoting properties as it can inter alia directly stimulate protein 
synthesis as well as reduce proteolysis in different tissues including skeletal 
muscle cells and indirectly influences the IGF-I hormone system (Demling 2005; 
Fujita et al. 2006; Hill et al. 1985; Straus 1984). The impact of a lack of insulin 
can be seen in the growth retardation of children in which diabetes was diagnosed 
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around puberty and insulin therapy is insufficient (Edelsten et al. 1981; Salardi et 
al. 1987; Tattersall et al. 1973). GIPRdn transgenic pigs used in this study also 
were adolescent and in a period of rapid growth. Therefore, it could be assumed 
that the reduced insulin secretion followed by lower anabolic function of this 
hormone in the liraglutide-treated GIPRdn transgenic pigs may additionally have 
mediated the massive body weight gain reducing effects. This would be in 
accordance with the findings in a previously described transgenic pig model of 
permanent neonatal diabetes that displayed significantly reduced fasting insulin 
levels at the age of 4.5 months and showed a distinct concurrent body weight 
reduction of about 40% in comparison to non-transgenic control littermates 
(Renner et al. 2012). 
2.2.2. No effect of liraglutide on the insulin-like growth factor system 
To evaluate the effect of liraglutide treatment on other growth-regulating peptides, 
serum levels of IGF-I, IGFBP-2 and -3 were measured before and after 
liraglutide/placebo treatment, in a randomly chosen subset of GIPRdn transgenic 
pigs respectively. IGF-I is a growth-promoting hormone that is released 
particularly by the liver mainly due to stimulation by growth hormone (GH), but 
also insulin can stimulate IGF-I secretion (Holt et al. 2008; Straus 1984). In the 
circulation IGF-I is mainly bound to high-affinity IGFBPs that regulate its 
bioavailability. IGFBP-2 is known to rather inhibit IGF-I action and thereby acts 
growth-inhibiting (Hoeflich et al. 2001; Hoeflich et al. 1999; Jones et al. 1995). 
IGFBP-3 is the binding protein where most of IGF-I in the circulation is bound to 
in a ternary complex with an acid-labile subunit (ALS) (Holman et al. 1996; Jones 
et al. 1995). Liraglutide treatment did not seem to influence the serum levels of 
these peptides, as the ratio of IGF-I, IGFBP-2 and -3 serum levels after vs. before 
therapy, indicating the degree of alteration during the treatment period, was not 
significantly different between liraglutide- and placebo-treated GIPRdn transgenic 
pigs of the prophylactic and the therapeutic trial. Thus, it seems unlikely that an 
involvement of these components of the insulin-like growth factor system 
contributed to the marked decrease in weight gain observed in adolescent 
liraglutide-treated GIPRdn transgenic pigs. 
2.2.3. Somatostatin levels in GIPRdn transgenic pigs 
Somatostatin is a peptide hormone that is also involved in the growth-regulating 
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system: It is inter alia secreted from delta-cells within the endocrine pancreas as 
well as the hypothalamus and functions as an inhibitor of the release of GH, 
thereby showing growth-inhibiting function (Barnett 2003; Hauge-Evans et al. 
2009; Kumar et al. 2010). Somatostatin is additionally able to inhibit insulin as 
well as glucagon secretion (Hauge-Evans et al. 2009). It was shown in rat and 
porcine isolated perfused pancreata as well as in cell lines that native GLP-1 has 
the ability to stimulate somatostatin release (Brubaker et al. 1997; Fehmann et al. 
1995; Fehmann et al. 1991; Orskov et al. 1988; Schmid et al. 1990), and similar 
findings were also reported for the GLP-1R agonist exendin-4 (Egido et al. 2004; 
Silvestre et al. 2003). In the present study the ratio of somatostatin plasma levels 
after vs. before therapy did not differ between liraglutide- and placebo-treated 
GIPRdn transgenic pigs of the prophylactic group, while liraglutide-treated GIPRdn 
transgenic pigs of the therapeutic group showed a higher post-treatment/pre-
treatment ratio. However, the level of significance was low (p=0.034) and only a 
subset of 4 liraglutide- and 4 placebo-treated GIPRdn transgenic pigs was 
investigated. When the mean concentrations before therapy as well as after 
therapy were directly compared between liraglutide- and placebo-treated GIPRdn 
transgenic pigs without calculating the ratio, no significant differences were 
observed. Thus, a stimulation of somatostatin secretion by liraglutide treatment 
with a following growth-inhibiting effect seems unlikely.  
2.2.4. Liraglutide dosage recommended for humans in adolescent GIPRdn 
transgenic pigs 
In this study the recommended human dosages of Victoza® from 0.6 mg up to 1.8 
mg per day (corresponding to 19-33 µg/kg in the prophylactic group and 10-25 
µg/kg in the therapeutic group) were used for the treatment of GIPRdn transgenic 
pigs. Previous studies investigating the effect of liraglutide treatment in minipig 
models used lower dosages of liraglutide (3.3 µg/kg, 7 µg/kg, 20 µg/kg) 
(Emamaullee et al. 2009; Raun et al. 2007b; Ribel et al. 2002). Although GIPRdn 
transgenic pigs showed undisturbed condition and behavior during liraglutide 
treatment it cannot be excluded that the higher dosage of Victoza® may have 
contributed to the massive body weight gain reducing effect. Another difference 
compared to previous studies including rodent models, porcine models and also 
the clinical human trials is the use of adolescent pigs in a phase of rapid growth 
and weight gain. Thus, it is possible that liraglutide treatment (particularly when 
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the recommended human dosage is used) has a greater influence on growth and 
body weight gain in the adolescent organisms compared to adult subjects. This 
could also serve as an explanation for a study in which it was shown that 
liraglutide treatment (7 µg/kg) caused an even stronger reducing effect on food 
intake compared to this study, but still only body weight reductions of 4-5% in 
18-month-old adult minipigs (Raun et al. 2007b). Another study also reported less 
body weight loss of about 20% in liraglutide-treated adult Yucutan miniature pigs 
during a treatment period of 6 weeks with up to 20 µg liraglutide/kg body weight 
for 60 days (Emamaullee et al. 2009). At the moment, Victoza® is only tested and 
approved for the use in adult type 2 diabetic subjects while appropriate data are 
lacking about its effect in adolescents suffering from type 2 diabetes (EMEA 
2009b; Flint et al. 2011; Novo Nordisk 2010). One recent study reported that 
mean body weight in type 2 diabetic adolescent subjects at a mean age of 14.8 
years after a 5-week liraglutide treatment with dosages up to 1.8 mg remained 
stable (Batellino 2012). In contrast to the present study the participants of the 
study of Batellino seemed to be obese as they showed a mean body weight of 
113.2 kg. Additionally, it has to be taken into account that in comparison to the 
90-day treatment period of the present study in adolescent pigs, that can be seen 
as a model of accelerated growth and development, a 5-week treatment in slower 
growing adolescent humans may not have been long enough to detect influences 
on body weight gain (Litten-Brown et al. 2010; Puiman et al. 2008). Adequate 
pharmacotherapy for the treatment of adolescent type 2 diabetic patients is 
urgently needed given the facts that the prevalence of younger people suffering 
from type 2 diabetes is steadily increasing and that only few pharmacological 
agents are approved for this indication (Bloomgarden 2004; Flint et al. 2011; 
George et al. 2013). Furthermore, GLP-1R agonists like liraglutide and exenatide 
are gaining more and more interest to be evaluated as possible drugs for the 
treatment of pediatric obesity because of their weight-reducing effect (Kelly et al. 
2012; Kelly et al. 2013; Sherafat-Kazemzadeh et al. 2013; Wald et al. 2009). Due 
to the findings in the present study, caution is warranted during prospective long-
term treatment trials in adolescent subjects and liraglutide dosages should be 
carefully evaluated and adjusted as the treatment may not only have a much more 
pronounced effect on body weight than in adult patients but also impair body and 
organ growth. 
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3. Effects of liraglutide treatment on glucose control in 
GIPRdn transgenic pigs 
The effect of liraglutide on glucose control in GIPRdn transgenic pigs was 
evaluated by performing oral as well as intravenous glucose tolerance tests in 
animals after an 18-hour fasting period prior to and after the treatment period. 
Furthermore, fasting glucose levels were investigated regularly during the 
treatment period. 
3.1. Improved glucose tolerance and insulin sensitivity in liraglutide-
treated GIPRdn transgenic pigs 
During oral glucose tolerance testing after the 90-day treatment period liraglutide-
treated GIPRdn transgenic pigs showed 22-27% reduced AUC glucose compared 
to placebo-treated GIPRdn transgenic pigs. AUC glucose was also significantly 
reduced by 15-22% during intravenous glucose tolerance tests. Thus, liraglutide 
treatment led to significant improvement of oral as well as intravenous glucose 
tolerance. During the oral glucose tolerance test pigs were fed a mixed meal 
consisting of commercial pig fodder and 50% glucose solution. Therefore the 
lower glucose values in the liraglutide-treated GIPRdn transgenic pigs compared to 
the placebo-treated ones can partly be explained by the known ability of 
liraglutide to delay gastric emptying with further delayed intestinal absorption and 
appearance of glucose in the circulation (Baggio et al. 2007; Ribel et al. 2002). 
However, intravenous glucose tolerance is not influenced by gastric emptying 
time and still was enhanced. Therefore it is likely that the improvement in glucose 
tolerance was additionally mediated by improved insulin sensitivity. The 
calculation of different insulin sensitivity indices including HOMA-IR, QUICKI 
and ISI (Matsuda) clearly showed that liraglutide treatment significantly improved 
insulin sensitivity compared to placebo treatment, which was also a frequent 
finding of studies in rodent and pig models (Cummings et al. 2010; Guo et al. 
2013; Li et al. 2011; Raun et al. 2007a; Ribel et al. 2002; Sturis et al. 2003; Yang 
et al. 2012). Increased fat mass is known to be associated with augmented release 
of fatty acids as well as inflammatory cytokines which all together supports the 
development of insulin resistance (Kahn et al. 2006). Therefore, the improvement 
in insulin sensitivity may partly be explained by the ability of liraglutide to 
decrease food intake and cause weight reduction going along with a loss of fat 
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mass (Raun et al. 2007a). Consequently, liraglutide treatment in rodents was also 
shown to be associated with significantly lower triglyceride levels in serum as 
well as in the liver (Cummings et al. 2010; Guo et al. 2013). It was also suggested 
that liraglutide treatment may increase lipid oxidation, as liraglutide-treated rats 
showed similar body weight compared to restricted fed rats but nevertheless had a 
lower amount of body fat (Cummings et al. 2010). Some studies also reported that 
liraglutide decreased some inflammatory biomarkers, although the results were 
not completely consistent (Courreges et al. 2008; Cummings et al. 2010; Guo et 
al. 2013; Parthsarathy et al. 2013). The mechanism of liraglutide to improve 
insulin sensitivity is complex and seems to include further effects than just the 
consequences of a reduced food intake and body weight, as it was e.g. shown that 
liraglutide-treated rats show lower fasting plasma insulin concentrations in 
comparison to non-treated restricted fed rats while both groups showed similar 
fasting glucose levels (Cummings et al. 2010). Further mechanisms influencing 
insulin sensitivity could involve direct effects of liraglutide on the liver, 
adipocytes and muscle cells that have also been described for native GLP-1 and 
would result in decreased hepatic glucose production and increased peripheral 
glucose uptake and storage (Abu-Hamdah et al. 2009; Burcelin et al. 2001; 
Cummings et al. 2010). This would be in line with a recent study that showed the 
ability of liraglutide to influence gene and protein expression in the liver as well 
as adipose tissue and thereby to improve the state of insulin resistance in a murine 
animal model (Li et al. 2011).  
3.2. Reduced insulin secretion in liraglutide-treated GIPRdn transgenic 
pigs 
In the present study liraglutide treatment caused a significant reduction of insulin 
secretion during a mixed meal oral glucose tolerance test in GIPRdn transgenic 
pigs compared to placebo treatment. At first sight it might be confusing that 
liraglutide, as an analogue of the potent insulinotropic hormone GLP-1, decreases 
insulin secretion. However, it has to be taken into account that the insulinotropic 
action of GLP-1 is strictly dependent on a certain threshold of glucose 
concentration and that insulin secretion is not or only slightly stimulated if blood 
glucose is around the normal fasting range (Nauck et al. 1993c; Qualmann et al. 
1995). Regarding the marginal elevation of blood glucose during oral glucose 
tolerance testing observed in liraglutide-treated GIPRdn transgenic pigs after the 
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treatment period with maximum concentration of only up to 124 mg/dl it is 
comprehensible that liraglutide did not act insulinotropic in this case. 
Furthermore, low blood glucose levels themselves lower the demand for insulin 
within the organism, independent of liraglutide. The fact that lower postprandial 
glucose levels mainly caused by the delayed gastric emptying are going along 
with also reduced postprandial insulin secretion has already been shown after 
administration of native GLP in humans (Meier et al. 2003; Nauck et al. 1997). A 
study of Ribel et al. reported an improvement of oral glucose tolerance after 
liraglutide treatment in hyperglycemic minipigs going along with no significant 
changes in insulin secretion, but this is not completely comparable to the present 
study as these minipigs showed an overall streptozotocin-related impaired insulin 
secretion and glucose was administered mixed with a smaller amount of pig 
fodder (Ribel et al. 2002). During oral glucose tolerance tests in rodents, it has to 
be taken into account that glucose is usually administered by gavage without any 
food, which may in turn influence glucose levels and the following insulin 
response by bypassing a delayed gastric emptying. Various results of liraglutide 
treatment on insulin secretion were detected during oral glucose tolerance tests in 
diabetic and non-diabetic rodents, underlining that effects of liraglutide on insulin 
secretion depend on glucose concentrations (Larsen et al. 2008; Raun et al. 2007a; 
Sturis et al. 2003). During the intravenous glucose tolerance test performed in the 
therapeutic group after liraglutide treatment, AUC insulin was decreased by 46% 
in comparison to placebo treatment. Together with the finding of also significantly 
lower blood glucose levels during the test this may be caused by the improved 
insulin sensitivity. However this is not in accordance with the results seen in the 
prophylactic group during the intravenous glucose tolerance test after the 
treatment period, because in this case glucose levels were also significantly lower 
but insulin secretion was not changed in liraglutide-treated compared to placebo-
treated GIPRdn transgenic pigs. Altogether it has to be mentioned that individual 
insulin values during intravenous glucose tolerance tests showed high variance 
and are therefore difficult to interpret. During the initial characterization of the 
GIPRdn transgenic pig model Renner et al. observed that these animals inter alia 
show reduced insulin secretion during glucose tolerance testing, which was 
confirmed in the present study, as insulin secretion was strongly reduced 
compared to wild-type pigs investigated in a previous study (Renner et al. 2010). 
This demonstrates consistent phenotypic changes in this animal model over 
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several generations (F4 in the present study). 
3.3. Unchanged fasting blood glucose in liraglutide-treated GIPRdn 
transgenic pigs 
During the whole treatment period there were no significant differences seen in 
fasting blood glucose levels between liraglutide- and placebo-treated GIPRdn 
transgenic pigs. Additionally, fasting blood glucose did not exceed the 
normoglycemic range (Kixmöller 2004; Kraft 2005). During the characterization 
of the GIPRdn transgenic pig model it was already shown that these pigs show 
unaltered fasting blood glucose levels at least during the determined time range up 
to the age of 2 years (Renner et al. 2010). An effect of liraglutide on fasting blood 
glucose levels in the GIPRdn transgenic pig model was therefore not expected 
because its insulinotropic effect is glucose-dependent (Nauck et al. 1993c; 
Qualmann et al. 1995). This is also in accordance with studies that show a potent 
basal blood glucose lowering effect of liraglutide in hyperglycemic rodent 
models, but not in normoglycemic rodent models (Bock et al. 2003b; Larsen et al. 
2008; Rolin et al. 2002; Shimoda et al. 2011; Sturis et al. 2003; Vrang et al. 
2012). 
4. Decreased total beta-cell volume in liraglutide-treated 
GIPRdn transgenic pigs 
In the present study, liraglutide-treated GIPRdn transgenic pigs showed decreased 
volume density and total volume of beta-cells in the pancreas compared to 
placebo-treated GIPRdn transgenic pigs. Although this finding was not significant 
in animals of the prophylactic group at an age of 5 months, a strong tendency was 
determined. Within the therapeutic group at an age of 8 months the reduction of 
volume density as well as total volume of beta-cells in the pancreas was 
significant. Nuclear profile counting within pancreatic sections suggested that the 
reduced beta-cell volume in liraglutide-treated animals is rather due to hypotrophy 
than hypoplasia compared to placebo-treated animals. The total volume of 
isolated beta-cells in the pancreas, a potential marker for islet neogenesis 
(Bouwens et al. 1998; Xu et al. 1999), did not show significant differences 
between liraglutide- and placebo-treated animals. Additionally, HOMA-β that can 
be interpreted as an index for beta-cell function (Matthews et al. 1985) was not 
significantly different between liraglutide- and placebo-treated GIPRdn transgenic 
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pigs and no histological differences were seen regarding insulin staining intensity 
and pattern in the pancreas. It is difficult to compare these results to other studies 
that used porcine models, as only one study partly evaluated the in vivo effect of 
liraglutide on the beta-cells in pigs and this study was performed under 
completely different conditions compared to the present study: After pancreatico-
duodenectomized Yucutan miniature pigs received a graft of isolated pancreatic 
islets into the portal circulation they were treated with liraglutide for 60 days and 
the proportion of beta-cells, determined only one year after transplantation, was 
not different between liraglutide- and placebo-treated pigs (Emamaullee et al. 
2009). In contrast to the present study, an increase of HOMA-β was frequently 
observed during clinical trials in type 2 diabetic patients and therefore an 
improvement of beta-cell function was suggested (Blonde et al. 2009; Garber 
2011). Beside these findings, data about the actual in vivo effect of liraglutide and 
other GLP-1R agonists on the beta-cells volume in humans are lacking because 
there are still no appropriate non-invasive imaging techniques for the 
quantification and evaluation of the human beta-cell volume available (Malaisse 
2005). However, the results of the present study regarding the beta-cell volume 
are not in accordance with in vivo studies that showed the ability of liraglutide to 
increase the beta-cell volume in rodent models, associated with enhanced beta-cell 
proliferation and/or decreased beta-cell apoptosis rate (Rolin et al. 2002; Shimoda 
et al. 2011; Sturis et al. 2003; Vrang et al. 2012). In vitro studies using rodent or 
porcine islet cells also determined a pro-proliferative and anti-apoptotic effect of 
liraglutide and showed that it can improve the survival of human islets in culture 
(Bregenholt et al. 2005; Emamaullee et al. 2009; Friedrichsen et al. 2006; Miao et 
al. 2013; Toso et al. 2010). While translating the results from basic research of in 
vivo studies with rodent models to human clinical application two important 
points have to be kept in mind: First of all, the pancreas of rodents shows a much 
higher capacity for regeneration and proliferation compared to the human 
pancreas (Butler et al. 2007; Menge et al. 2008). Therefore it can be doubted if the 
liraglutide mediated increases of the total beta-cell volume in rodents are 
representative for the human organism. Second, it is well known that liraglutide 
shows a much shorter half-life in rodents (4-8 h) compared to humans (13-15 h) 
(EMEA 2009a). That is the reason why liraglutide is administered twice daily in 
most rodent studies compared to the suitability of a once daily administration in 
humans, which all together results in different exposure times and plasma 
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liraglutide levels that may additionally influence the effect of liraglutide (Knudsen 
et al. 2000; Raun et al. 2007a; Sturis et al. 2003). Regarding these facts the pig 
that shows similar liraglutide half-life (14 h) compared to the human and 
additionally higher physiologic and pathophysiologic similarities can be seen as a 
more representative model (EMEA 2009a; Swindle et al. 2012). Furthermore, 
liraglutide did not increase the beta-cell volume in all studies using rodent models 
as there are also published reports where beta-cell volume was unaltered or even 
lowered after liraglutide treatment (Brand et al. 2009; Guo et al. 2013; Larsen et 
al. 2008; Raun et al. 2007a; Rolin et al. 2002; Sturis et al. 2003). Some authors 
suggested that the trophic effect of liraglutide on beta-cells may be dependent on 
the individual metabolic status of the animals and only occurs when 
hyperglycemia is concomitantly evident within the organism (Knudsen 2010; 
Sturis et al. 2003). Indeed, in most of the studies an increase of beta-cell volume 
could be proven in hyperglycemic rodent models like diabetic ZDF rats or 
diabetic db/db mice (Rolin et al. 2002; Sturis et al. 2003; Vrang et al. 2012). 
However, also non-diabetic Sprague Dawley rats showed greater beta-cell volume 
after liraglutide treatment and liraglutide additionally increased beta-cell volume 
in normoglycemic m/m mice. It has to be mentioned that the duration of these two 
studies was rather short-term (1 week and 2 weeks) and that the effect seen in the 
Sprague Dawley rats was only temporary as it was vanished after 6 weeks of 
liraglutide treatment (Bock et al. 2003b; Shimoda et al. 2011). Furthermore, in 
other studies liraglutide treatment of hyperglycemic rodent models like severely 
diabetic ZDF rats failed to increase beta-cell volume as no differences were seen 
in comparison to placebo treatment (Brand et al. 2009; Larsen et al. 2008). 
Therefore the hypothesis that liraglutide continuously increases beta-cell volume 
in hyperglycemic rodent models but not in normoglycemic ones is partly 
disproved, maybe also underlined by the fact that it has been shown in studies of 
Buteau et al. for native GLP-1 in Ins-1 cell lines that the stimulation of cell 
proliferation, in comparison to its insulinotropic effect, seems not to be glucose 
dependent (Buteau et al. 2001; Buteau et al. 1999). The various results of the in 
vivo effect of liraglutide on beta-cells in rodent models suggest that a lot of factors 
like age, different metabolic status, duration of treatment and dosage may all 
together influence its presence and extent (Rolin et al. 2002). Additionally, 
liraglutide is able to potently improve glucose control as it acts insulinotropic in 
hyperglycemic subjects and decreases food intake also in normoglycemic subjects 
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(Blonde et al. 2009; Bock et al. 2003b; Larsen et al. 2008; Sturis et al. 2003). The 
improvement of glucose control could alleviate the destructive impact of 
glucotoxicity and lipotoxicity on beta-cells in diabetic subjects and this would in 
turn reduce the rate of beta-cell apoptosis and thereby save beta-cell volume 
(Federici et al. 2001; Leibowitz et al. 2001; Shimabukuro et al. 1998). This would 
mean that the beneficial impact of liraglutide on beta-cells shown in many studies 
is not completely mediated by direct trophic effects but also indirectly by 
improvements of glycemic control, which is difficult to differentiate. As the 
degree of liraglutide mediated improvement of glycemic control can vary between 
different diabetic rodent models and also within the same diabetic animal model 
dependent on the initial metabolic state this may partly explain the inconsistent 
results regarding its effect on the beta-cell volume observed in rodents (Larsen et 
al. 2008; Rolin et al. 2002; Vrang et al. 2012). For the calculation of the total beta-
cell volume in the present study, pancreas weight was included, which showed a 
tendency to be decreased in liraglutide-treated GIPRdn transgenic pigs compared 
to placebo-treated ones in both groups, but no significance was reached. As 
liraglutide-treated GIPRdn transgenic pigs showed a drastic reduction of body 
weight gain compared to placebo-treated ones, the total beta-cell volume was also 
divided by the individual body weight of the pigs and this parameter (V(β-
cell,Pan)/BW) neither showed significant differences in the prophylactic group nor in 
the therapeutic group. This is in accordance with previous reports describing a 
linear correlation between the beta-cell volume and the body weight in both rats 
and pigs (Bock et al. 2003a; Montanya et al. 2000). Increased body weight is only 
one factor among others like pregnancy or increased glucose and fat supply that 
amplify the demand for insulin within the organism and therefore can cause a 
compensatory increase of beta-cell volume to a certain extent (Bock et al. 2003a; 
Bonner-Weir et al. 1989; Bouwens et al. 2005; Steil et al. 2001). As liraglutide-
treated GIPRdn transgenic pigs showed strongly reduced food intake up to 50% 
during ad libitum feeding in comparison to placebo-treated animals they also 
received less nutrients including glucose and fat. Therefore it might be considered 
that their demand for insulin as well as the stimulation of beta-cells is lower. This 
could serve as an explanation for the tendency of a decreased HOMA-β as an 
indicator for beta-cell function (Matthews et al. 1985) observed in liraglutide-
treated animals in both groups compared to placebo-treated animals. Furthermore, 
it is likely that liraglutide did not have direct inhibiting effects on the beta-cells 
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but that the indirect effect mediating the reduced food intake and body weight is 
responsible for the decreased total beta-cell volume in liraglutide-treated GIPRdn 
transgenic pigs. This would be in accordance with the fact that liraglutide-treated 
GIPRdn transgenic pigs in the present study show very similar total beta-cell 
volume when compared to restrictive fed untreated GIPRdn transgenic pigs in the 
study of Renner et al. (2010). 
5. Concluding remarks and perspectives 
In conclusion, a 90-day treatment period of adolescent GIPRdn transgenic pigs 
with the long-acting GLP-1R agonist liraglutide provoked principle clinical 
effects observed in type 2 diabetic humans: Enhanced intravenous as well as oral 
glucose tolerance, an improvement of several insulin sensitivity indices as well as 
a reduction of food intake and body weight. However, the effect on body weight 
was much more dramatic than after treatment of adult type 2 diabetic subjects. 
Further investigation should be kept on to accurately clarify the reasons for this 
marked inhibition of weight gain. Underlying mechanisms might involve a 
reduced secretion of the anabolic hormone insulin. To address this hypothesis, 
transcriptome profiling of skeletal muscle tissue could be useful to detect 
alterations in insulin-stimulated gene expression pattern, which would underline a 
reduced insulin secretion as an important factor for the different body weight gain 
seen in the present study. Skeletal muscle would be a preferred tissue because it is 
a primary target for insulin actions and represents a major proportion of the body 
weight (Klip et al. 1990; Wang et al. 1992; Wang et al. 1996). The use of the 
human recommended dosage of liraglutide combined with the treatment of 
adolescent pigs could also have contributed to the strong body weight reducing 
effect. Therefore special care is warranted for prospective long-term liraglutide 
treatment trials involving adolescent patients and accurate dosages have to be 
evaluated carefully. Liraglutide treatment decreased the total beta-cell volume in 
GIPRdn transgenic pigs maybe indirectly by decreasing food intake and thereby 
mediating a reduced nutrient intake. In vitro studies using rodent or porcine islets 
determined a pro-proliferative and anti-apoptotic effect of liraglutide and in vivo 
studies using rodent models are inconsistent in their findings regarding the effect 
of liraglutide on beta-cells (Brand et al. 2009; Bregenholt et al. 2005; Friedrichsen 
et al. 2006; Guo et al. 2013; Larsen et al. 2008; Miao et al. 2013; Raun et al. 
2007a; Rolin et al. 2002; Shimoda et al. 2011; Sturis et al. 2003; Toso et al. 2010; 
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Vrang et al. 2012). Therefore it would be interesting to gather further insights into 
the in vitro effect of liraglutide on isolated islets of GIPRdn transgenic pigs, 
mainly regarding the information if liraglutide is able to stimulate proliferation or 
inhibit apoptosis in islets of this pig model. It has already been described that the 
GIPRdn transgenic pig model shows key findings of a prediabetic stage but does 
not show a clinically overt diabetes in a determined range of 2 years (Renner et al. 
2010). However, the feeding of a high fat diet could be used to promote obesity as 
well as insulin resistance and thereby challenge a clinical manifestation of 
diabetes mellitus in this pig model going along with the development of 
hyperglycemia. If this worked, another 90-day treatment period with liraglutide 
could bring useful information about the impact of the initial metabolic state in 
the GIPRdn transgenic pig model on the effect of liraglutide. Additionally, the 
effects of liraglutide could be tested in other pig models like e.g. the INSC94Y 
transgenic pig model that inter alia exhibits hyperglycemia already soon after 
birth (Renner et al. 2012). At the moment, numerous DPP-4 inhibitors and GLP-
1R agonists are not approved yet but under development (Khan et al. 2012). 
Additionally, a great point of interest for the future can be seen in the 
development of dual agonist drugs like GLP-1/gastrin agonists or in molecules 
that can activate the GLP-1R and concomitantly are antagonists of the glucagon 
receptor (Claus et al. 2007; Fosgerau et al. 2013). Therefore, the GIPRdn 
transgenic pig model could further be used for the preclinical evaluation of 
appropriate therapeutic dosages as well as for testing the efficacy and safety of 
these new drugs. 
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VII. SUMMARY 
Effects of the long acting glucagon-like peptide-1 receptor (GLP-1R) agonist 
liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic 
polypeptide receptor (GIPR) function 
Pancreatic beta-cell failure and decline are major pathogenetic principles for the 
development and progressive course of type 2 diabetes mellitus. Thus, GLP-1R 
agonists are a promising option for the treatment of type 2 diabetes as they seem 
to have the potential to increase the beta-cell volume in rodent models. However, 
data are lacking about their in vivo effect on human beta-cells because of the 
absence of appropriate non-invasive imaging techniques for quantification of the 
beta-cell volume. Large animal models like the pig that show strong physiological 
and pathophysiological similarities to humans are a useful and necessary addition 
to further clarify the effects of GLP-1R agonists on the organism. 
Therefore, the effect of the long-acting GLP-1R agonist liraglutide on glycemic 
control, body weight, food intake and especially the total beta-cell volume was 
evaluated in transgenic pigs that express a dominant-negative glucose-dependent 
insulinotropic polypeptide receptor (GIPRdn) in the pancreatic beta-cells. This 
large animal model seemed to be especially suitable for the present study as it 
shows key findings of a prediabetic state: An impaired function of the incretin 
hormone glucose-dependent insulinotropic polypeptide (GIP) going along with 
impaired glucose tolerance and progressive reduction of the beta-cell volume. 
Two different age groups of GIPRdn transgenic pigs (prophylactic group: 2 
months of age, no reduction of beta-cell volume; therapeutic group: 5 months of 
age, 35% reduction of beta-cell volume) were treated with subcutaneous injection 
of liraglutide (dose range 0.6 mg – 1.8 mg, depending on body weight) or placebo 
once daily for 90 days. Prior to and after the treatment period glucose tolerance 
was evaluated by performing oral as well as intravenous glucose tolerance tests. 
Finally animals were subjected to necropsy and the total beta-cell volume was 
determined by quantitative-stereological analyses. 
In both age groups of GIPRdn transgenic pigs, body weight of liraglutide-treated 
pigs was lower by 30-40% in comparison to placebo-treated animals, which may 
at least partly be explained by the concomitant 20-50% reduced food intake. 
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Intravenous as well as oral glucose tolerance was improved by liraglutide 
treatment. In the mixed meal oral glucose tolerance test at the end of the treatment 
period liraglutide-treated animals exhibited only a very moderate increase of 
blood glucose, probably due to the known effect of liraglutide on gastric 
emptying. This was associated with significantly smaller AUC insulin in 
liraglutide- vs. placebo-treated animals. Further, liraglutide treatment reduced the 
HOMA-IR and increased several insulin sensitivity indices. The total beta-cell 
volume of liraglutide-treated animals was decreased in comparison to placebo-
treated ones, most probably due to the reduced food intake and delayed release of 
glucose from the stomach. The total beta-cell volume related to body weight did 
not differ between liraglutide- and placebo-treated GIPRdn transgenic pigs. 
In conclusion, the GIPRdn transgenic pig model recapitulates principle clinical 
effects of liraglutide observed in type 2 diabetic humans like improved glucose 
tolerance and insulin sensitivity as well as a reduction of body weight and food 
intake. However, the reduction of body weight gain observed in adolescent pigs 
was much more dramatic than the body weight loss of adult patients. Thus, special 
care is warranted in prospective long-term treatment trials involving adolescent 
patients. In contrast to rodent models, there was no evidence for an increasing 
effect of liraglutide treatment on the total beta-cell volume in the GIPRdn 
transgenic pig model. 
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VIII. ZUSAMMENFASSUNG 
Auswirkungen des langwirksamen Glukagon-ähnlichen Peptid-1 Rezeptor 
(GLP-1R) Agonisten Liraglutide auf heranwachsende Schweine mit gestörter 
Funktion des Glukose-abhängigen insulinotropen Polypeptid Rezeptors 
(GIPR) 
Das Versagen und der Verlust von pankreatischen Beta-Zellen gehören zu den 
wichtigsten Faktoren die für die Entwicklung und den progressiven Verlauf des 
Typ 2 Diabetes mellitus verantwortlich sind. GLP-1R Agonisten stellen eine 
vielversprechende Option für die Behandlung des Typ 2 Diabetes mellitus dar, da 
sie in einigen Studien in Nagermodellen das Beta-Zellvolumen erhöhen konnten. 
Über den in vivo Effekt auf humane Beta-Zellen ist allerdings noch nichts 
bekannt, was vor allem damit zusammenhängt dass beim Menschen bislang noch 
keine nicht-invasiven Methoden zur Quantifizierung des Beta-Zellvolumens in 
vivo vorhanden sind. Großtiermodelle wie das Schwein sind dem menschlichen 
Organismus bezüglich physiologischer und pathophysiologischer Abläufe sehr 
ähnlich und stellen deshalb eine sinnvolle und notwendige Ergänzung zu den 
Nagermodellen dar, um die Auswirkungen von GLP-1R Agonisten auf den 
Organismus genauer zu untersuchen. Aus diesem Grund wurden in der 
vorliegenden Studie die Auswirkungen des langwirksamen GLP-1R Agonisten 
Liraglutide auf die Glukosekontrolle, das Körpergewicht, die Futteraufnahme 
sowie besonders auf das Gesamt-Beta-Zellvolumen in transgenen Schweinen 
untersucht, die einen dominant-negativen GIPR (GIPRdn) in den pankreatischen 
Beta-Zellen exprimieren. Dieses Großtiermodell erschien besonders geeignet für 
diese Studie weil es wesentliche Merkmale eines prädiabetischen Zustands zeigt: 
Eine gestörte Funktion des Inkretinhormons GIP und außerdem altersabhängig 
eine verminderte Glukosetoleranz und Insulinsekretion, die begleitet wird von 
einem progressiven Beta-Zellverlust. Zwei verschieden Altersgruppen von GIPRdn 
transgenen Schweinen wurde 90 Tage lang einmal täglich subkutan Liraglutide 
(Dosisbereich 0.6 mg – 1.8 mg, abhängig vom Körpergewicht) oder Placebo 
gespritzt (prophylaktische Gruppe: 2 Monate alt, unverändertes Beta-
Zellvolumen; therapeutische Gruppe: 5 Monate alt, bereits 35% reduziertes Beta-
Zellvolumen). Die Glukosetoleranz vor und nach der Behandlung wurde durch 
orale sowie intravenöse Glukosetoleranztests untersucht. Am Ende des 
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Behandlungszeitraums wurden die Tiere euthanasiert und das Beta-Zellvolumen 
wurde mittels quantitativ-stereologischer Analysen bestimmt.  
Die Behandlung mit Liraglutide führte in beiden Altersgruppen zu einer massiven 
Hemmung der Körpergewichtsentwicklung (30-40% Reduktion des 
Körpergewichts im Vergleich zu Placebo behandelten Tieren am Ende der 
Behandlungsperiode), was zumindest teilweise durch eine 20-50% reduzierte 
Futteraufnahme zu erklären war. Außerdem führte die Behandlung mit Liraglutide 
zu einer verbesserten oralen und intravenösen Glukosetoleranz. Während des 
oralen Glukosetoleranztests am Ende der Therapie zeigten Liraglutide behandelte 
Tiere einen nur sehr moderaten Anstieg der Glukosespiegel. Da die Glukose 
während dieses Tests gemischt mit Futter verabreicht wurde, könnte dieses 
Ergebnis auf den bekannten Effekt von Liraglutide auf die Magenentleerung 
zurückzuführen sein. Auch die AUC für Insulin war während diesem Test in 
Liraglutide behandelten Tieren signifikant niedriger als bei Placebo behandelten 
Tieren. Des Weiteren senkte die Behandlung mit Liraglutide den HOMA-IR-
Index und erhöhte einige Insulinsensitivitäts-Indices. Das Gesamt-Beta-
Zellvolumen war im Vergleich zu Placebo behandelten Schweinen bei Liraglutide 
behandelten Tieren niedriger, wahrscheinlich aufgrund der reduzierten 
Futteraufnahme und der stark protrahierten Freisetzung von Glukose aus dem 
Magen. Bezogen auf das Körpergewicht konnte zwischen Liraglutide und Placebo 
behandelten Tieren kein Unterschied im Gesamt-Beta-Zellvolumen festgestellt 
werden. 
Das GIPRdn transgene Schweinemodell zeigte nach Liraglutide Behandlung viele 
klinische Effekte die auch beim humanen Typ 2 Diabetiker beobachtet wurden. 
Dazu gehören die Verbesserung der Glukosetoleranz und der Insulinsensitivität 
sowie das geringere Körpergewicht und die reduzierte Futteraufnahme im 
Vergleich zur Placebo Behandlung. Allerdings war die geringere 
Körpergewichtszunahme der heranwachsenden transgenen Schweine in dieser 
Studie viel stärker ausgeprägt als sie beim erwachsenen Menschen zu 
beobachtende Körpergewichtsreduktion. Deshalb sollten zukünftige Langzeit-
Behandlungsstudien von heranwachsenden humanen Patienten mit erhöhter 
Vorsicht durchgeführt werden. Im Gegensatz zum Nagermodell konnte kein 
Hinweis darauf gefunden werden, dass Liraglutide einen vermehrenden Effekt auf 
das Beta-Zellvolumen im GIPRdn transgenen Schweinemodell hat. 
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